



TOGETHER FOR IMPACT TOGETHER FOR HEALTH

2025-26
Annual Report



Contents



CORPORATE OVERVIEW

• Together for Impact	02
• Who We are	03
• Executive Chairman's Message	10
• Managing Director's Desk	13
• Business Model	16
• Integrated Strategy	19
• Value Creation Approach	21
• From Indian Roots to Global Reach	23
• ESG Highlights – Responsible Manufacturing for a Sustainable Future	28
• Creating Value Through Social and Relationship Capital	32

STATUTORY REPORTS

• Management Discussion and Analysis	35
• Directors' Report	66

FINANCIAL STATEMENTS

• Independent Auditor's Report	95
• Balance Sheet	108
• Statement of Profit and Loss	109
• Statement of Cash Flows	110
• Notes to the Financial Statements	111

AGM NOTICE 135

CORPORATE INFORMATION 145

TOGETHER FOR IMPACT

We believe the long-term success of our company—and our social license to operate—depends on our ability to demonstrate that working together with global stakeholders makes us more than just a business. We position ourselves as a critical driver of global health security and human well-being.

By embracing collaboration, advancing innovation, and keeping the well-being of our go-to-market partners at the center of everything we do, we help shape a healthier and more sustainable future. We recognize that while the challenges are significant, the potential for meaningful, positive impact grows stronger when our efforts are united.

We prioritize the safety, efficacy, and accessibility of our products. We are committed to delivering high-quality pharmaceutical products that improve health outcomes, support well-being, and make a meaningful difference in patients' lives worldwide.

Through innovation and collaboration, we have the power to build a healthier, more sustainable world for all. With an unwavering commitment to enduring relationships, we are poised to transform our vision into a tangible reality.

“

**FOR A STRONGER TOMORROW...
WE LEAD WITH PURPOSE.**

Who We Are

BUILDING TRUST, ADVANCING GLOBAL HEALTHCARE



Accretion® Pharmaceuticals Limited is a dedicated, fast growing Contract Development and Manufacturing Organisation (CDMO) specialising in the development, scale-up, and commercial manufacture of high-quality pharmaceutical formulations. Established in 2012, we have built a resilient foundation rooted in innovation, quality, and operational excellence, emerging as a trusted partner in the global healthcare landscape.



Our name, **Accretion**, meaning "coming together and growing through gradual accumulation, reflects our core philosophy of sustainable progress. We are committed to steadily building knowledge, strengthening capabilities, earning trust, and fostering enduring partnerships that create long-term value.



Building on this strong foundation, the Company achieved a significant milestone in its growth journey with the successful completion of its **initial Public Offering (IPO)** and listing on the NSE Emerge SME Platform on **21 May 2025**. The public issue raised approximately **₹ 2,975.46 lacs** to support the Company's expansion plans and strategic growth initiatives. The IPO was **oversubscribed by 7.67 times**, reflecting strong investor confidence in our business model, manufacturing capabilities, and long-term growth prospects. With an enhanced capital base and strengthened market presence, Accretion Pharmaceuticals Limited is well positioned to accelerate its growth strategy expand its operational capabilities, and create sustainable long-term value for all stakeholders.



Accretion Pharmaceuticals Limited combines scientific rigour with operational dependability to deliver compliant, quality-driven manufacturing solutions. Our global footprint and robust regulatory portfolio underscore our commitment to international quality standards. With a strong domestic and global presence, we supply life-saving and health-enhancing medicines to more than **30+ countries** across Africa, Southeast Asia, and Latin America, contributing to improved healthcare outcomes worldwide.



Our commitment to quality is validated by a comprehensive suite of national and international certifications:



Manufacturing & Lab Practices:

- WHO-cGMP, GLP



International GMP Approvals:

- Cambodia GMP, Rwanda GMP, Nigeria GMP, Malawi GMP



ISO Certifications:

- ISO 9001 : 2015 (Quality Management)
- ISO 14001 : 2015 (Environmental Management)
- ISO 22000 : 2018 (Food Safety Management)



Headquartered in the industrial hub of **Ahmedabad, Gujarat, India**, Accretion Pharmaceuticals Limited operates an avant-garde, technologically advanced, and highly scalable manufacturing facility. As of 31 March, 2026, our total installed capacity stands at a formidable **1,635 Million**, broken down across diverse delivery formats to meet versatile global demands:



 Installed Capacity	For the year ended 31 March, 2026 (in Million)
 Tablet Section (MoU - Numbers)	1000
 Oral Liquid Section (MoU - Bottle)	22
 External Perpetration Section (MoU - Tube)	9
 Capsule Section (MoU - Numbers)	450
 Oral Powder Section (MoU - Bottle & Pouch)	154



Our Mission

To deliver state-of-the-art pharmaceutical manufacturing solutions that consistently exceed client expectations. We are fiercely committed to combating diseases and advancing global health by providing innovative, high-quality medicines at competitive prices—striving towards a world free of ailments.



Our Vision

Driven by our technologically advanced and scalable manufacturing unit, our vision is to make a vital contribution to global medicine by harnessing our full potential to achieve optimal therapeutic results. We aim to be the premier global partner in pharmaceutical development and manufacturing, renowned worldwide for our innovation, reliability, and unyielding commitment to quality.



Visionary Pioneers | Board of Directors

At the core of Accretion Pharmaceuticals Limited's success is a highly experienced and cohesive management team. All Directors and Promoters hold foundational qualifications in Pharmacy (B.Pharm), ensuring that the Company's leadership remains deeply rooted in pharmaceutical science, product quality, and regulatory understanding. Complementing their technical expertise, members of the leadership team have pursued advanced postgraduate qualifications aligned with their respective functional domains, enabling them to lead with both scientific precision and commercial acumen. This unique blend of academic excellence, domain expertise, and practical industry experience enables the Company to maintain high standards of operational efficiency, regulatory compliance, innovation, and sustainable value creation.

BUILDING A BETTER FUTURE TOGETHER



Mr. Harshad Nanubhai Rathod

Promoter, Executive Director & CFO

Mr. Harshad Nanubhai Rathod serves as the Promoter, Executive Director, and Chief Financial Officer (CFO) of Accretion Pharmaceuticals Limited, bringing over 16 years of distinguished experience to the pharmaceutical realm. Armed with a Bachelor's degree in Pharmacy from Gujarat University and an MBA from Madhyanchal Professional University, Bhopal, his unique blend of technical expertise and business acumen forms the cornerstone of his strategic leadership. Mr. Rathod masterfully identified high-growth opportunities and provided critical strategic guidance. A natural leader and inspiring motivator, he seamlessly aligns financial stewardship with operational excellence, empowering the team to achieve peak performance while driving the Company toward a vibrant and sustainable future.



Mr. Vivek Ashok Kumar Patel

Promoter and Managing Director

Mr. Vivek Ashok Kumar Patel is the Promoter and Managing Director of Accretion Pharmaceuticals Limited, bringing over 16 years of diverse and rich experience to the organization. He holds a Bachelor's degree in Pharmacy from Gujarat University and an MBA in Pharma from the prestigious DY Patil Institute, establishing a powerful foundation of technical knowledge and specialized business acumen. Mr. Patel's ability to seamlessly blend production insights with sharp marketing acumen, he stands as a dynamic leader who continuously drives innovation and operational excellence across all facets of the company's endeavours.



Mr. Hardik Mukundbhai Prajapati

Promoter and Executive Director

Mr. Hardik Mukundbhai Prajapati serves as the Promoter and Executive Director of Accretion Pharmaceuticals Limited, bringing over 16 years of deep, hands-on experience in pharmaceutical production to the leadership team. He holds a Bachelor's degree in Pharmacy from Gujarat University and a Master's degree in Pharmacy from Gujarat Technological University, anchoring his career in robust technical excellence. Mr. Prajapati characterized by his unwavering commitment to innovation and precision, his technical mastery and entrepreneurial insight are pivotal in shaping a bright, progressive future for Accretion Pharmaceuticals Limited.



Mr. Mayur Popatlal Sojitra

Promoter and Non-Executive Director

Mr. Mayur Popatlal Sojitra serves as the Promoter and Non-Executive Director of Accretion Pharmaceuticals Limited, embodying strategic excellence and a global perspective. He holds a Bachelor's degree in Pharmacy from Gujarat University and an MBA in International Business from the University of Greenwich, London, providing him with a unique blend of technical pharmaceutical expertise and advanced global market insights. Boasting over 14 years of rich experience in the pharmaceutical industry, Mr. Sojitra crafts the company's bold vision for expanding into stringent regulatory markets. His strategic foresight and commitment to innovation are instrumental in guiding Accretion Pharmaceuticals Limited toward international growth and global leadership.


Ms. Grishma Ajayrao Shewale

Non-Executive Independent Director

Ms. Grishma Ajayrao Shewale serves as a Non-Executive Independent Director of the company, bringing over 10 years of robust experience as a Company Secretary and Compliance Officer. Celebrated for her exceptional communication skills and decisive leadership qualities, she possesses extensive expertise in navigating complex regulatory environments. Her core proficiencies include managing the listing processes, drafting meticulous due diligence reports, and overseeing the preparation of comprehensive annual reports and annual returns. Furthermore, Ms. Shewale is highly proficient in corporate governance and regulatory compliance, particularly in filing essential e-forms with the Registrar of Companies (ROC), making her an invaluable asset to the board's oversight capabilities.


Mr. Chand Rameshbhai Kanabar

Non-Executive Independent Director

Mr. Chand Rameshbhai Kanabar serves as a Non-Executive Independent Director of the company, having been appointed to the Board with effect from 19 April, 2025. A methodical and versatile professional, he brings several years of comprehensive experience in overseeing daily organizational operations, executing corporate strategies, and implementing robust business plans. Mr. Kanabar's diverse background spans crucial financial and commercial domains, with past roles including Audit Assistant at V M Vithlani & Co, Senior Executive in Finance & Accounts at Kunvarji Wealth Solutions, and a key role in Sales and Business Development at Shiv Investment. His hardworking approach and well-rounded expertise in evaluating financial performance and strategic growth significantly strengthen the board's independent oversight.

**Mrs. Nishtha Harivanshi Pamnani***Non-Executive Independent Director*

Mrs. Nishtha Harivanshi Pamnani serves as a Non-Executive Independent Director of the company, having been appointed to the Board with effect from 10 June, 2025. A qualified Company Secretary, she holds an MBA in Finance from Sikkim Manipal University and a BBA from Biyani Girls College (affiliated with the University of Rajasthan), establishing a robust academic foundation in business and finance. Mrs. Pamnani brings over 9 years of extensive experience in corporate governance, legal compliance, securities laws, and regulatory frameworks. With her in-depth expertise in secretarial practices, SEBI regulations, and corporate law, paired with a practical understanding of finance and accounting functions, her governance-first approach significantly enhances the Board's strategic oversight and ethical corporate management.

EXECUTIVE CHAIRMAN'S MESSAGE

AT THE INTERSECTION OF SCIENCE AND SCALE, WE ARCHITECT THE END-TO-END DEVELOPMENT AND MANUFACTURING ECOSYSTEMS THAT TRANSFORM BREAKTHROUGH IDEAS INTO TANGIBLE THERAPEUTIC OUTCOMES

Dear Shareholders,

It is my pleasure to present the Annual Report of Accretion Pharmaceuticals Limited for the financial year 2025–26. As your Chairman, I am pleased to report that **our company is not just observing this transformation – we are architecting it.**

Our journey reflects a balanced approach—combining growth with discipline, innovation with reliability, and ambition with a strong foundation of values. As the global pharmaceutical landscape evolves, we remain focused on aligning our strengths with emerging opportunities, ensuring that we create sustainable value for all stakeholders.

FINANCIAL RESILIENCE AND STRATEGIC GROWTH

In the financial year 2025–26, we delivered a robust financial performance characterized by 56.21% revenue growth and an EBITDA margin of 16.68% reflecting the strength of our business model and operational discipline. More importantly, we have maintained a carefully and disciplined capital allocation strategy. By optimizing our cost of capital and reinvesting in what we define as “Smart Infrastructure”—technology-led, efficiency-driven, and future-ready assets—we are ensuring that our growth remains both sustainable and value-accretive.

As a WHO-cGMP compliant, GLP-compliant, and ISO-certified CDMO pharmaceutical company, we continue to operate under the highest global standards of quality, safety, and regulatory excellence.

KEY HIGHLIGHTS



56.21%

Revenue Growth

Strong top-line growth driven by scale and execution excellence.



16.68%

EBITDA Margin

Reflecting operational strength and cost efficiency.



Global Quality Standards

WHO-cGMP, GLP & ISO compliant with robust quality system.



Strategic Partnerships

Expanding global footprint through strong client relationships.



Future-Focused Investments

Advanced technology, capacity expansion & talent development for long-term leadership.

Our robust quality management systems, validated manufacturing processes, and strong regulatory framework enable us to reliably serve clients across regulated and semi-regulated markets with confidence and consistency.

I am equally proud of the strategic direction we are pursuing. Our investments in advanced technologies, capacity expansion, and talent development are thoughtfully aligned with our long-term vision of becoming a globally trusted CDMO partner. At the same time, we continue to deepen relationships with existing clients while actively forging new partnerships across regulated and emerging markets, further strengthening our global footprint and long-term growth visibility.

STRENGTHENING THE GLOBAL HEALTHCARE ARCHITECTURE

The “**Global Gateway**” approach focuses on our role as a bridge between Indian manufacturing excellence and global market needs, enabling the scale-up of cGMP excellence from India to the world across emerging markets. In parallel, the “Strategic Expansion” approach emphasizes the technical and regulatory dimension, including plant registrations and product registration strategy.

With a presence in over 30+ countries through direct exports and merchant exporters, we are strengthening our footprint across key regions such as Africa, Southeast Asia, and Latin America through targeted market strategies, including local registrations and boom plant registrations supported by cGMP-compliant manufacturing capabilities.

In these global markets, we are actively pursuing dossier filings, product approvals, and regulatory clearances supported by robust documentation, stringent quality systems, and globally aligned manufacturing standards. Our emphasis on regulatory excellence ensures that every plant registration and product approval is fully compliant with international guidelines, enabling faster market access and long-term commercial stability. This approach not only strengthens our credibility as a trusted CDMO partner but also enhances our ability to serve diverse healthcare systems with agility and consistency. Ultimately, this transition from a transactional vendor to a strategic global partner is reflected in our growing share of complex modality contracts, which deliver higher margins and long-term stability.

GO AHEAD

The journey ahead presents significant opportunity along with greater responsibility. As the global healthcare industry increasingly depends on agile and reliable CDMO partners, we are confident in our ability to deliver sustained value through excellence, innovation, and strong governance.

Our clear ambition is to provide fully integrated, end – to – end CDMO solutions from development to commercialization — thereby creating long-term value for all stakeholders.

Rooted in India and serving global markets, we are committed to shaping the future of pharmaceutical manufacturing through innovation, collaboration, and purpose-driven growth.

The future of pharma is increasingly complex, data-driven, and highly personalized. In 2026, we are not just manufacturing pills; we are manufacturing **hope, health, and longer lives**. By aligning our technological roadmap with visionary government policies and the evolving needs of global partners, we are positioned for a decade of unprecedented opportunity and sustainable growth.

CLOSING MESSAGE

I extend my deepest gratitude to our dedicated teams whose commitment and relentless pursuit of excellence continue to push the boundaries of what is possible in pharmaceutical innovation. I also express my sincere appreciation to our valued stakeholders, clients, suppliers, and strategic partners for their unwavering trust, collaboration, and confidence in our long-term vision. My heartfelt thanks also go to the regulatory authorities for their continued guidance and support.

“

Together, we are building a **resilient, globally respected** organization poised for **sustained impact** and **growth**.

With warm regards,

Mr. Harshad Nanubhai Rathod

Chairman, Director and CFO

DIN: 09108392

MANAGING DIRECTOR'S DESK

“PIONEERING THE NEW ERA : PRECISION, POLICY, AND PURPOSE” REFLECTS OUR STRATEGIC EVOLUTION AS A CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CDMO) IN THE PHARMACEUTICAL SECTOR. WE ARE STEADILY TRANSFORMING FROM A CONVENTIONAL SERVICE PROVIDER INTO A TRUSTED CO-INNOVATION PARTNER FOR THE GLOBAL LIFE SCIENCES INDUSTRY.

Dear Esteemed Shareholders,

This year marks a significant milestone in our journey as we continue to evolve within the dynamic global pharmaceutical CDMO landscape. Amid shifting market conditions and rising global healthcare demands, our Company has remained firmly focused on strengthening capabilities, enhancing operational excellence, and consistently delivering value to all stakeholders.

Our approach is anchored in **3** guiding principles:

Precision defines our commitment to manufacturing excellence and uncompromising product quality.

Policy enables us to effectively navigate complex and evolving regulatory environments across global markets.

Purpose drives our mission to improve patient outcomes and expand access to critical therapies worldwide.

With a strong foundation in India, we combine high-quality, cost-efficient manufacturing with deep scientific expertise and robust regulatory compliance. Our integrated capabilities allow us to support partners across the entire value chain—from early-stage development to commercial-scale production—serving both domestic and international markets with reliability and scale.

KEY HIGHLIGHTS



Strategic Evolution

Transitioning from a service provider to a trusted co-innovation partner in global life science.



Global Focus

Strengthening capabilities to meet rising global healthcare demands



Operational Excellence

Enhancing efficiency and delivering consistent value to all stakeholders.



Building Partnership

Delivering agile, scalable solutions through trust, quality, and sustainability.

THE NEW ERA OF PHARMA

Our strategic direction as a CDMO is centered on shaping the future of global healthcare. Our ambition is to become the world's most trusted partner in the journey from molecule to medicine, driven by manufacturing excellence, innovation, and a deep sense of scientific and technological purpose.

From our strong base in India, we are building a globally recognized, innovation-led organization that delivers high-quality pharmaceutical solutions designed to improve lives across markets. At the core of our approach lies a commitment to reliability, regulatory excellence, and cost-efficient manufacturing, supported by continuous investment in research, development, and advanced technologies.

We believe in fostering long-term partnerships built on trust, quality, and transparency, while maintaining a strong focus on sustainability and responsible operations. By delivering agile, integrated, and scalable CDMO solutions, we aim to accelerate the development and availability of life-changing therapies, empower our partners, and create meaningful impact on patient outcomes worldwide.

GLOBAL OUTLOOK AND INDUSTRY DEMAND

The global CDMO market is projected to reach approximately USD 400 billion by 2030, growing at a compound annual growth rate of around 9%, reflecting the increasing reliance of the pharmaceutical industry on outsourced development and manufacturing partnerships. This growth trajectory is further reinforced by rising geopolitical fragmentation, which is encouraging global pharma companies to actively de-risk and geographically diversify their supply networks across multiple regions.

In this context, India continues to strengthen its position as a preferred global pharmaceutical manufacturing hub, supported by a unique combination of scale, cost competitiveness, scientific capability, and strong adherence to global regulatory standards. Our Company is strategically aligned with this transition and is well-positioned to benefit from these evolving industry dynamics by deepening its integration into global supply chains.

Our vision remains firmly anchored in ensuring that “Made in India” becomes synonymous with “World-Class Quality.” We are steadily progressing toward becoming a trusted partner for emerging markets across Africa and the Middle East, while simultaneously and consistently meeting the stringent regulatory and quality expectations of highly regulated markets such as the United States and Europe.

PERFORMANCE FY 2025–26

We are pleased to report that the Company has achieved a significant milestone in FY 2025–26, with turnover increasing from ₹57.38 crore in FY 2024–25 to ₹89.63 crore in FY 2025–26, reflecting strong growth momentum and expanding business traction across key markets.

The Company delivered a year of meaningful progress, marked by strong financial performance and operational discipline. Net sales surged to ₹89.63 crore, reflecting a substantial year-on-year growth from ₹57.38 crore, driven by expanded market reach, enhanced customer relationships, and robust demand for our pharmaceutical products and CDMO services.

The Company's profit after tax (PAT) rose to ₹9.67 crore in FY 2025–26 compared to ₹6.79 crore in FY 2024–25, underscoring stronger profitability driven by improved margins, effective cost management, and prudent financial discipline.

We are no longer just a cost-arbitrage play. Our financial strength in 2026 is built on intellectual arbitrage—where value is created through scientific capability, process innovation, regulatory strength, and manufacturing excellence rather than cost alone. By maintaining a lean and efficient balance sheet and reinvesting in next-generation manufacturing capabilities, we are positioning the Company for sustainable long-term growth.

This strategic transformation ensures that our stakeholders benefit from the ongoing reorganization of the global pharmaceutical supply chain, where CDMOs with agility, compliance, and innovation-led capabilities will lead the future

THANK YOU

I would like to express my sincere gratitude to our esteemed shareholders, valued customers, dedicated employees, and trusted partners for their continued faith, trust, and unwavering support. Your encouragement remains the cornerstone of our progress and growth. We remain committed to building a future-ready organization that consistently delivers value and contributes meaningfully to global healthcare.

“

Together, we are not just building a company—we are building a **healthier, stronger**, and more **resilient world**.

With warm regards,

Mr. Vivek Ashokkumar Patel

Managing Director

DIN: 09130357

BUSINESS MODEL

The operational workflow of our Company is structured to ensure efficiency, quality, and reliability across all stages of pharmaceutical manufacturing. The process flow is outlined below:



ORDER GENERATION

The Company operates primarily under a B2B business model, specializing in the manufacturing of pharmaceutical products for domestic marketers and merchant exporters on a loan license and contract manufacturing basis. Our long-standing relationships, market reputation, and consistent product quality have enabled us to build a strong base of repeat clientele, ensuring business continuity and sustainability. The sales and marketing function, led by our Promoter Directors, actively engages with clients through direct interactions, strategic visits, and targeted marketing initiatives. This facilitates the generation of orders from both domestic markets and international requirements routed through merchant exporters, while also supporting new business development.

PURCHASE / RECEIPT OF RAW MATERIAL

Raw materials are sourced strictly in accordance with order specifications and contractual requirements. The procurement team identifies and engages with approved vendors and manufacturers of API, excipient and packing material. A structured vendor selection process is followed, wherein quotations are solicited, evaluated, and benchmarked based on pricing, quality, and compliance parameters. Procurement decisions are made after thorough analysis to ensure cost efficiency and adherence to quality standards. Given the nature of contract manufacturing and loan licensing, sourcing is restricted to approved vendors wherever applicable.

RAW MATERIAL QUALITY CONTROL

Upon receipt at the manufacturing facility, all raw materials undergo stringent quality inspection to ensure compliance with predefined specifications and regulatory standards. Our in-house Quality Control (QC) team is equipped with the necessary infrastructure and expertise to conduct comprehensive testing. Additionally, where mandated by clients, we collaborate with accredited third-party laboratories to provide independent quality certifications alongside our internal QC validations.

MANUFACTURING OF PHARMACEUTICAL PRODUCTS

Manufacturing operations are carried out at our facility located in Sanand, Ahmedabad, Gujarat, India which is equipped with standard and precision-driven machinery designed for efficient and scalable pharmaceutical production. Production is executed in accordance with validated formulations, approved compositions, and regulatory guidelines. The facility is progressively moving towards enhanced automation to minimize human intervention, improve process consistency, and optimize operational efficiency.

FINISHED PRODUCT QUALITY CHECK

Each batch of finished products is subjected to rigorous quality control procedures to ensure conformity with prescribed standards. Batch-wise sample testing is conducted by the Quality Control (QC) team, and only products that meet all quality parameters are approved for further processing and dispatch.

PACKAGING & LABELLING

Packaging plays a critical role in maintaining product integrity and regulatory compliance. Currently, packaging operations are carried out with strict supervision to ensure accuracy. Primary packaging includes mandatory product disclosures such as manufacturing date, expiry date, batch number, and Maximum Retail Price (MRP). The primary packs are subsequently consolidated into secondary or bulk packaging as per client specifications.

SUPPLY TO MARKETERS

Post-packaging, finished goods are stored in dedicated storage areas within the manufacturing facility under appropriate conditions to preserve product quality. Distribution is executed based on client instructions, ensuring timely and secure delivery to specified destinations. The Company utilizes reliable third-party logistics providers to manage transportation efficiently.



INTEGRATED STRATEGY

The Company has adopted an integrated growth strategy to capitalize on opportunities in the global pharmaceutical sector. Through a combination of operational excellence, product diversification, and competitive positioning, the Company aims to strengthen its market presence and enhance long-term shareholder value. Its strategic focus remains on expanding into regulated and semi-regulated markets while maintaining high standards of quality, compliance, and efficiency.



VISIONARY LEADERSHIP

The Company is led by a highly accomplished technocrat and an experienced management team with deep industry expertise. The Promoters play a pivotal role in driving both strategic direction and day-to-day operations. Their entrepreneurial vision, combined with strong leadership capabilities, has been instrumental in the Company's sustained growth and execution of strategic initiatives. The organization also recognizes that a skilled and motivated workforce is essential to maintaining a competitive advantage.



INTEGRATED BUSINESS MODEL

Our integrated and diversified business model provides agility and resilience to effectively respond to evolving market dynamics. This approach enables us to consistently deliver precision, quality, and value to our partners and customers while supporting sustainable business growth.



WIDE RANGE OF PRODUCTS

The Company is committed to delivering high-quality healthcare products that meet international standards and trade partner's expectations. With a growing and diversified product portfolio, we serve a broad customer base across both domestic and international markets. Continuous expansion of our product offerings has strengthened our reputation as a reliable global pharmaceutical manufacturer.



STATE-OF-THE-ART MANUFACTURING

Our manufacturing facility in Ahmedabad, Gujarat, India reflects our strong commitment to quality, safety, and environmental responsibility. Equipped with advanced infrastructure and robust production capabilities, the facility enables the consistent manufacture of high-quality pharmaceutical products at scale.



LONG-STANDING RELATIONSHIP WITH CLIENTS AND SUPPLIERS

We place significant emphasis on building and maintaining long-term relationships with our clients and suppliers. Our sales and marketing functions are led by experienced promoters / Directors, who bring extensive industry knowledge and contribute to strengthening business partnerships and expanding market reach.



QUALITY STANDARDS

Quality remains central to our operations and success. We are committed to continuous improvement across all stages of the production process. Our adherence to internationally recognized standards is demonstrated through certifications such as ISO 9001:2015 for quality management systems and ISO 14001:2015 for environmental management systems. This commitment ensures the delivery of globally competitive products to our customers.



ROBUST GLOBAL PRESENCE

The Company has established a strong domestic presence in India, complemented by a growing international footprint with exports to over 30+ countries across Africa, Southeast Asia, and Latin America. This expanding global reach reflects increasing acceptance of our products in international markets and supports our strategy of geographic diversification.



LEGACY BUSINESS PROCESS & MANAGEMENT

Our operations are anchored in well-established and continuously evolving business processes, supported by an efficient and responsive supply chain network. We have cultivated long-standing relationships with key stakeholders, including customers, suppliers, and partners, built on trust, reliability, and consistent performance. Strengthened by strong organizational credibility and market goodwill, these capabilities enhance our ability to adapt to dynamic market conditions, ensure operational resilience, and deliver consistent and efficient execution across all aspects of our business.



CONSISTENT FINANCIAL GROWTH

The Company has demonstrated a sustained track record of financial performance, driven by consistent revenue growth, stable and healthy operating margins, and a disciplined approach to capital allocation. Our ability to effectively manage costs, optimize resource utilization, and enhance operational efficiencies has contributed to improved profitability over time. This strong financial foundation reflects the resilience and scalability of our operating model, while reinforcing our commitment to delivering sustainable growth and long-term value creation for our stakeholders.

VALUE CREATION APPROACH



STRATEGIC OVERVIEW

As a Contract Development and Manufacturing Organization (CDMO), the Company's strategy is centered on delivering integrated, end-to-end solutions across the pharmaceutical value chain. We are strategically focused on high-growth therapeutic segments characterized by significant unmet medical needs. This approach is underpinned by four core pillars: scientific excellence, accelerated speed-to-market, uncompromising quality standards, and a partner-centric operating model that aligns our success with that of our clients.



GEOGRAPHIC FOOTPRINTS

To effectively serve an increasingly globalized pharmaceutical industry, the Company has strategically expanded and optimized its geographic footprint. We are focused on securing regulatory approvals for our facilities and products across key international markets, enabling direct exports and seamless global market access. This localized and compliant presence mitigates supply chain risks, strengthens real-time collaboration, and offers our partners a diversified regulatory advantage. Going forward, we aim to drive growth by expanding product registrations and entering new geographies.



CAPACITY EXPANSION

In response to the growing global trend toward pharmaceutical outsourcing the Company continues to invest in expanding its development and manufacturing capacities. We are executing a robust, multi-year capacity expansion program designed to enhance scalability, flexibility, and operational efficiency. These investments enable us to support a broad spectrum of products and modalities—from early-stage development through to commercial-scale manufacturing—while maintaining best-in-class quality and compliance standards.



INNOVATION & INVESTMENTS

Innovation remains a cornerstone of the Company's value creation framework. During the year, we further strengthened our capabilities in emerging modalities and advanced process technologies. Sustained investments in research and development, analytical sciences, and regulatory expertise have enabled the creation of proprietary platforms and intellectual property, enhancing our differentiation in the market. Our portfolio breadth now encompasses end-to-end capabilities, from advanced analytical testing to global supply chain management.



LEVERAGING OUR MARKET SKILLS & RELATIONSHIP

The Company's strength lies in the depth of its industry expertise and long-standing relationships. We position ourselves not merely as a service provider, but as a strategic partner to our clients. By aligning our internal capabilities and strategic priorities with the evolving needs of the pharmaceutical sector, we ensure that our offerings remain relevant and forward-looking. Through a collaborative, client-centric approach, we deliver tailored solutions that build trust, encourage repeat engagements, and foster enduring partnerships.



CUSTOMER SATISFACTION

Customer satisfaction remains a central focus, evidenced by strong client retention, repeat business, and a robust pipeline of contracted programs. While continuing to nurture deep relationships with key customers, the Company has actively diversified its client base across geographies and therapeutic segments. This approach enhances revenue stability and mitigates concentration risk. Our performance is further validated by consistently high ratings in customer satisfaction assessments and long standing collaborations with leading global pharmaceutical innovators.



RISK ASSESSMENT AND SENSITIVITY ANALYSIS

The Company adopts a disciplined and proactive approach to risk management, with continuous identification and monitoring of key risks, including client concentration, regulatory compliance, pricing pressures, and pipeline variability. Sensitivity analyses are conducted on critical assumptions such as growth rates, operating margins, and discount factors to evaluate business resilience under different scenarios. This ensures robustness in strategic decision-making and supports sustainable value creation over the long term.



FROM INDIAN ROOTS TO GLOBAL REACH

The global pharmaceutical industry is undergoing a profound structural transformation. Supply chain resilience, regulatory compliance, innovation-led manufacturing, and geographic diversification have become strategic imperatives for pharmaceutical companies worldwide. Against this evolving landscape, India has strengthened its position as one of the world's most trusted pharmaceutical manufacturing destinations, supported by decades of investment in scientific talent, world-class quality systems, and globally compliant manufacturing infrastructure.

As multinational pharmaceutical and biotechnology companies seek to diversify manufacturing beyond traditional sourcing geographies, India is emerging as a preferred long-term partner for research, development, and commercial manufacturing. The country's expanding capabilities across the pharmaceutical value chain position it at the forefront of the next phase of global pharmaceutical outsourcing.

INDIA'S PHARMACEUTICAL EVOLUTION

India's pharmaceutical sector has evolved from serving primarily domestic healthcare needs into a globally integrated ecosystem encompassing research and development, process chemistry, active pharmaceutical ingredients (APIs), finished formulations, biologics, vaccines, and Contract Development and Manufacturing Organisations (CDMOs).

Today, India supplies affordable, high-quality medicines to more than 200 countries, serving highly regulated markets including the United States, Europe, Japan, Australia, and Canada. The country's global reputation has been built on four enduring strengths:



Manufacturing Scale



Regulatory Compliance



Cost-Efficient Innovation



Scientific Excellence

This transformation has positioned India as a critical contributor to global healthcare while reinforcing its role as a reliable manufacturing partner for leading pharmaceutical innovators.

INDIA'S GLOBAL PHARMACEUTICAL LEADERSHIP

India continues to play an indispensable role in the global pharmaceutical industry and remains among the world's largest producers of medicines.

KEY INDICATORS	LATEST POSITION
Domestic pharmaceutical market	~USD 60 billion
Pharmaceutical Exports (FY 2024-25)	USD 30.47 billion
Export destinations	200+ countries
Share of global generic medicines	~20% by volume
Share of global vaccine supply	~60%
USFDA-approved manufacturing facilities outside the United State	650+
Share of global pharmaceutical market	~5.7% by value

India is the world's third-largest pharmaceutical producer by volume and the eleventh largest by value. Indian manufacturers account for nearly one-fifth of global generic medicine supplies while playing a significant role in the production of vaccines, antiretrovirals, and essential medicines for both developed and emerging markets.

The country's pharmaceutical exports have expanded nearly sixteen-fold since FY2000-01, reflecting sustained international confidence in India's manufacturing capabilities, regulatory standards, and quality systems.

INDIA'S EXPANDING CDMO OPPORTUNITY

The global pharmaceutical outsourcing model continues to gain momentum as innovator companies increasingly partner with specialized manufacturers to accelerate product development, improve operational flexibility, and optimize capital allocation.

MARKET OVERVIEW

MARKET	ESTIMATED SIZE
Global Pharmaceutical CDMO Market	USD 170–220 billion
Indian CDMO Market (2025)	USD 8–9 billion

Although India currently represents only around 4–5% of the global CDMO market, it is among the fastest-growing outsourcing destinations worldwide. The industry is expected to sustain high-single-digit to low-double-digit growth over the medium term, supported by increasing global outsourcing demand and expanding capabilities in complex manufacturing technologies.

Growth is being driven by rising demand for:

- Small molecules
- Complex APIs
- Peptides
- Biologics
- Antibody-drug conjugates (ADCs)
- High-potency APIs (HPAPIs)
- Sterile injectables
- Complex formulations

This presents significant headroom for expansion as India continues to move up the pharmaceutical value chain.

WHY GLOBAL PHARMACEUTICAL COMPANIES CONTINUE TO CHOOSE INDIA

India's emergence as a preferred pharmaceutical outsourcing destination is supported by multiple structural advantages that extend beyond cost competitiveness.



SCIENTIFIC AND TECHNICAL EXCELLENCE

India possesses one of the world's largest pools of pharmaceutical scientists, synthetic chemists, formulation specialists, process engineers, and regulatory professionals. This enables comprehensive end-to-end development capabilities, from early-stage research through commercial-scale manufacturing.



GLOBAL REGULATORY COMPLIANCE

India hosts the highest number of USFDA-approved pharmaceutical manufacturing facilities outside the United States. Manufacturing sites are regularly inspected by leading international regulatory agencies, including the USFDA, EMA, MHRA, PMDA, TGA, and Health Canada, reinforcing India's reputation for quality, reliability, and compliance.



INTEGRATED MANUFACTURING ECOSYSTEM

Strong process chemistry expertise, integrated supply chains, engineering capabilities, and large-scale manufacturing infrastructure enable Indian companies to deliver globally competitive solutions while maintaining rigorous quality standards.



CHINA+1 SUPPLY CHAIN DIVERSIFICATION

Evolving geopolitical dynamics and the increasing emphasis on supply chain resilience have accelerated global efforts to diversify manufacturing networks beyond traditional sourcing locations. India has emerged as a key beneficiary of this strategic shift, offering multinational pharmaceutical companies a trusted and scalable alternative for both development and commercial manufacturing.

Recent industry trends also suggest that increased regulatory scrutiny affecting certain manufacturing facilities in other geographies has further strengthened customer engagement with Indian CDMOs.

FROM COST ADVANTAGE TO CAPABILITY ADVANTAGE

India's pharmaceutical outsourcing industry has undergone a significant transformation over the past decade. While cost competitiveness remains an important advantage, the country's value proposition today is increasingly defined by scientific capability, technological expertise, quality excellence, and innovation.

Global pharmaceutical and biotechnology companies now partner with Indian CDMOs not only for manufacturing efficiency but also for their ability to support the complete product life-cycle.

Leading Indian CDMOs are expected to provide:

- Accelerated product development and reduced time-to-market
- Advanced process chemistry and complex molecule expertise
- Seamless scale-up from laboratory development to commercial manufacturing.
- Robust regulatory compliance across major global markets
- Reliable, resilient, and diversified supply chains
- Comprehensive life-cycle management support

This evolution reflects India's transition from being primarily a low-cost manufacturing destination to becoming a strategic innovation and development partner for global pharmaceutical companies.

THE GLOBAL CDMO MARKET: A LONG-TERM STRUCTURAL GROWTH OPPORTUNITY

The pharmaceutical outsourcing model continues to evolve from transactional manufacturing relationships toward long-term strategic partnerships.

Innovator pharmaceutical companies are increasingly outsourcing a broader range of activities, including

- Process development
- Analytical development
- Formulation development
- Clinical trial manufacturing
- Commercial manufacturing
- Technology transfer
- Life-cycle management

Industry estimates from leading consulting and market research organizations including McKinsey, Boston Consulting Group (BCG), Grand View Research, and Frost & Sullivan—value the global pharmaceutical CDMO market at approximately USD 170–220 billion, with sustained long-term growth expected over the coming decade.

Key growth drivers include:

- Increased pharmaceutical outsourcing
- Expansion of biologics and biosimilars
- Precision medicine
- Specialty therapies
- Accelerated drug development timelines
- Growing demand for complex manufacturing technologies

Although India currently accounts for only a modest share of the global CDMO market, its combination of scientific talent, manufacturing excellence, regulatory credibility, and cost competitiveness provides significant opportunities to increase its global market share.

SUSTAINABILITY, COMPLIANCE AND TRUST

As pharmaceutical supply chains become increasingly global and complex, sustainability, governance, and operational excellence are emerging as key differentiators in outsourcing decisions.

Global pharmaceutical companies increasingly evaluate manufacturing partners not only on quality, cost, and delivery performance but also on:

- Environmental stewardship
- Carbon footprint reduction
- Water conservation
- Responsible sourcing
- Cybersecurity
- Data integrity
- ESG performance
- Corporate governance

Indian pharmaceutical manufacturers are responding pro-actively through investments in digital manufacturing technologies, automation, renewable energy, solvent recovery systems, zero-liquid-discharge facilities, waste minimization initiatives, and advanced quality management systems.

These investments strengthen regulatory compliance while supporting customers' sustainability objectives and reinforcing long-term business resilience.

LOOK AHEAD

The future of pharmaceutical outsourcing will increasingly be shaped by scientific innovation, quality excellence, regulatory reliability, and trusted strategic partnerships.

India is well positioned to benefit from this transformation. Its expanding scientific capabilities, globally compliant manufacturing infrastructure, skilled workforce, and proven execution across complex pharmaceutical modalities have established the country as a preferred destination for contract development and manufacturing.

For differentiated CDMO companies, the opportunity extends far beyond manufacturing. It lies in partnering with global innovators to accelerate the development, scale-up, and commercial production of the next generation of medicines—transforming **Indian roots into global reach** while contributing meaningfully to better healthcare outcomes worldwide.





ESG HIGHLIGHTS – RESPONSIBLE MANUFACTURING FOR A SUSTAINABLE FUTURE

At Accretion Pharmaceuticals Limited, sustainability is integrated into our manufacturing philosophy and long-term growth strategy. Through responsible resource management, operational efficiency, and continuous process improvement, we strive to create value for stakeholders while minimizing our environmental footprint. We balance business growth with environmental responsibility, creating sustainable value for customers, employees, communities, and future generations.

ENVIRONMENTAL STEWARDSHIP & GREEN MANUFACTURING

We remain committed to responsible environmental stewardship through systematic resource optimization, low-carbon infrastructure investments, and compliance-driven operations.



OPERATIONAL EFFICIENCY & INFRASTRUCTURE EXCELLENCE

- **Advanced Manufacturing Infrastructure:** Deployment of modern, energy efficient manufacturing equipment designed to optimize power consumption and elevate operational productivity.
- **Climate & Resource Control:** Integration of advanced HVAC systems and closed-loop water distribution networks explicitly engineered to optimize energy and water management.
- **Digital Integration:** Actively promoting paperless documentation and digital process integration to significantly reduce material consumption while enhancing operational transparency.



COMPLIANCE & WASTE MANAGEMENT



STANDARDIZED SYSTEM

Proudly maintaining an **Environmental Management System certified to ISO 14001:2015 standards**, ensuring standard-compliant, sustainable manufacturing practices.



RESOURCE CONSERVATIONS

Enforcement of optimized water utilization and strict, controlled waste handling processes to support comprehensive resource conservation and adhere to rigorous environmental compliance guidelines.

OPTIMIZED LOGISTICS & SUPPLY CHAIN

Minimizing our environmental impact requires look-ahead planning from the production floor all the way through global delivery.



REDUCING TRANSPORTATION IMPACT

Streamlined logistics planning and highly optimized distribution networks ensure a minimal environmental footprint by curtailing fuel consumption and transportation-related emissions.



GLOBAL EFFICIENCY

Maintaining a keen focus on maximizing supply chain efficiency while executing reliable, safe product deliveries across international pharmaceutical channels.

SOCIAL COMMITMENT & ETHICAL GOVERNANCE

People remain at the center of our sustainability journey. We are dedicated to fostering a safe, inclusive, and growth-oriented workplace while simultaneously improving global healthcare accessibility.

WORKFORCE DEVELOPMENT & WELL-BEING

- **Future-Ready Talent:** Building a skilled, motivated, and progressive workforce by facilitating continuous learning and comprehensive professional development programs.
- **Occupational Health:** Sustaining excellent standards of employee safety, workplace hygiene, and occupational health practices across our entire state-of-the-art facility.
- **Culture of Innovation:** Nurturing deep employee engagement, cross functional collaboration, and an operating mind-set built heavily on accountability and trust.

ETHICAL & INCLUSIVE CULTURE

- **Uncompromising Integrity:** Rigidly enforcing ethical business conduct, core corporate integrity, and meticulous regulatory compliance across 100% of our operations.

- **Diversity & Inclusion:** Promoting equal opportunities, mutual respect, and diversity in our workspace to unlock multifaceted solutions for global problems.
- **Stakeholder Trust:** Strengthening long-standing partnerships through open transparency and responsible corporate governance practices.

DRIVING GLOBAL HEALTHCARE IMPACT

As a growing, high-performance **Contract Development and Manufacturing Organization (CDMO)**, Accretion Pharmaceuticals Limited leverages its capabilities to drive meaningful change in global therapeutics.

CORE CAPABILITY	STRATEGIC SCOPE & STANDARDS	IMPACT VALUE
Global Formulation Supply	Direct/indirect presence across 30+ countries	Enhancing world access to high-quality, generic & branded treatments.
CDMO Excellence	World-class machinery meeting international quality benchmarks	Assisting international partners with reliable, robust supply chains.
Healthcare Accessibility	Cost-effective manufacturing methodologies	Ensuring affordable, high-quality pharmaceutical products reach those in need.



CREATING VALUE THROUGH SOCIAL AND RELATIONSHIP CAPITAL

At Accretion Pharmaceuticals Limited, we view Corporate Social Responsibility (CSR) not as a siloed regulatory obligation, but as an indispensable cornerstone of our corporate ethos. We firmly believe that the long-term sustainability and commercial vitality of our enterprise are deeply intertwined with the well-being, trust, and resilience of the societies in which we operate. In an era where corporate accountability is paramount, our focus remains steadfast on cultivating meaningful Social and Relationship Capital. This capital represents the networks of trust, shared values, and mutual respect that we actively develop with our communities, healthcare partners, and statutory bodies.

Our overarching CSR strategy deliberately transcends the basic mandates of statutory compliance. Instead, it is built around a proactive framework aimed at improving the foundational pillars of public health: healthcare accessibility, economic affordability, and the localized availability of quality medical treatments. By strategically deploying our resources, we aim to bridge historical disparities in public health, champion preventive care, and substantially upgrade public health infrastructure. We accomplish this through direct initiatives as well as highly collaborative, strategic partnerships with reputed non-governmental bodies and public foundations.

To ensure transparency, structural integrity, and maximum community impact, all social capital programs at Accretion Pharmaceuticals Limited are governed by a robust, board-level oversight mechanism. Our framework is meticulously aligned with the provisions of Schedule VII of the Companies Act, 2013, providing a legally compliant and socially auditable baseline for all financial outlays. The CSR Committee of the Board rigorously evaluates proposed interventions, ensuring that every rupee spent is directed toward sustainable, measurable, and impactful healthcare interventions.

As part of this commitment, during FY 2025–26, **the Company contributed ₹12,11,111 towards the construction of a new building by the Lilavati Foundation in Gandhinagar, Gujarat, India.** This initiative supports the development of healthcare-related infrastructure and reflects our commitment to strengthening community resources that can contribute to improved access to quality healthcare services. Through such initiatives, the Company seeks to support social infrastructure development and contribute to broader community welfare. We believe that investments in healthcare infrastructure play a vital role in enhancing the quality of life and promoting long-term social well-being.

Our efforts are guided by the principle that responsible corporate growth must be accompanied by meaningful contributions to society. By collaborating with institutions and organizations working toward community development, we aim to create lasting positive outcomes for stakeholders while reinforcing trust, goodwill, and sustainable relationships.

Moving forward, Accretion Pharmaceuticals Limited remains passionately committed to the philosophy that sustainable corporate growth must always go hand-in-hand with societal progression. We recognize that the challenges facing public health are constantly evolving, requiring a corporate response that is both agile and deeply empathetic.

We will continue to actively seek out high-impact projects, strengthen our relationships with local communities, and invest in sustainable health initiatives. By continuing to build our Social and Relationship Capital, we ensure that our business growth remains a powerful force for good—consistently delivering long-term, holistic value for our shareholders, our partners, and society as a whole.

“

We firmly believe that the long-term **sustainability and commercial** vitality of our enterprise are deeply intertwined with the **well-being, trust, and resilience** of the societies in which we operate.



STATUTORY REPORTS

MANAGEMENT DISCUSSION AND ANALYSIS

FOR THE FINANCIAL YEAR ENDED 31 MARCH, 2026

CAUTIONARY STATEMENT

Forward looking statement

Statements in this Management Discussion and Analysis of Financial Condition and Results of Operations of the Company describing the Company's objectives, expectations or predictions may be forward looking within the meaning of applicable securities laws and regulations. Forward looking statements are based on certain assumptions and expectations of future events.

The Company cannot guarantee that these assumptions and expectations are accurate or will be realized. The Company assumes no responsibility to publicly amend, modify or revise forward looking statements, on the basis of any subsequent developments, information or events. Actual results may differ materially from those expressed in the statement. Important factors that could influence the Company's operations include changes in government regulations, tax laws, economic developments within the country and such other factors globally.

The financial statements are prepared as per the Accounting Standard guidelines and comply with the Accounting Standards notified under Section 129 of the Companies Act, 2013 read with the Companies (Accounting Standards) Rules, 2015. The management of Accretion Pharmaceuticals Limited has used estimates and judgments relating to the financial statements on a prudent and reasonable basis, in order that the financial statements, reflect in a true and fair manner, the state of affairs and profit for the year.

The following discussions on our financial condition and result of operations should be read together with our audited financial statements and the notes to these statements included in the annual report. Unless otherwise specified or the context otherwise requires, all references herein to "we", "us", "our", "the Company", "Accretion", "ACCPL" are to Accretion Pharmaceuticals Limited.

GLOBAL ECONOMY

The global economy demonstrated notable resilience during FY 2025-26, maintaining steady growth despite significant headwinds from trade policy uncertainty and geopolitical tensions. According to the IMF January 2026 World Economic Outlook Update – titled 'Global Economy: Steady amid Divergent Forces' – global real GDP growth held steady at 3.3% in 2025, matching the 2024 outturn and representing an upward revision of 0.2 percentage points from the October 2025 WEO projection. This positive revision was driven by front-loading of trade activity prior to tariff implementation, improved financial conditions, fiscal stimulus in select key economies, and the structural resilience of domestic demand across major markets. Headline global inflation continued its disinflationary trajectory, easing to approximately 4.1% in 2025 from 5.8% in 2024, supported by softer commodity prices, disciplined monetary policy, and improved supply chain conditions. Advanced economy inflation converged towards central bank targets at approximately 2.5% in 2025.



World trade demonstrated stronger-than-anticipated performance through FY 2025-26. According to the WTO's Q3 2025 Trade Monitor, actual merchandise trade volume grew approximately 4.5% year-on-year in the first nine months of 2025, significantly outperforming the April 2025 baseline forecast of -0.2%. The total value of world merchandise exports reached US\$ 24.43 trillion in 2024, while commercial services exports climbed to US\$ 8.69 trillion (+9% YoY). The escalating tariff environment introduced by the US Administration – including a 10% global baseline tariff in April 2025, sector-specific measures through the year, and a 100% tariff on branded pharmaceutical imports effective October 2025 – created significant uncertainty and front-loading effects. However, trade proved resilient through calendar 2025, with WTO data recording a record high in the dollar value of world trade volume in Q3 2025 even as volumes stabilised.

Regional performance remained characteristically divergent. Emerging and Developing Asia outperformed strongly at 5.4% growth in 2025, led by India at an exceptional 7.3%. The United States expanded at 2.1%, constrained by trade policy uncertainty and the lagged effects of prior monetary tightening, while the Euro Area's recovery remained subdued at 1.4%. Sub-Saharan Africa demonstrated resilience at 4.4%, and Middle East and Central Asia accelerated to 3.7%, supported by energy revenues and strategic investment.

Source: <https://www.imf.org/en/publications/weo/issues/2026/01/19/world-economic-outlook-update-january-2026> | <https://www.imf.org/en/publications/weo/issues/2025/04/22/world-economic-outlook-april-2025> | <https://www.imf.org/en/publications/weo/issues/2025/10/14/world-economic-outlook-october-2025>


Source: https://www.wto.org/english/news_e/news26_e/stat_28jan26_271_e.htm | https://www.wto.org/english/news_e/news25_e/tfore_08aug25_e.htm | https://www.wto.org/english/res_e/publications_e/trade_outlook25_e.htm

OUTLOOK

The global economy is projected to sustain growth at 3.3% in 2026, matching 2025 estimates and representing an upward revision of 0.2 percentage points from October 2025 projections. This stability reflects structural economic resilience even as trade policy uncertainty, geopolitical conflicts, and potential tariff escalation remain significant downside risks. Global inflation is expected to ease further to 3.8% in 2026, approaching targets across advanced economies. World trade growth is projected to moderate towards 0.5-1.8% in 2026 as front-loading effects dissipate – reinforcing the importance of supply chain diversification and domestic market depth for pharmaceutical exporters. Central bank rate easing cycles are expected to support investment and consumption in 2026, providing a measured tailwind to global pharmaceutical demand.

Source: <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2233792®=3&lang=1> | https://www.mospi.gov.in/uploads/latestReleases/latest_release_1767781372753_1380ce82-f5a5-440d-99e6-e6b35af0deb5_GDP_Press_Note_on_FAE_2025-26.pdf | <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2212087®=3&lang=2>

GLOBAL ECONOMIC GROWTH PROJECTIONS — 2024 TO 2026 (REAL GDP GROWTH RATE, % CHANGE — IMF WORLD ECONOMIC OUTLOOK UPDATE, JANUARY 2026)



Source: IMF World Economic Outlook Update, January 2026 | <https://www.imf.org/en/publications/weo/issues/2026/01/19/world-economic-outl...> | WTO Global Trade Statistics | https://www.wto.org/english/news_e/news26_e/stat_28jan26_271_e.htm

INDIAN ECONOMY

India continued to consolidate its position as the world's fastest-growing major economy during FY 2025-26. The Second Advance Estimate released by the Ministry of Statistics and Programme Implementation (MoSPI) in February 2026 estimated India's real GDP growth at 7.6% under the revised base year (2022-23), with quarterly growth rates of 7.8% in Q1, 8.4% in Q2, and 7.8% in Q3 FY 2025-26 – reflecting broad based and sustained economic momentum. Under the earlier base year (2011-12), the First Advance Estimate placed growth at 7.4%, with real GDP at ₹201.90 lac crore. The RBI had progressively upgraded its growth projection during the year to 7.3%, acknowledging the economy's structural resilience. The IMF, in its January 2026 WEO, projected India's fiscal-year GDP growth at 7.3% for FY25 and 6.4% for FY26 (under IMF methodology), making India the fastest-growing G20 economy by a significant margin.

A landmark macroeconomic achievement of FY 2025-26 was the dramatic moderation of inflation to historically low levels. The Consumer Price Index (CPI) inflation for the full year is estimated by the RBI at approximately 2.1% – well below the 4% midpoint target, representing the lowest annual average in several years. Monthly CPI inflation declined sharply through the year, reaching 0.25% in October 2025 (a record low under the then-prevailing 2012=100 base year series) before moderating to 3.21% in February 2026 under the new 2024=100 base year. This benign inflationary environment enabled the Monetary Policy Committee to reduce the repo rate in calibrated steps, easing financial conditions and supporting credit growth, private consumption and capital investment across the economy.

On the fiscal front, the Government maintained disciplined macroeconomic management, holding the fiscal deficit at 4.4% of GDP (₹15.69 lac crore) – precisely on target with the Budget Estimate, as confirmed by the Revised Estimate in the Union Budget 2026-27 presented on February 1, 2026. India's external sector remained robust, with total exports (merchandise and services) reaching USD 790.86 billion in April-February FY 2025-26, growing 5.79% year-on-year, and on track to cross the Commerce Ministry's target of USD 850 billion for the full fiscal year. Gross FDI inflows maintained strong momentum at USD 73.31 billion in April-December 2025 (+16% YoY), and India's forex reserves peaked at an all-time high of USD 728.5 billion in late February 2026.

Source: <https://ddnews.gov.in/en/rbi-projects-inflation-at-2-1-in-fy26-revises-fy27-growth-outlook-upward/> | <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2178447®=3&lang=2> | <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2238889®=3&lang=2> | https://www.mospi.gov.in/uploads/latestReleases/latest_release_1770891893893_6b458c0a-c327-4fef-a554-41131ea67273_Press_Release_of_CPI_for_Jan26.pdf


Source: <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2098352®=3&lang=2> | <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221458®=3&lang=2> | <https://ddnews.gov.in/en/indias-exports-grow-5-79-to-790-86-billion-between-april-2025-february-2026/> | <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2244385®=3&lang=2> | <https://www.ibef.org/economy/foreign-direct-investment> | https://www.business-standard.com/markets/capital-market-news/india-s-forex-reserves-fall-around-30-billion-in-march-126040600313_1.html

OUTLOOK

India is positioned for sustained strong growth in the coming years, supported by macro stability, manageable inflation, resilient consumption, and an accelerating private capex cycle. The IMF projects India's growth at approximately 6.4% in FY 2026-27 under its methodology, while domestic projections from RBI and the Finance Ministry point to sustained 7%+ growth. Key enablers include continued public infrastructure investment, deepening digital economy penetration, expanding health insurance coverage under Ayushman Bharat, and India's growing role as a preferred manufacturing destination under China+1 supply chain strategies. Maintaining counter-cyclical fiscal discipline, accelerating credit access for MSMEs, and continuing export diversification will be essential for sustained outperformance. Geopolitical tensions, global commodity price volatility, and any further escalation of trade protectionism remain the primary external risks to India's growth trajectory.

Source: <https://www.grandviewresearch.com/industry-analysis/pharmaceutical-market-report> | <https://www.fortunebusinessinsights.com/impact-of-covid-19-on-pharmaceuticals-market-102685>

INDIA GDP GROWTH RATE — FY 2022-23 TO FY 2025-26 (Real GDP Growth Rate, % YoY — MoSPI Advance Estimates)




Source: MoSPI Second Advance Estimate, February 2026 | <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2233792>

MoSPI First Advance Estimate | <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2212087>

YEAR-ON-YEAR CPI INFLATION RATE — FY 2025-26

(Monthly CPI Inflation %, Year-on-Year — Consumer Price Index, India)



Source: MoSPI CPI Press Releases

<https://www.pib.gov.in/PressReleasePage.aspx?PRID=2178447>

<https://www.pib.gov.in/PressReleasePage.aspx?PRID=2202940>

<https://www.pib.gov.in/PressReleasePage.aspx?PRID=2238889>

<https://ddnews.gov.in/en/rbi-projects-inflation-at-2-1-in-fy26-revises-fy27-g...>




GLOBAL PHARMA INDUSTRY OVERVIEW

The global pharmaceutical industry remains one of the world's most economically significant and structurally resilient sectors, underpinned by fundamental and non discretionary demand drivers: an ageing global population, rising prevalence of chronic and lifestyle-related diseases, expanding healthcare access in emerging markets, and continuous scientific innovation. According to Grand View Research's 2025 analysis, the global pharmaceutical market was valued at approximately USD 1,645.75 billion in 2024 and is projected to reach USD 2,776.74 billion by 2033, growing at a compound annual growth rate (CAGR) of 6.08%. Alternative sizing from Fortune Business Insights places the 2025 base at USD 1,999.24 billion, projecting expansion to USD 4,035.35 billion by 2034 at a CAGR of 8.19%. Across methodologies, the consensus supports a substantial multi-trillion-dollar market growing at a sustained mid-to-high single-digit CAGR through the end of the decade.

MARKET SIZE & GROWTH PROJECTIONS


GRAND VIEW RESEARCH (2025)

Global Pharmaceutical Market



FORTUNE BUSINESS INSIGHTS (2025)

Global Pharmaceutical Market



PHARMACEUTICAL INDUSTRY PRODUCT CLASSIFICATION

The global pharmaceutical ecosystem comprises several distinct and interrelated product segments, each with unique manufacturing, regulatory, and market dynamics:

Source: <https://www.grandviewresearch.com/horizon/outlook/pharmaceuticals-market-size/global> | <https://www.grandviewresearch.com/industry-analysis/pharmaceutical-market-report>

- **Active Pharmaceutical Ingredients (API):** The core chemical compounds responsible for the therapeutic effect in medicines. India is among the world's top three API manufacturers globally, with the PLI scheme accelerating domestic API self-sufficiency.
- **Formulations (Drug Products):** Finished dosage forms combining APIs with excipients, including tablets, capsules, injectables, ointments and oral liquids. This segment encompasses the primary manufacturing scope of Accretion Pharmaceuticals Limited.
- **Contract Development and Manufacturing Organisations (CDMOs):** Service providers offering outsourced drug development, manufacturing, and regulatory support. This is the highest-growth structural segment within the pharmaceutical industry.
- **Biologics and Biosimilars:** Complex products derived from living organisms, including vaccines, monoclonal antibodies, cell and gene therapies. The fastest-growing pharmaceutical category globally, with a CAGR of 7.17%.
- **Over-the-Counter (OTC) Products:** Medicines available without prescription for common ailments, supported by the USD 6.3 global wellness economy and growing consumer health awareness.
- **Nutraceuticals and Dietary Supplements:** Products providing nutritional and preventive health benefits, experiencing accelerating demand across both developed and emerging markets.

PERFORMANCE IN FY 2024-25

In FY 2024-25, global pharmaceutical demand continued its steady upward trajectory, driven by growing incidence of chronic diseases, an expanding elderly population, and wider healthcare access in emerging markets. Specialty drugs, biologics, and treatments for oncology, diabetes, autoimmune disorders and infectious diseases experienced particularly strong volume growth. Conventional (small molecule) drugs continued to hold the largest market share at approximately 54.24% in 2025, while biologics and biosimilars – growing at a CAGR of 7.17% – rapidly expanded their share. Generic drugs, growing at a CAGR of 7.2%, gained further traction as healthcare systems globally prioritised cost containment. The oncology segment represented 17.62% of the total market by disease indication. Obesity therapeutics emerged as the fastest-growing sub-segment, driven by demand for GLP-1 agonists, with a CAGR of 12.73%.

Source: <https://foleyhoag.com/news-and-insights/publications/alerts-and-updates/2025/september/100-us-tariff-on-branded-patented-drugs-effective-october-1-2025/> | <https://www.ropesgray.com/en/insights/alerts/2026/04/100-on-brand-us-imposes-new-tariffs-and-key-exemptions-on-patented-pharmaceuticals> | <https://www.delveinsight.com/blog/us-tariffs-2025-impact-healthcare-pharma-strategies> | <https://pmc.ncbi.nlm.nih.gov/articles/PMC12123191/>

CHALLENGES AND HEADWINDS

Despite fundamental resilience, FY 2025-26 brought substantial headwinds to the global pharmaceutical sector. The most consequential development was the escalation of US pharmaceutical trade policy: beginning with a 10% global baseline tariff in April 2025, the US Administration progressively tightened measures throughout the year. A Section 232 investigation into pharmaceutical imports was launched in April 2025, culminating in a 100% ad valorem tariff on branded and patented pharmaceutical imports effective October 1, 2025.

A formal presidential proclamation in April 2026 codified this framework, while generics were notably exempted – a critical distinction that directly benefits Indian generic and CDMO manufacturers. The US pharmaceutical trade deficit stood at USD 139 billion in 2024, and major global companies collectively committed over USD 265 billion in US manufacturing investments in response. Supply chain disruptions, escalating R&D costs, prolonged regulatory approval timelines, and pricing pressures from governments and payers further tested sector profitability across the year.

GLOBAL PHARMACEUTICALS MARKET SIZE (Market Value in US\$ Billion – 2023, 2024 and 2033 Projection)

YEAR	Market Size (US\$ Billion)	CAGR / Remarks
2023	USD 1,562.0 Bn	Base Period
2024	USD 1,645.8 Bn	~5.4% growth YoY (Grand View Research)
2025 (Estimated)	USD 1,738.0 Bn	~5.6% growth YoY
2033 (Projected)	USD 2,776.7 Bn	CAGR of 6.08% (2026–2033)

Source: Grand View Research, 2025

<https://www.grandviewresearch.com/industry-analysis/pharmaceutical-market-report>

Fortune Business Insights

<https://www.fortunebusinessinsights.com/impact-of-covid-19-on-pharmaceuticals..>



GLOBAL CDMO INDUSTRY

The global Contract Development and Manufacturing Organisation (CDMO) industry has established itself as a critical and structurally growing pillar of the pharmaceutical supply chain. By enabling drug developers – from large multinational innovators to emerging biotech firms – to access world-class manufacturing expertise, regulatory compliance capabilities, and scalable production without bearing the full capital burden of in-house infrastructure, CDMOs have become indispensable partners in pharmaceutical value creation. The increasing complexity of new drug modalities (biologics, ADCs, cell and gene therapies), rising development costs, and the strategic imperative of supply chain diversification have collectively accelerated the pharmaceutical industry's shift towards outsourced manufacturing.

According to Fortune Business Insights, the global CDMO market was valued at USD 238.92 billion in 2024, with 2025 estimated at USD 255.01 billion. The market is projected to reach USD 465.24 billion by 2032, growing at a robust CAGR of 9.0% (2025–2032). An updated March 2026 analysis extended the projection to 2034, estimating the market at USD 580.72 billion, growing at a CAGR of 9.90% (2026–2034). This sustained double-digit growth trajectory—nearly 1.5x the rate of the broader pharmaceutical market – underscores the accelerating structural shift towards outsourcing within the global pharmaceutical industry.

KEY DRIVERS

- Increasing outsourcing by small and mid-sized pharmaceutical companies lacking in-house manufacturing capabilities, seeking to reduce fixed capital costs and access specialised expertise in complex formulation development
- Rapid growth of biologic and complex therapy CDMOs, driven by the global surge in biosimilar approvals, monoclonal antibody development, and emerging modalities such as ADCs and nucleic acid therapeutics
- US tariff-driven supply chain restructuring, paradoxically benefiting established CDMO hubs in India and select European countries as global pharmaceutical companies accelerate supply chain diversification before building new US domestic capacity
- Strategic mergers and acquisitions among CDMO players enhancing service breadth, geographic reach and end-to-end manufacturing capabilities for complex modalities
- Increasing adoption of digitalisation, AI-driven process optimisation, and sustainable manufacturing practices across the CDMO sector, raising quality standards and operational efficiency

Source: <https://www.fortunebusinessinsights.com/contract-development-and-manufacturing-organization-cdmo-outsourcing-market-102502> | <https://www.fortunebusinessinsights.com/press-release/contract-development-and-manufacturing-organization-cdmo-market-9673>


Source: <https://www.fortunebusinessinsights.com/contract-development-and-manufacturing-organization-cdmo-outsourcing-market-102502> | <https://www.india-briefing.com/news/indias-rise-as-a-global-cdmo-powerhouse-36108.html/>

REGIONAL DYNAMICS

North America held the largest CDMO market share at 38.50% (USD 98.1 billion) in 2025, supported by a robust CDMO infrastructure, high clinical trial activity, and a dense concentration of pharmaceutical innovators.

Europe contributed approximately 25.30% (USD 64.24 billion), driven by demand for biologics manufacturing and stringent regulatory-quality-driven outsourcing.

Asia-Pacific, representing approximately 25.20% (USD 64.15 billion) of the 2025 market, is the fastest-growing region – with India and China as primary hubs due to their cost advantages, depth of scientific workforce, and growing regulatory capabilities. The BIOSECURE Act in the United States, restricting federal contracts with certain Chinese biotech firms, has materially accelerated the shift of CDMO mandate towards India, creating significant incremental demand.



GLOBAL CDMO MARKET SIZE 2024–2034

(Market Value in US\$ Billion — Fortune Business Insights, 2026)

YEAR	Market Size (US\$ Billion)	CAGR / Remarks
2024	USD 238.92 Bn	Actual
2025	USD 255.01 Bn	Base Year
2026	USD 273.40 Bn	Estimate
2028	USD 330.22 Bn	Interpolated @ 9.90% CAGR
2030	USD 398.84 Bn	Interpolated @ 9.90% CAGR
2032	USD 465.24 Bn	Projected
2034	USD 580.72 Bn	Projected

Source: Fortune Business Insights, March 2026 |

<https://www.fortunebusinessinsights.com/contract-development-and-manufacturin...> |

<https://www.fortunebusinessinsights.com/press-release/contract-development-an...>

INDUSTRY TRENDS

AI-Enabled R&D and Technology-Driven Operations

Pharmaceutical companies are increasingly leveraging Artificial Intelligence (AI) and Machine Learning (ML) to accelerate drug discovery, design more efficient clinical trials, optimise manufacturing processes, and enhance supply chain responsiveness. Generative AI platforms are reducing molecule design timelines from years to months, while AI-driven predictive analytics enables proactive quality management and real-time process monitoring. A national supercomputing facility at NIPER Guwahati and Amgen's USD 200 million investment in an AI/data science centre in Hyderabad exemplify the growing convergence of cutting-edge technology and pharmaceutical science in India.

Patent Expiries and Rise of Biosimilars / Specialty Drugs

A significant wave of blockbuster drug patent expirations is creating substantial addressable market opportunities for high-quality generic and biosimilar manufacturers. With over USD 300 billion in branded drug revenues facing patent cliffs through the late 2020s, the market for complex generics and biosimilars is expanding rapidly. This trend directly benefits Indian pharmaceutical manufacturers – including CDMO-oriented companies – that have built strong capabilities in high-quality, cost-competitive formulation manufacturing across multiple therapeutic categories.

Trade Risks and Supply Chain Resilience

The escalation of US import tariffs on branded pharmaceuticals and persistent geopolitical tensions have intensified the global focus on supply chain diversification. Pharmaceutical companies are actively pursuing multi-sourcing strategies for APIs and finished formulations, reducing single-country dependence. This structural shift is creating substantial new opportunities for Indian manufacturers, with Indian CDMOs reporting over 50% year-on-year increases in Requests for Proposals (RFPs) from global pharmaceutical clients. The exemption of generic pharmaceuticals from US tariff measures validates India's indispensable role in global pharmaceutical supply chains.

Shift Towards Self-Care, OTC and Wellness Products

Post-pandemic behavioural shifts have catalysed sustained demand for preventive healthcare, self-care products and consumer wellness formulations. The global wellness economy, valued at USD 6.3 trillion and forecast to reach USD 9 trillion by 2028, continues to drive demand for nutraceuticals, over-the-counter therapeutics, medicated skincare and personal care products. This trend expands the addressable market for versatile CDMO manufacturers capable of producing pharmaceutical-grade formulations across both prescription and consumer wellness categories.

Higher Standards in Manufacturing Quality and Regulatory Compliance

Regulators globally are raising the bar for pharmaceutical manufacturing quality, demanding digital records, data integrity protocols, continuous process validation, and real-time quality monitoring. Manufacturers that hold internationally recognised certifications – WHO-cGMP, ISO, GLP – and invest proactively in quality systems are increasingly preferred by global buyers seeking reliable, compliant supply partners. The pharmaceutical manufacturing market is growing at 7-8% annually, and quality-certified facilities are capturing a premium in the CDMO outsourcing market.

Source: <https://www.weforum.org/stories/2025/01/2025-can-be-a-pivotal-year-of-progress-for-pharma> | <https://www.grandviewresearch.com/industry-analysis/pharmaceutical-manufacturing-market> | <https://globalwellnessinstitute.org/press-room/press-releases/the-global-wellness-economy-reaches-a-new-peak-of-6-3-trillion-and-is-forecast-to-hit-9-trillion-by-2028>



REGIONAL DYNAMICS

North America

North America remains the world's largest pharmaceutical market, accounting for approximately 41.80% of global revenues in 2025. The United States continues to dominate, driven by high per-capita pharmaceutical spending, robust demand for biologics, specialty medicines, and oncology treatments. However, the sector faces intensifying policy headwinds: government-mandated drug price negotiations under the Inflation Reduction Act, aggressive tariff measures on imported branded drugs (100% duty effective October 2025), and sustained public scrutiny of pharmaceutical pricing are reshaping the commercial landscape. Major companies are committing substantial capital to US domestic manufacturing, creating complex market dynamics with long-term implications for global supply chain architectures.


Europe

Europe's pharmaceutical market operates in an environment of subdued economic growth, tightly controlled drug pricing, and strong government focus on supply security and healthcare cost containment. There is robust and growing demand for biosimilars – where multiple European markets have among the highest adoption rates globally – and high-quality generics. The EU's comprehensive pharmaceutical legislation overhaul, focused on incentivising innovation while improving medicine accessibility, is reshaping the regulatory and commercial landscape. Regulatory authorities are emphasising supply chain resilience and strategic autonomy in pharmaceutical manufacturing, creating opportunities for approved non-European manufacturers that consistently demonstrate EMA-standard quality compliance.

Asia – Pacific

Asia-Pacific is the world's fastest-growing pharmaceutical market, underpinned by rising healthcare coverage, expanding middle-class demand, significant government investment in healthcare infrastructure, and a highly cost-competitive manufacturing base. India and China remain the pre-eminent pharmaceutical manufacturing hubs, while ASEAN markets offer rapidly expanding demand for branded and generic medicines. India's CDMO sector is experiencing particularly dynamic growth, as regulatory capabilities deepen and China+1 supply diversification strategies gain traction. The broader Asia-Pacific healthcare market is projected to reach USD 5 trillion by 2030, contributing approximately 40% to global healthcare growth – creating a significant and expanding market context for Indian pharmaceutical manufacturers.

Source: <https://www.imf.org/en/publications/weo/issues/2026/01/19/world-economic-outlook-update-january-2026> | <https://www.fortunebusinessinsights.com/contract-development-and-manufacturing-organization-cdmo-outsourcing-market-102502>



GLOBAL PHARMA OUTLOOK

The global pharmaceutical industry is positioned for sustained mid-to-high single-digit growth over the next 3-5 years, underpinned by fundamental, non-discretionary demand drivers: an ageing global population, rising prevalence of chronic and lifestyle diseases, expanding healthcare access in emerging markets, and continuous scientific and medical innovation. The industry is expected to reach approximately USD 2.00-2.35 trillion by 2030, with biologics, biosimilars, complex generics, and consumer wellness products representing the primary growth vectors.

Advances in AI-enabled drug discovery, digital health integration, and personalised medicine will reshape the sector's innovation paradigm, while supply chain resilience – a strategic imperative following the disruptions of the COVID-19 pandemic and subsequent geopolitical shocks – will continue to drive outsourcing to diversified, quality-certified manufacturers. Regional dynamics will diverge: North America and Europe will focus on pricing efficiency, biosimilar adoption, and reshoring incentives; Asia-Pacific – led by India – will lead in volume growth, supported by manufacturing competitiveness, rising domestic healthcare access, and China+I-driven CDMO outsourcing expansion.

Critically, the exemption of generic pharmaceuticals from US tariff measures – despite the imposition of 100% duties on branded and patented drugs – provides a structural tailwind for Indian generic and CDMO manufacturers. As innovators invest in new US domestic capacity (a process estimated to take 5-8 years to materialise at scale), India's established, WHO-cGMP and FDA-approved manufacturing base remains indispensable to global pharmaceutical supply chains throughout the medium term. Management of Accretion Pharmaceuticals Limited believes that the Company is well-positioned to capitalise on these favourable structural dynamics.

Source: <https://www.ibef.org/industry/pharmaceutical-india> | <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221080> | <https://health.medicaldialogues.in/latest-news/indias-pharma-sector-3rd-largest-by-volume-11th-by-value-globally-167056>

Source: <https://www.grandviewresearch.com/industry-analysis/pharmaceutical-market-report> | <https://www.ropesgray.com/en/insights/alerts/2026/04/100-on-brand-us-imposes-new-tariffs-and-key-exemptions-on-patented-pharmaceuticals> | <https://www.fortunebusinessinsights.com/impact-of-covid-19-on-pharmaceuticals-market-102685>



INDIAN PHARMA INDUSTRY OVERVIEW

India's pharmaceutical industry occupies an unrivalled position in the global healthcare ecosystem. The country ranks 3rd globally by production volume and – as confirmed by the Economic Survey 2025-26 – has been upgraded to 11th globally by value, a significant advancement reflecting the sector's growing sophistication and output quality. India produces over 60% of the world's vaccines, supplies approximately 20% of global generic medicines by volume, and manufactures approximately 60,000 generic brands across 60 therapeutic categories. With over 3,000 pharmaceutical companies, approximately 10,500 manufacturing facilities, and the highest number of US FDA-approved manufacturing plants outside the United States (650+), India's pharmaceutical infrastructure is without peer among emerging market nations. The industry's cumulative turnover in FY 2023-24 was ₹4,17,345 crore, with a five-year average growth rate of 10.08%.

India's pharmaceutical sector serves as a critical pillar of the nation's export economy. Pharmaceutical exports surged to USD 30.47 billion in FY 2024-25 (+9.4% YoY), and in FY 2025-26 (April-February), exports reached USD 28.29 billion (+5.6%), on track for another strong full-year performance. The United States remains the largest single export destination at approximately 31% of total pharmaceutical exports. Africa, Europe, and emerging Asian markets represent significant and expanding export volumes, directly relevant to ACCPL's primary export geographies. The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana has issued 42.48 crore Ayushman cards (as of December 2025) and authorised health coverage of ₹1.60 lac crore, dramatically expanding the domestic pharmaceutical demand base. The Jan Aushadhi Kendra network crossed 18,646 operational outlets by March 2026, making quality generic medicines accessible across India.

Source: <https://ddnews.gov.in/en/indian-pharma-exports-jump-over-9-to-usd-30-47-billion-in-2024-25-commerce-secretary/> | <https://www.tribuneindia.com/news/india/indias-pharma-exports-cross-usd-28-billion-till-february-likely-to-end-up-with-growth-in-rupee-terms-in-fy26> | <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2210432> | <https://www.pib.gov.in/PressReleaseDetailm.aspx?PRID=2222493> | <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2236292>

Source: <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2204595> | <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2158120> | <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2201284®=3&lang=1>

Performance in FY 2025-26

India's pharmaceutical industry demonstrated continued global leadership in FY 2025-26. Export performance remained robust with pharma exports crossing USD 28 billion by end-February, on track for a record annual performance. Domestic market growth was driven by rising chronic disease prevalence, health insurance expansion under Ayushman Bharat, and government subsidy programmes for essential medicines. The PLI schemes delivered measurable outcomes: cumulative investment under PLI-Pharmaceuticals reached ₹40,294 crore, 87,535 direct jobs were created, and ₹2,328 crore in incentives were disbursed in FY25 alone. India's transition to a net exporter of bulk drugs represents a landmark structural achievement in reducing import vulnerability. Overall, the industry reinforced its standing as the 'Pharmacy of the World', delivering affordable, quality medicines to patients across 150+ countries.

Source: <https://www.ropesgray.com/en/insights/alerts/2026/04/100-on-brand-us-imposes-new-tariffs-and-key-exemptions-on-patented-pharmaceuticals> | <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2158120> | <https://www.ibef.org/industry/pharmaceutical-india>

Challenges

Despite strong fundamentals, the Indian pharmaceutical industry navigated several challenges in FY 2025-26. The threatened imposition of US tariffs on generic pharmaceuticals – though ultimately exempted in the final framework – created a period of significant uncertainty in the first half of the year, temporarily affecting investment decisions. Regulatory tightening in key export markets demanded sustained investment in quality compliance and data integrity systems. Dependence on imported APIs and Key Starting Materials, primarily from China, remains a structural vulnerability, though PLI-driven domestic API production is progressively reducing this dependence. Domestic price controls under the Drug Price Control Order (DPCO) continued to limit pricing flexibility across a significant segment of the market, while competitive intensity in the export generics market maintained pressure on per-unit margins.

Source: <https://web-assets.bcg.com/45/16/f1efbcae4bb7a0a270fbfc9ab496/bcg-ipso-whitepaper-unleashing-the-tiger.pdf> | <https://www.bcg.com/publications/2025/india-unleashing-the-tiger-indian-crdmo-sector> | <https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/indias-cdmo-market-set-to-double-by-2028-amid-asias-healthcare-boom/articleshow/118086689.cms>

INDIAN PHARMACEUTICAL MARKET

(Market Value in US\$ Billion – 2021 to 2030 Projection)

YEAR	Market Size (US\$ Billion)	Context
2021	USD 41 Bn	Post-pandemic base
FY 2023-24	USD 50 Bn	3rd by volume; upgraded to 11th by value
FY 2025-26 (Est.)	USD ~60 Bn	Robust export and domestic growth
2030 (Projected)	USD 120-130 Bn	CAGR ~10%; Bain & Co. / IBEF projection

Source: IBEF India Pharma Report 2025

<https://www.ibef.org/industry/pharmaceutical-india> |

Economic Survey 2025-26

<https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221080> |

<https://www.ibef.org/blogs/indian-pharma-industry-to-touch-us-130-billion-by-...>



INDIAN CDMO INDUSTRY

India's Contract Development and Manufacturing Organisation (CDMO) sector is experiencing an extraordinary period of growth and global recognition. According to the BCG-IPSO White Paper ('Unleashing the Tiger') released in February 2025 – a landmark collaborative report by the Boston Consulting Group and India's Innovative Pharmaceutical Services Organisation – India's broader CDMO market is valued at approximately USD 7 billion and is projected to double to USD 14 billion by 2028, capturing 4-5% of the global CDMO market. The narrower CRDMO (Contract Research, Development and Manufacturing) segment, estimated at USD 3-3.5 billion in 2024, is projected to reach USD 22-25 billion by 2035 at a CAGR of approximately 15% – nearly double the global average rate of expansion.

KEY DRIVERS OF GROWTH

- **Strong API and Generic Drug Manufacturing:** India's established expertise in Active Pharmaceutical Ingredients and generic drug production – backed by the world's largest number of FDA-approved manufacturing facilities outside the US – provides an unmatched foundation for CDMO growth and client confidence.
- **Cost Competitiveness:** Indian CDMO services are priced approximately 20% lower than Chinese counterparts and 70-80% lower than Western facilities in terms of operational costs, delivering compelling value propositions to global pharmaceutical clients seeking to optimise their outsourcing economics.
- **Supply Chain Diversification:** Global pharmaceutical companies are actively diversifying supply chains in response to the BIOSECURE Act, US-China trade tensions, and COVID-era supply shocks. Indian CDMOs witnessed a 50% year-on-year surge in RFPs in 2024, with momentum continuing strongly into FY 2025-26.
- **Regulatory Strength:** With 650+ USFDA-approved plants and 2,000+ WHO-GMP approved facilities, India's regulatory credentials across all major markets are unmatched among emerging pharmaceutical manufacturing hubs.
- **IPSO Formation:** The establishment of the Innovative Pharmaceutical Services Organisation – a consortium of 11 leading Indian CRDMOs – in 2025 signals the sector's growing strategic cohesion, collective lobbying capability, and global ambition.

Source: <https://www.india-briefing.com/news/indias-rise-as-a-global-cdmO-powerhouse-36108.html/> | <https://www.biospectrumindia.com/features/18/27404/can-indias-cdmOs-lead-the-next-biopharma-wave.html>

Broader APAC Healthcare Context

India's CDMO growth is embedded within the broader Asia-Pacific healthcare expansion. The APAC healthcare market is projected to reach USD 5 trillion by 2030, contributing approximately 40% to global healthcare growth – driven by rising income levels, expanding health insurance coverage, and significant government investment in healthcare infrastructure. India is positioned to capture a disproportionate share of APAC's pharmaceutical manufacturing growth given its established infrastructure, deep regulatory track record, comprehensive product capabilities, and structural cost advantages.

Source: <https://ddnews.gov.in/en/indian-pharma-exports-jump-over-9-to-usd-30-47-billion-in-2024-25-commerce-secretary/> | <https://www.tribuneindia.com/news/india/indias-pharma-exports-cross-usd-28-billion-till-february-likely-to-end-up-with-growth-in-rupee-terms-in-fy26> | <https://www.ropesgray.com/en/insights/alerts/2026/04/100-on-brand-us-imposes-new-tariffs-and-key-exemptions-on-patented-pharmaceuticals>

Perks of Outsourcing Drug Production to India



Extensive government support for local drug manufacturing through PLI, SPI, PRIP, PMBJP and FDI liberalisation schemes, reducing risk for long-term manufacturing partnerships



Second-largest pharmaceutical and scientific workforce globally, offering depth, breadth and cost efficiency of technical expertise



Among the most competitive pharmaceutical manufacturing cost structures in the world, including labour, utilities and infrastructure



Capital expenditure up to 70% lower than comparable developed-country pharmaceutical manufacturing facilities, reducing capital deployment risk for outsourcing clients



Vast raw material availability, established domestic supply chain ecosystems, and a large domestic customer base providing scale and sourcing efficiency



Highest number of USFDA-approved and WHO-GMP approved manufacturing facilities outside the United States, providing regulatory assurance to global buyers

Key Government Initiatives

Initiative	Focus Area	Financial Outlay / Key Update (FY 2025-26)
Strengthening of Pharmaceutical Industry (SPI) Scheme	Infrastructure support & technology upgradation for pharma clusters and MSMEs	₹500 Crores (FY 2021-22 to FY 2025-26); 7 API-CF projects approved; 210 registrations under RPTUAS; max incentive raised to ₹2 crore per beneficiary (Sep 2024)
PLI Scheme Pharmaceutical Formulations	Boost domestic pharmaceutical manufacturing and exports	₹15,000 Crores outlay; ₹40,294 crore cumulative investment grounded; ₹2,328 crore disbursed in FY25; 87,535 direct jobs created; 28 greenfield sites established
PLI Scheme Bulk Drugs / APIs	Reduce API import dependence; build domestic self-reliance	₹6,940 Crores outlay; 34 projects commissioned; India became net exporter of bulk drugs in FY25 (surplus ₹2,280 crore vs. deficit ₹1,930 crore in FY22)
Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP)	Affordable generic medicines via Jan Aushadhi Kendras	18,646 Kendras operational (March 2026); 2,110 medicines + 315 surgical items listed; FY25 sales ₹2,022.47 crore; cumulative citizen savings ~₹38,000 crore
FDI Liberalisation in Pharma	Attract foreign investment in pharmaceutical manufacturing	100% FDI (greenfield); up to 74% FDI automatic route (brownfield); FDI inflows April–December 2025: US\$ 73.31 billion (+16% YoY)
Budget Allocation (FY 2025-26) Dept. of Pharmaceuticals	Strengthen pharmaceutical infrastructure, innovation and manufacturing	₹5,268.72 Crores (+28.8% over FY25 BE); includes ₹1,400 crore for Bulk Drug Parks and ₹1,460 crore for Medical Device Parks
Promotion of Research & Innovation in Pharma (PRIP Scheme)	Encourage pharma & MedTech R&D, innovation and Centres of Excellence	₹5,000 Crores (FY 2023-28); 7 Centres of Excellence at NIPERs; 111 research projects approved; ₹720.97 crore already supporting CoEs and active research

Source: <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2204595> | <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2158120> | <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2236292> | <https://www.pib.gov.in/PressReleaseDetailm.aspx?PRID=1805146> | <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2173970> | <https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/indias-cdmo-market-set-to-double-by-2028-amid-asias-healthcare-boom/articleshow/118086689.cms>

KEY INDUSTRY TRENDS

Export Momentum and Biosimilar-Led Growth Despite Tariff Uncertainty

Indian pharmaceutical exports maintained their strong upward trajectory in FY 2025-26, with exports crossing USD 28.29 billion in April-February and expected to achieve approximately USD 30 billion for the full year – matching FY 2024-25's record performance. Despite the uncertainty created by threatened US tariff measures on generics earlier in the year, Indian pharmaceutical companies retained their dominant position in the US generic drug market, supplying approximately 47% of US generic drug prescriptions. The exemption of generic pharmaceuticals from the final US tariff proclamation of April 2026 validated India's strategic indispensability to the US healthcare system and reinforced the structural sustainability of India's pharmaceutical export model.

Source: <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2158120> | <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2236292> | <https://www.ibef.org/news/electronics-pharma-sectors-corner-70-of-production-linked-incentive-pli-disbursements-in-fy25>

Policy Push — PLI for APIs and Expansion of Affordable Generic Access

The Production Linked Incentive scheme for bulk drugs delivered landmark results in FY 2024-25, and momentum continued into FY 2025-26: India became a net exporter of bulk drugs, with the trade balance swinging from a ₹1,930 crore deficit in FY 2021-22 to a ₹2,280 crore surplus. The fifth round of the PLI scheme for bulk drug manufacturing was launched to further expand domestic API capacity. Simultaneously, the Jan Aushadhi Kendra network crossed 18,646 outlets by March 2026, making quality generic medicines accessible at 50-90% lower prices than branded equivalents to millions of Indians – driving domestic generic pharmaceutical consumption volumes.

Technology and Investment Acceleration — AI, Drug Discovery and Global Majors

India is witnessing a material upgrade in pharmaceutical research infrastructure and digital capabilities. A national supercomputing facility at NIPER Guwahati targets AI and computational chemistry workloads for drug discovery. Amgen's USD 200 million investment in a Hyderabad AI/data science technology centre marks a landmark commitment by a global innovator to India's scientific capabilities. The formation of IPSO – the 11-member Indian CRDMO consortium – signals the sector's collective aspiration to compete at the highest tiers of global pharmaceutical outsourcing, including complex biologics and novel drug modalities.

Regulatory Strengthening and Quality Elevation

Facing international regulatory scrutiny, the Indian pharmaceutical industry has responded with significant investments in quality systems, data integrity infrastructure and manufacturing compliance. The government has simultaneously strengthened the CDSCO framework, expanded drug testing capacity, and introduced risk-based inspection protocols. Companies holding WHO-cGMP, ISO and other international certifications are increasingly preferred by global buyers, creating a meaningful quality premium in the CDMO and export formulation market – directly benefiting manufacturers like Accretion Pharmaceuticals that have maintained certified standards throughout.

Source: <https://www.pib.gov.in/PressReleaseDetailm.aspx?PRID=2148570> | <https://www.india-briefing.com/news/indias-rise-as-a-global-cdmo-powerhouse-36108.html/> | <https://timesofindia.indiatimes.com/city/guwahati/citys-supercomputing-facility-to-enhance-drug-innovation-in-ne/articleshow/123311305.cms>

Source: <https://www.ibef.org/blogs/indian-pharma-industry-to-touch-us-130-billion-by-2030> | <https://www.ibef.org/industry/pharmaceutical-india> | <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221080>
Source: <https://ddnews.gov.in/en/indian-pharma-exports-jump-over-9-to-usd-30-47-billion-in-2024-25-commerce-secretary/> | <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2158120> | <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2204595> | https://www.business-standard.com/economy/news/agri-pharma-electronics-engineering-made-up-50-of-fy25-exports-govt-125051600462_1.html

INDIAN PHARMA OUTLOOK

Growth and Opportunities

The Indian pharmaceutical industry is well-positioned for sustained, robust growth over the medium-to-long term. The domestic market is projected to reach USD 65-70 billion by the end of FY 2025-26 and USD 120-130 billion by 2030, growing at a CAGR of approximately 10% – driven by a compelling confluence of structural demand drivers, comprehensive policy support, and deepening global competitive advantages. Key growth opportunities include the rapid expansion of biosimilar manufacturing capabilities, the deepening of the CDMO sector as global outsourcing mandates shift towards India under China+1 strategies, and the progressive scaling of domestic API production under PLI incentives. The India-UK Free Trade Agreement, under advanced negotiation, is expected to eliminate tariffs on Indian pharmaceutical exports to the UK and ease regulatory barriers, further expanding India's global pharmaceutical footprint. India's unique and comprehensive positioning across the full pharmaceutical value chain – from APIs and generic formulations to CDMO services and emerging biologics – creates a resilient and diversified export and domestic growth platform.

Challenges

Despite the optimistic medium-term outlook, the Indian pharmaceutical sector faces several challenges requiring proactive management. Regulatory tightening and pricing pressures in key export markets continue to demand sustained investment in quality compliance and regulatory affairs capabilities. The structural dependence on imported APIs and KSMs – particularly from China – remains a vulnerability despite meaningful progress under PLI schemes. Any future broadening of US tariff measures to encompass generic pharmaceuticals would represent a significant headwind, though the political economy of such a move is complex given India's role in keeping US drug prices affordable. Domestic price controls under the DPCO continue to limit pricing flexibility, while talent competition, rising scientific workforce costs, and infrastructure requirements for complex drug modalities pose medium-term operational pressures for the sector.

Source: <https://www.ibef.org/industry/pharmaceutical-india> | <https://www.ibef.org/blogs/indian-pharma-industry-to-touch-us-130-billion-by-2030> | <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221080> | <https://health.medicaldialogues.in/latest-news/indias-pharma-sector-3rd-largest-by-volume-11th-by-value-globally-167056>



COMPANY OVERVIEW

Accretion Pharmaceuticals Limited, headquartered at 29, Xcelon Industrial Park-1, Behind Intas Pharmaceuticals, Vasna-Chacharwadi, Taluka Sanand, District Ahmedabad – 382 213, Gujarat, India was established in 2012 and has grown into a dynamic, full-spectrum Contract Development and Manufacturing Organisation (CDMO) serving both domestic and international pharmaceutical markets. The Company's WHO-cGMP, GLP and ISO-certified manufacturing facility in Ahmedabad produces a comprehensive range of pharmaceutical formulations across all major dosage forms, including Tablets, Capsules, Oral Liquids (Syrups, Suspensions, Drops), External Preparations (Ointments, Creams, Gels, Lotions, Medicated Shampoos, Mouthwash) and Oral Powders (Sachets, Dry Syrups). ACCPL's therapeutic portfolio spans antibiotics, antibacterials, antifungals, antihistamines, antiallergics, antitussives, anticold preparations, antiulcer, antacid, vitamin and supplement formulations, and cardiac therapeutics – providing significant commercial resilience across therapeutic demand cycles.

Accretion's business model is built on delivering high-quality, cost-competitive contract manufacturing services to pharmaceutical companies and merchant exporters, enabling its clients to bring affordable medicines to market efficiently. The Company exports to 30+ countries, with primary markets in Africa, Southeast Asia, and Latin America – regions with rapidly growing pharmaceutical demand and strong acceptance of high-quality Indian generic formulations. The Company's robust financial growth, strategic focus on direct exports, and diversified product portfolio position it for sustained success in the CDMO segment.

A defining milestone was achieved in FY 2025-26 when Accretion Pharmaceuticals Limited completed its Initial Public Offering on the NSE Emerge SME Platform. The IPO – comprising a fresh issue of 29,46,000 equity shares at ₹101 per share – was oversubscribed 7.67 times, reflecting strong investor confidence in the Company's business model and growth prospects. The listing on 21 May, 2025 raised approximately ₹2,975.46 Lacs, which the Company is deploying towards working capital augmentation and capacity expansion. Post-IPO, the paid-up capital stands at ₹11,11,60,000 (1,11,16,000 equity shares of ₹10 each). The Company is promoted by Mr. Harshad Nanubhai Rathod (Chairman, Director & CFO), Mr. Vivek Ashokkumar Patel (Managing Director), Mr. Hardik Mukundbhai Prajapati (Director) and Mr. Mayur Popatlal Sojitra (Director).



Position of Accretion Pharmaceuticals Limited in the Global Pharma Landscape

- Leverages India's cost-effective, quality-certified manufacturing infrastructure to deliver high-quality generic formulations at globally competitive prices to 30+ country markets.
- Export market diversification across Africa, Southeast Asia and Latin America — high-growth regions with accelerating pharmaceutical demand and favourable acceptance of Indian generics.
- WHO-cGMP, GLP, ISO certifications, Cambodia GMP, Rwanda GMP, Nigeria GMP, Malawi GMP provide international regulatory assurance and fulfil quality requirements of export destination country drug regulatory authorities.
- Niche CDMO positioning: specialising in full-service outsourced manufacturing across a comprehensive range of dosage forms — a breadth of capability that differentiates the Company as a one-stop partner.
- IPO proceeds being strategically deployed to expand manufacturing capacity and strengthen working capital, positioning the Company for accelerated revenue growth in FY 2026-27 and beyond.
- Well-placed to benefit from global pharmaceutical companies' China+1 supply diversification strategies, creating incremental CDMO outsourcing mandates for quality certified Indian manufacturers.

Position of Accretion Pharmaceuticals Limited in the India Pharma Landscape

- Operates as a dynamic, certified CDMO from its Ahmedabad facility strategically located in Gujarat, one of India's premier pharmaceutical manufacturing and export clusters.
- Comprehensive range of formulations across multiple dosage forms and therapeutic categories, reinforcing competitive capabilities in the generics contract manufacturing segment.
- Strong, long-term client relationships enabling tailored, customer-centric manufacturing solutions and sustained revenue visibility.
- Skilled pharmaceutical workforce aligned with cGMP principles, enhancing operational efficiency, product quality and regulatory compliance across all manufacturing operations.
- Beneficiary of India's comprehensive pharmaceutical sector support framework Production Linked Incentive (PLI), Promotion of Research and Innovation in Pharma MedTech Sector (PRIP), Scheme for Strengthening of Pharmaceuticals Industry (SPI), Ayushman Bharat — supporting long-term CDMO sector growth and market expansion.

FINANCIAL PERFORMANCE

For FY 2025-26, the company reported revenues of approximately ₹8,962.71 Lacs (₹89.63 crore) and Net Profit After Tax of approximately ₹966.73 Lacs (₹9.67 crore) as compared to FY 2024-2025 revenues of ₹5,737.62 Lacs (₹57.38 crore), with a net profit of approximately ₹679.35 Lacs (₹6.79 crore) — representing strong year-on-year growth momentum. The deployment of IPO proceeds toward working capital and capacity expansion supported continued revenue growth in H2 FY26 and is expected to sustain momentum beyond.

REVENUE FROM OPERATIONS (₹ IN LACS)

(FY 2023-24 to FY 2025-26 — Accretion Pharmaceuticals Limited)

Financial Year	Revenue from Operations(₹Lacs)	YoY Growth
FY 2023-24	₹3,366.52 Lacs	Base Year
FY 2024-25	₹5,737.62 Lacs	+70.4%
FY 2025-26	₹8,962.71 Lacs	+56.21%

EBITDA AND EBITDA MARGIN

(FY 2023-24 to FY 2025-26 — ₹ Lacs and Percentage)

Financial Year	EBITDA (₹ Lacs)	EBITDA Margin (%)
FY 2023-24	₹748.93 Lacs	22.25%
FY 2024-25	₹1,188.08 Lacs	20.71%
FY 2025-26	₹1495.14 Lacs	16.68%

PROFIT AFTER TAX (PAT) AND NET PROFIT MARGIN

(FY 2023-24 to FY 2025-26 — ₹ Lacs and Percentage)

Financial Year	PAT (₹ Lacs)	Net Profit Margin (%)
FY 2023-24	₹387.52 Lacs	11.51%
FY 2024-25	₹679.35 Lacs	11.84%
FY 2025-26	₹966.75Lacs	10.79%

VERTICAL-WISE REVENUE MIX — FY 2025-26**(Domestic vs. Export Revenue Distribution — Accretion Pharmaceuticals Limited)**

Revenue Vertical	Approximate Revenue Share	Key Markets / Remarks
Export Revenue	~₹ 766.45 lacs	Africa, Southeast Asia, Latin America, Middle East — 30+ countries
Domestic Revenue	~₹ 8196.27 lacs	India — merchant exporters and domestic pharmaceutical clients

FINANCIAL RATIO

The following table presents the key financial ratios of Accretion Pharmaceuticals Limited:

Particulars	FY 2025-26	FY 2024-25	% Change	Reason for Change
Debtors Turnover Ratio	5.27	6.57	(20%)	Receivables grew faster than sales; longer collection cycle.
Inventory Turnover Ratio	3.16	2.78	13.46%	Higher revenue base improved stock turnover.
Interest Coverage Ratio	16.39	7.80	110%	Lower interest cost and higher EBIT post-IPO deleveraging
Current Ratio	2.90	1.44	101.28%	A significant increase in current assets and improvement in the Company's liquidity position as compared to the previous year
Debt-Equity Ratio	0.23	0.92	(75.59%)	Reduction in borrowings and/ or increase in shareholders' equity.
Operating Profit Margin (%)	15.54%	19.52%	(20%)	Higher input and overhead costs during capacity scale-up.
Net Profit Ratio (%)	10.79%	11.84%	(8.90%)	Operating margin dip, partly offset by lower interest outgo.
Return on Net Worth (%)	17.67%	44.44%	(60%)	Enlarged equity base post-IPO dilutes near-term returns.

INTERNAL CONTROL AND ITS ADEQUACY

Accretion Pharmaceuticals Limited has established a robust and comprehensive internal control system commensurate with the scale, complexity and nature of its operations. The internal control framework provides reasonable assurance regarding the achievement of operational, financial, and compliance objectives. The framework is designed to ensure:

- **Accuracy and Reliability of Financial Reporting:** The Company maintains rigorous financial reporting controls, including a structured chart of accounts, periodic management reviews, reconciliation procedures, and a structured month-end and year-end closing process. These controls ensure financial statements are prepared in accordance with applicable accounting standards and present a true and fair view of the Company's financial position and performance, consistent with SEBI Listing Regulations, 2015 requirements applicable to listed SME entities.
- **Compliance with Applicable Laws, Regulations and Internal Policies:** The Company has implemented a comprehensive compliance management framework covering all applicable regulatory requirements – including the Companies Act, 2013, SEBI Listing Regulations, 2015, GST, Income Tax Act, Customs Regulations, Pharmaceutical Manufacturing Regulations (Schedule M, WHO-cGMP), Environmental Standards, and NSE Emerge SME listing Obligations. A dedicated compliance calendar and periodic legal and secretarial reviews ensure timely and complete adherence across all regulatory domains.
- **Operational Efficiency and Safeguarding of Assets:** Operational controls encompass production planning and scheduling, inventory management and valuation, procurement and vendor management procedures, quality assurance and quality control protocols, and fixed asset management including periodic physical verification. Access to systems and manufacturing areas is appropriately restricted. The Company's WHO-cGMP framework provides an additional, internationally validated layer of operational discipline and quality governance.
- **Prevention and Detection of Frauds and Errors:** The Company maintains a zero-tolerance policy for fraud and has implemented segregation of duties, multi-level authorisation hierarchies, surprise stock counts and cash verifications, and a Board-approved whistleblower policy as key preventive mechanisms. The internal audit function is conducted by independent qualified professionals, with findings and management responses reported directly to the Audit Committee of the Board on a periodic basis.

The Audit Committee of the Board of Directors provides strategic oversight over the internal control framework, reviews internal audit findings, monitors the implementation of corrective actions, and ensures that internal controls remain effective, risk-focused, and aligned with the Company's growth objectives. The Audit Committee met periodically during FY 2025-26 to review and discuss internal control matters. Management believes that the existing internal control system is adequate and operating effectively, providing reasonable assurance regarding the reliability of financial and operational information.

RISK MANAGEMENT

Operating in a globally competitive, scientifically complex, and heavily regulated industry, Accretion Pharmaceuticals Limited recognises that effective risk identification, assessment and mitigation is integral to achieving sustainable growth and protecting shareholder value. The Company's risk management framework is embedded in strategic and operational decision-making and is overseen by the Board of Directors and its Committees. Key risk categories, their nature, and the Company's mitigating strategies are detailed below:



Regulatory Risk

Nature of Risk: The pharmaceutical manufacturing sector is subject to stringent and continuously evolving regulatory requirements across domestic and international jurisdictions, including the Central Drugs Standard Control Organisation (CDSCO) in India, the US FDA, WHO Prequalification, and country-specific regulatory bodies across 30+ export destination markets. Any regulatory action – including warning letters, import alerts, manufacturing suspensions or product recalls – could materially impact the Company's operations, client relationships and reputation. International regulatory bodies are progressively raising standards for manufacturing quality, data integrity and documentation.

Mitigation: The Company mitigates regulatory risk through continuous monitoring of regulatory developments across all key markets, proactive investment in quality management systems, maintenance of WHO-cGMP, GLP and ISO certifications, regular internal quality audits and third-party regulatory audits, dedicated regulatory affairs personnel, and ongoing training of manufacturing staff in current Good Manufacturing Practice (cGMP) requirements.

Market Risk

Nature of Risk: The Company faces pricing pressures from pharmaceutical market dynamics, competitive intensity from other CDMO manufacturers, and exposure to demand fluctuations in export markets. Foreign currency risk — particularly USD, EUR and other export market currencies against the Indian Rupee — can impact export realisations and profitability. Client concentration risk, with significant revenues derived from a limited number of key clients, amplifies the impact of any single client relationship change.

Mitigation: The Company addresses market risk through continuous product portfolio diversification across dosage forms and therapeutic categories, active expansion into new export geographies (targeting 40+ countries), development of direct client relationships to reduce dependence on merchant intermediaries, and progressive pricing optimisation through higher-margin product and market focus. Currency risk is monitored regularly, with natural hedging and operational adjustments employed where feasible.

Operational Risk

Nature of Risk: Dependence on an uninterrupted supply of raw materials — particularly imported Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), primarily from China — poses supply chain vulnerability. Any disruption in raw material availability due to geopolitical factors, supplier concentration, quality issues, or import policy changes could impact production schedules and customer commitments. Operational risks also include manufacturing process failures, equipment downtime, and human resource attrition in key technical roles.

Mitigation: The Company maintains relationships with multiple qualified suppliers across geographies for critical materials, maintains strategic raw material inventory buffers commensurate with production requirements, and is progressively qualifying alternative domestic API sources as PLI-driven Indian API production expands. The IPO funded working capital provides additional flexibility for raw material procurement and inventory management. Preventive maintenance programmes and trained personnel reduce equipment and process risk.

Financial Risk

Nature of Risk: The Company's financial risks include interest rate exposure on borrowings (substantially reduced post-IPO deleveraging), working capital pressures from the extended receivables cycle inherent in the export CDMO business model, and the risk of customer defaults or delayed payments impacting cash flows. Elevated debtor days in the export business require active working capital management and can constrain operational flexibility.

Mitigation: Post-IPO debt reduction has materially lowered interest exposure and the debt-equity ratio. The Company actively manages the receivables cycle through rigorous credit assessment of new clients, regular collection follow-up, and maintenance of Letters of Credit and advance payment terms for new export relationships. Progressive client diversification is expected to reduce concentration risk over the medium term. The strengthened equity base post-IPO provides financial resilience.


Reputational Risk

Nature of Risk: In the pharmaceutical industry, product quality is the non-negotiable foundation of commercial relationships and market trust. Any quality lapse, product recall, adverse patient event, or regulatory action associated with the Company's manufactured products could cause immediate and lasting reputational damage, impacting existing client relationships, the Company's ability to win new mandates, and its standing with regulatory authorities in export markets.

Mitigation: ACCPL maintains stringent quality control systems at every stage of the manufacturing process — from incoming raw material testing and approval, through in-process quality controls, to final product release testing and stability monitoring. The Company's WHO-cGMP and ISO certifications provide continuous external validation of its quality management systems. Ongoing investment in quality infrastructure, testing equipment and personnel training reinforces this commitment. A dedicated Quality Assurance team operates independently from production to provide objective quality governance.

SWOT ANALYSIS

The following 2x2 matrix presents a structured assessment of Accretion Pharmaceuticals Limited's internal strengths and weaknesses, and the external opportunities and threats shaping its operating environment as of FY 2025-26:



STRENGTHS

- Extensive expertise across diverse pharmaceutical capabilities and advanced manufacturing technologies.
- Proven track record of consistent quality and on-time delivery across 30+ export markets.
- Established long-term client relationships with reputed merchant exporters and direct customers.
- Highly experienced management team and skilled workforce with deep pharmaceutical industry knowledge.
- WHO-cGMP, GLP and ISO-certified Ahmedabad facility ensuring world class operational and quality excellence.
- IPO-funded capacity expansion and working capital reinforcement enhancing scalability and market reach.
- Operates five production lines Tablets, Capsules, Oral Liquids, Oral Powders, and External Preparations and supported by a wide and diverse product portfolio.

WEAKNESSES

- Dependence on imported Key Starting Materials (KSMs) and APIs affecting supply reliability and delivery schedules.
- Revenue concentration risk significant share of income from a limited number of clients.
- Exposure to foreign currency fluctuations impacting export realisations and margins.
- Elevated debtor days and working capital cycle requiring active monitoring and management.

OPPORTUNITIES

- Global pharmaceutical companies increasingly choosing India as preferred CDMO partner under China+1 supply diversification strategy.
- Rapid expansion in CDMO demand from emerging markets — Africa, Southeast Asia, Latin America and Middle East & Central Asia.
- Government PLI schemes, PRIP, PMBJP and enhanced DoP budget creating a conducive ecosystem for contract manufacturers.
- Rising demand for affordable generics, OTC wellness products and nutraceuticals in domestic and export markets.

THREATS

- Evolving regulatory policies and rising quality standards could increase compliance costs and disrupt business continuity.
- US tariff escalation and geopolitical trade tensions may disrupt global pharmaceutical supply chains.
- Competitive pressure from larger Indian and global CDMO and generic players may compress margins and market share.
- Price controls, reimbursement pressures and currency headwinds in key export markets affecting profitability.

DIRECTOR'S REPORT

To,

The Members,

The Directors have the pleasure of presenting the Third (3rd) Annual Report of your Company together with the Audited Financial Statement for the year ended 31 March, 2026.

FINANCIAL SUMMARY AND HIGHLIGHTS

The Company's financial performance for the year ended on 31 March, 2026 is summarized below:

Particulars	For the year ended 31 March, 2026	For the year ended 31 March, 2025
Revenue from operation	8962.72	5737.62
Add : other Income	19.05	9.44
Total Income	8981.77	5747.06
Less: Total Expenditure	7673.46	4770.68
Profit/(Loss) before Tax	1308.31	976.38
Less: Tax Expenses	341.56	297.03
Profit/(Loss) for the year from continuing operations	966.75	679.35
Earning per equity share (Face value ₹ 10/-) (Basic and Diluted in ₹)	9.03	8.48

The Company reports rise in the revenue from operations of ₹ 8962.72 lacs as compared to the previous year of ₹ 5737.62 lacs. After providing for interest, depreciation and taxes, the net profit for the year stood at ₹ 966.75 lacs as compared to ₹ 679.35 lacs in the previous year. EPS for the year was ₹ 9.03 per share as compared to ₹ 8.48 per share in the previous year. Detailed working on operation of the Company is provided in the management discussion and analysis report as forms part of this.

MATERIAL EVENT – LISTING ON STOCK EXCHANGES

The Company marked a monumental milestone in the history of the Company with the successful completion of its Initial Public Offering (IPO). The issue garnered overwhelming market response, achieving an overall subscription of 7.67 times across all investor categories.

To unlock the benefits of public listing, enhance corporate brand equity, and establish a robust public market for its equity shares in India, the Company successfully listed its shares on the stock exchange. The capital raise comprised a fresh issue of 29,46,000 equity shares of face value of ₹ 10/- each, aggregating to ₹ 2,975.46 Lacs.

The equity shares of the Company were officially listed and commenced trading on the SME platform of the National Stock Exchange of India Limited (NSE Emerge) on 21 May, 2025.

THE STATE OF COMPANY'S AFFAIRS

The Company is a rapidly emerging Indian Contract Development and Manufacturing Organization (CDMO), dedicated to manufacturing and marketing high-quality pharmaceutical formulations. Powered by a vision to deliver healthcare solutions that adhere to stringent international quality standards at competitive price points, the Company has established a robust domestic market presence and continues to strategically expand its global footprint.

Our comprehensive product portfolio spans a diverse range of therapeutic segments and dosage forms, classified under the following core categories – Tablets, Capsules, Oral Liquid, Oral Powder (Sachet, Dry Syrup) and External Preparations (Ointment, Cream, Gel, Lotion, Medicated Shampoo, Mouthwash, Dusting Powder).

MANAGEMENT DISCUSSION AND ANALYSIS (MDA)

The Management Discussion and Analysis Report providing the detailed overview of the Company's performance, industry trends, business and risks involved has been provided separately and forms part of this report.

DIVIDEND

The Company has consistently pursued a path of expansion to drive long term growth. In line with the need to conserve the Company's resources, the Board of Directors has not recommended any dividend for the financial year ended 31 March, 2026.

TRANSFER TO GENERAL RESERVES

The Board of Directors has decided not to transfer any amount to the General Reserves for the year under review.

SHARE CAPITAL

Authorised Share Capital:

- As on 31 March, 2026, the Authorised Share Capital of the Company is ₹ 13,00,00,000/- consisting 1,30,00,000 equity shares of ₹ 10/- each.

Paid up Share Capital:

- As on 1 April, 2025, the Paid-Up Capital of the Company is ₹ 8,17,00,000/- consisting 81,70,000 equity shares of ₹ 10/- each fully paid-up.
- The Paid-Up Capital of the Company was increased from ₹ 8,17,00,000/- to ₹ 11,11,60,000/- due to allotment of 29,46,000 equity shares of ₹ 10/- each to public pursuant fresh issue IPO dated 19 May, 2025.
- As on 31 March, 2026, the Paid-Up Capital of the Company is ₹ 11,11,60,000/- consisting 1,11,16,000 equity shares of ₹ 10/- each fully paid-up.

DETAILS OF SUBSIDIARY / JOINT VENTURES / ASSOCIATE COMPANIES

As on 31 March, 2026, the Company does not have any Subsidiaries, Joint Venture and Associate Companies. Therefore, pursuant to the provisions of Section 129(3) of the Companies Act, 2013, the statement containing salient features of the financial statements of subsidiaries or associate companies or Joint ventures in Form AOC-1 is not required.

PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS UNDER SECTION 186

During the year under review, the Company has not given any loan, not provided guarantee or security and not made any investment under the provisions of section 186 of the Companies Act, 2013.

PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES

All Related Party Transactions entered during the financial year 2025-26 were in compliance to the provisions of law and were entered with the approval of Audit Committee, Board and Shareholders, wherever applicable. All related party transactions executed during the financial year were on arm's length basis, ordinary course of business and in accordance with the provisions of the Act and the rules made thereunder, the SEBI Listing Regulations and your Company's Policy on Related Party Transactions. Further, there were no related party transactions which could be considered material based on the definition of material transaction as mentioned under Regulation 23 of the SEBI Listing Regulations. Accordingly, the disclosure in Form AOC-2 pursuant to compliance of Section 134(3)(h) of the Companies Act, 2013 and Rule 8(2) of the Companies (Accounts) Rules, 2014 is not applicable to the Company for 2025-26 and hence does not form part of this report.

Your Company did not enter into any related party transactions during the year under review, which could be prejudicial to the interest of minority shareholder.

The disclosures as required are provided in accounting standard in relation to transactions with related parties which are forming the part of the notes to Financial Statements. The policy on Related Party Transaction is available on the website of the Company www.accretionpharma.com.

DEPOSITS

The Company has neither accepted nor renewed any deposits from the public within the meaning of Section 73 of the Companies Act, 2013 read with the Companies (Acceptance of Deposits) Rules, 2014 during the year under review.

MATERIAL CHANGES AND COMMITMENTS, IF ANY, AFFECTING THE FINANCIAL POSITION OF THE COMPANY WHICH HAVE OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR OF THE COMPANY TO WHICH THE FINANCIAL STATEMENTS RELATE AND THE DATE OF THE REPORT

There is no change taken place which affect the financial position of the Company between the end of the financial year of the Company to which the Financial Statements relate and the date of the report during the year under review.

CHANGE IN THE NATURE OF BUSINESS, IF ANY

There is no change in the nature of the business of the Company.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

A statement containing information on Conservation of energy, Technology absorption and foreign exchange earnings and outgo stipulated under Section 134(3)(m) of the Companies Act, 2013 read with Rule 8 of the Companies (Accounts) Rules, 2014, is annexed herewith as **Annexure A** to this Report.

DIRECTORS AND KEY MANAGERIAL PERSONNEL

Your Company has well constituted Board in accordance with the provisions of the Companies Act, 2013 and Article of Association of the Company.

Appointment

- Mr. Chand Rameshbhai Kanabar: Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors appointed Mr. Chand Rameshbhai Kanabar as an Additional Director designated as Non Executive Independent Director with effect from 19 April 2025, for a first term of five (5) consecutive years and subsequently, the Shareholders approved his appointment as a Non-Executive Independent Director at the 2nd Annual General Meeting of the Company held on 25 September 2025.
- Ms. Nishtha Harivanshi Pamnani: Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors appointed Ms. Nishtha Harivanshi Pamnani as an Additional Director designated as Non Executive Independent Director with effect from 10 June, 2025, for a first term of five (5) consecutive years and subsequently, the Shareholders approved her appointment as a Non-Executive Independent Director at the 2nd Annual General Meeting of the Company held on 25 September 2025.
- Mr. Mayur Popatlal Sojitra: Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors re-designated Mr. Mayur Popatlal Sojitra (DIN: 09108404), Executive Director as the Non-Executive Non-Independent of the Company and subsequently, the Shareholders approved his re-designation as Non-Executive Non-Independent at the 2nd Annual General Meeting of the Company held on 25 September 2025.
- CS Roshni Shah: The Board of Directors has appointed CS Roshni Shah as Company Secretary and Compliance Officer of the Company with effect from 01 September, 2025, in its Board Meeting held on 01 September, 2025.

Cessation

- Mr. Shyam Bhadresh Kapadia has resigned from the post of Non-Executive Independent Director of the Company with effect from 19 April, 2025.
- Mr. Vijay Bharatbhai Anadkat has resigned from the post of Non-Executive Independent Director of the Company with effect from 26 May, 2025.
- CS Bhavika Dhaval Makadia has resigned from the post of Company Secretary and Compliance Officer of the Company with effect from 01 September, 2025.

Retiring By Rotation

Mr. Hardik Mukundbhai Prajapati, Director, will retire by rotation and being eligible, offers himself for re-appointment as per the provisions of the Companies Act, 2013. A resolution seeking Members approval for his re-appointment forms part of the 3rd AGM Notice.

Apart from this, none of the Directors and Key Managerial Personnel have been appointed, ceased or resigned during the period under review.

BOARD OF DIRECTORS

The Company has a balanced Board of Directors, comprising an optimal mix of Executive and Non-Executive Directors, including Independent Directors and a Woman Director, as mandated by applicable law. This composition plays a vital role in Board processes, providing independent judgment on matters of strategy and performance. The Board consists of eminent individuals from diverse fields, each bringing valuable experience and expertise to the Company.

The composition of the Board, attendance at the Board Meetings during the year ended on 31 March, 2026 are given below:

Name of Director	Category	Attendance of Meetings during 2025-26	
		Board Meeting held during his/her tenure	Board Meeting attended during his/her tenure
Harshad Nanubhai Rathod	Chairman and Director and Chief Financial Officer	8	7
Vivek Ashokkumar Patel	Managing Director	8	8
Hardik Mukundbhai Prajapati	Executive Director	8	8
Mayur Popatlal Sojitra	Non-Executive Director	8	8
Grishma Ajayrao Shewale	Independent Director	8	8
Shyam Bhadresh Kapadia [#]	Independent Director	1	1
Vijay Bharatbhai Anadkat [@]	Independent Director	4	4
Chand Rameshbhai Kanabar [^]	Independent Director	7	7
Nishtha Harivanshi Pamnani ^{\$}	Independent Director	3	3

[#]Mr. Shyam Bhadresh Kapadia has resigned w.e.f. 19 April, 2025.

[@]Mr. Vijay Bharatbhai Anadkat has resigned w.e.f. 26 May, 2025.

[^]Mr. Chand Rameshbhai Kanabar has appointed as Independent Director w.e.f. 19 April, 2025.

^{\$}Ms. Nishtha Harivanshi Pamnani has appointed as Independent Director w.e.f. 10 June, 2025.

Number of meetings of the Board of Directors

During the year under review, 8 (Eight) Board Meetings were held on 19 April, 2025, 06 May, 2025, 13 May, 2025, 19 May, 2025, 10 June, 2025, 01 September, 2025, 14 November, 2025 and 10 March, 2026. The provisions of Companies Act, 2013 were adhered to while considering the time gap between two meetings.

BOARD PERFORMANCE EVALUATION

Pursuant to the provisions of the Companies Act, 2013 and Rules made there under, the Board has carried the evaluation of performance of Individual Directors including Independent Directors, Board as Whole and its Committees and performance of the Chairman of the Board, on the basis of qualification, experience, knowledge & competency, availability & attendance and fulfillment of functions assigned by the Board / Law, initiative and team work, commitment, contribution and integrity, independence, independent views and judgment, compliances with policies of the company, code of conduct & ethics, availability & attendance, adequacy of committee composition and expertise, evaluation of risk, grievance redressal for investors, conflict of interest, stakeholder value and responsibility, corporate culture and values and various other criteria as recommended by the Nomination and Remuneration Committee of the Company. The Directors expressed their satisfaction with the evaluation process and outcome.

Further, Separate meeting of Independent Directors was held on 10 March, 2026, without the presence of Non- Independent Directors, inter-alia, to review performance of Chairperson and Non-Independent Directors of the Company, to review performance of the entire Board of Directors of the Company, to assess the quality, quantity and timeliness of flow of information and to ensure adequate deliberations on related party transaction.

DECLARATION BY INDEPENDENT DIRECTORS

All the Independent Directors of the Company have given their declarations to the Company under Section 149(7) of the Companies Act, 2013 read with Regulation 25(8) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 that they meet the criteria of independence as provided under Section 149(6) of the Companies Act, 2013 read with Regulation 16(1)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. They have further declared that they are not debarred or disqualified from being appointed or continuing as directors of companies by the SEBI /Ministry of Corporate Affairs or any such statutory authority. The terms and conditions of the appointment of Independent Directors have been disclosed on the website of the Company www.accretionpharma.com.

In the opinion of the Board, all the Independent Directors are persons of integrity and possess the requisite expertise, experience, and proficiency to effectively discharge their duties and responsibilities.

COMMITTEE

A. Audit Committee

The Audit Committee serves as a vital link between the Management, Statutory Auditors, Internal Auditors, and the Board of Directors, overseeing the financial reporting process of the Company. Its primary role is to monitor the integrity of financial reporting, review the Company's internal financial control systems and governance practices, and evaluate the effectiveness of statutory and internal audit functions.

The Audit Committee has been constituted by the Board of the Directors in compliance with the provisions of Section 177 of the Companies Act, 2013 read with the rules made thereunder and Regulation 18 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) read with Part C of Schedule II of the SEBI Listing Regulations and the powers, role and terms of reference of the Committee are in accordance with the aforesaid requirements of the Act and SEBI Listing Regulations. Apart from the above, the Committee also carries out such functions /responsibilities entrusted on it by the Board of Directors from time to time. The Company Secretary of the Company acts as a Secretary to the Committee. The Chairman of the Committee is an Independent Director having knowledge in Finance.

During the year under review, the Audit Committee held Five (5) meetings on 19 April, 2025, 10 June, 2025, 01 September, 2025, 14 November, 2025 and 10 March, 2026. Time elapsed between two meetings never exceeded 120 days.

The composition of the Audit Committee and the details of the meetings attended by its members during the financial year ended 31 March, 2026 are as under:

Name of Committee Members	Designation	Category	Meeting held during his/her tenure	Meeting attended during his/her tenure
Shyam Bhadresh Kapadia [#]	Chairperson	Independent Director	1	1
Vijay Bharatbhai Anadkat [@]	Chairperson	Independent Director	1	1
Chand Rameshbhai Kanabar [^]	Chairperson	Independent Director	4	4
Harshad Nanubhai Rathod	Member	Director and CFO	5	4
Grishma Ajayrao Shewale	Member	Independent Director	5	5

[#]Mr. Shyam Bhadresh Kapadia ceased to be a Member of the Committee upon his resignation from the Board w.e.f. 19 April 2025.

[@]Mr. Vijay Bharatbhai Anadkat was appointed as the Chairperson of the Committee w.e.f. 19 April 2025 and ceased to be the Chairperson and a Member of the Committee upon his resignation from the Board w.e.f. 26 May 2025.

[^]Mr. Chand Rameshbhai Kanabar was appointed as a Member of the Committee w.e.f. 19 April 2025 and as the Chairperson of the Committee w.e.f. 10 June 2025.

During the year, the Board has accepted all the recommendations made by the Audit Committee

B. Nomination and Remuneration Committee

The Nomination and Remuneration Committee (NRC) has been constituted by the Board of the Directors in compliance with the provisions of Section 178 of the Companies Act, 2013 read with the rules made thereunder and Regulation 19 of the SEBI Listing Regulations read with Part D of Schedule II of the SEBI Listing Regulations and the powers, role and terms of reference of the Committee are in accordance with the aforesaid requirements of the Act and SEBI Listing Regulations.

Apart from the above, the Committee also carries out such functions/responsibilities entrusted on it by the Board of Directors from time to time. The Company Secretary of the Company acts as a Secretary to the Committee.

During the year under review, the Nomination & Remuneration Committee held Three (3) meeting on 19 April, 2025, 10 June, 2025 and 01 September, 2025.

The composition of the Nomination & Remuneration Committee and the details of the meetings attended by its members during the financial year ended 31 March, 2026 are as under:

Name of Committee Members	Designation	Category	Meeting held during his/her tenure	Meeting attended during his/her tenure
Shyam Bhadresh Kapadia [#]	Chairperson	Independent Director	1	1
Vijay Bharatbhai Anadkat [@]	Chairperson	Independent Director	1	1
Chand Rameshbhai Kanabar [^]	Chairperson	Independent Director	2	2
Harshad Nanubhai Rathod	Member	Director and CFO	3	2
Grishma Ajayrao Shewale	Member	Independent Director	3	3
Nishtha Harivanshi Pamnani [§]	Member	Independent Director	1	1

[#]Mr. Shyam Bhadresh Kapadia ceased to be a Member of the Committee upon his resignation from the Board w.e.f. 19 April 2025.

[@]Mr. Vijay Bharatbhai Anadkat was appointed as the Chairperson of the Committee w.e.f. 19 April 2025 and ceased to be the Chairperson and a Member of the Committee upon his resignation from the Board w.e.f. 26 May 2025.

[^]Mr. Chand Rameshbhai Kanabar was appointed as a Member of the Committee w.e.f. 19 April 2025 and as the Chairperson of the Committee w.e.f. 10 June 2025.

[§]Ms. Nishtha Harivanshi Pamnani was appointed as a Member of the Committee w.e.f. 10 June, 2025.

C. Stakeholders' Relationship Committee

The Stakeholders' Relationship Committee (SRC) has been constituted by the Board of the Directors in compliance with the provisions of Section 178 of the Companies Act, 2013 read with the rules made thereunder and Regulation 20 of the SEBI Listing Regulations read with Part D of Schedule II of the SEBI Listing Regulations and the powers, role and terms of reference of the Committee are in accordance with the aforesaid requirements of the Act and SEBI Listing Regulations. Apart from the above, the Committee also carries out such functions/responsibilities entrusted on it by the Board of Directors from time to time. The Company Secretary of the Company acts as a Secretary to the Committee.

During the year under review, the Stakeholders' Relationship Committee held One (1) meeting on 10 March, 2026.

The composition of the Stakeholders' Relationship Committee and the details of the meetings attended by its members during the financial year ended 31 March, 2026 are as under:

Name of Committee Members	Designation	Category	Meeting held during his/her tenure	Meeting attended during his/her tenure
Shyam Bhadresh Kapadia [#]	Chairperson	Independent Director	-----	-----
Vijay Bharatbhai Anadkat [@]	Chairperson	Independent Director	-----	-----
Chand Rameshbhai Kanabar [^]	Chairperson	Independent Director	1	1
Harshad Nanubhai Rathod	Member	Director and CFO	1	1
Grishma Ajayrao Shewale	Member	Independent Director	1	1

[#]Mr. Shyam Bhadresh Kapadia ceased to be a Member of the Committee upon his resignation from the Board w.e.f. 19 April 2025.

[@]Mr. Vijay Bharatbhai Anadkat was appointed as the Chairperson of the Committee w.e.f. 19 April 2025 and ceased to be the Chairperson and a Member of the Committee upon his resignation from the Board w.e.f. 26 May 2025.

[^]Mr. Chand Rameshbhai Kanabar was appointed as a Member of the Committee w.e.f. 19 April 2025 and as the Chairperson of the Committee w.e.f. 10 June 2025.

D. Corporate Social Responsibility Committee

The Corporate Social Responsibility (CSR) Committee has been constituted by the Board of the Directors in compliance with the requirements of Section 135 of the Companies Act, 2013 and rules made there under. The CSR Policy is available on the website of the Company www.accretionpharma.com. The powers, role and terms of reference of the Corporate Social Responsibility Committee covers the areas as mentioned under Section 135 of the Companies Act, 2013 and Companies (Corporate Social Responsibility Policy) Rules, 2014. Apart from the above, the Committee also carries out such functions/ responsibilities entrusted on it by the Board of Directors from time to time.

During the year under review, the Corporate Social Responsibility held One (1) meeting on 01 September, 2025.

The composition of the Corporate Social Responsibility Committee as on 31 March, 2026 is as under:

Name of Committee Members	Designation	Category	Meeting held during his/her tenure	Meeting attended during his/her tenure
Vivek Ashokkumar Patel	Chairperson	Managing Director	1	1
Harshad Nanubhai Rathod	Member	Director and CFO	1	1
Hardik Mukundbhai Prajapati	Member	Director	1	1
Vijay Bharatbhai Anadkat [@]	Member	Independent Director	-----	-----
Chand Rameshbhai Kanabar [^]	Member	Independent Director	1	1

[@]Mr. Vijay Bharatbhai Anadkat ceased to be a Member of the Committee upon his resignation from the Board w.e.f. 26 May 2025.

[^]Mr. Chand Rameshbhai Kanabar was appointed as a Member of the Committee w.e.f. 10 June 2025.

NOMINATION AND REMUNERATION POLICY

The Board has, on the recommendation of the Nomination and Remuneration Committee framed a policy for selection and appointment of Directors, Senior Management and their remuneration. Details of Remuneration under Section 197(12) of the Companies Act, 2013 and details required under Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are also stated in **Annexure B** which forms part of this Annual Report. Nomination and Remuneration policy can be assessed at www.accretionpharma.com.

The Remuneration policy covers the remuneration for the Directors (Chairman, Managing Director, Independent Directors and other Non-executive Directors) and other employees (under senior management cadre and management cadre).

PARTICULARS OF EMPLOYEES

The information pertaining to employee drawing remuneration as per Section 197(12) of the Companies Act, 2013 read with per Rule 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, pertaining to the names and other particulars of employees is available for inspection at the registered office of the Company during business hours on working days of the Company up to the date of ensuing AGM. Having regard to the provisions of Section 134 and Section 136 of the Companies Act, 2013, the Reports and Accounts are being sent to the Members excluding such information. Any Shareholder interested in obtaining a copy of the same may write to the Company Secretary and Compliance Officer either at the Registered Office address or by email to compliance@accretionpharma.com.

HUMAN RESOURCES

The Company firmly believes that its human capital is the cornerstone of its sustained growth, operational excellence, and long-term value creation. Recognizing that a skilled, engaged, and motivated workforce is fundamental to achieving its strategic objectives, the Company continues to strengthen its people practices by fostering a culture of integrity, collaboration, innovation, and continuous learning. The Company remains committed to providing an inclusive, performance-driven, and enabling work environment that encourages professional growth, employee well-being, and organisational excellence.

The Company continues to invest in building organisational capability through structured learning and development initiatives, leadership development programmes, talent management practices, and employee engagement interventions. These initiatives are aimed at enhancing employee competencies, strengthening leadership capabilities, and fostering a future-ready workforce aligned with the Company's evolving business priorities.

As on 31 March 2026, the Company had a total workforce of 132 employees, as compared to 121 employees as on 31 March 2025. The Company remains committed to attracting, developing, and retaining high-calibre talent while strengthening organisational capabilities to support sustainable growth and the successful execution of its long-term strategic objectives.

VIGIL MECHANISM / WHISTLE BLOWER POLICY

Pursuant to the provisions of section 177(10) of the Companies Act, 2013 and Regulation 22 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a Vigil Mechanism or 'Whistle Blower Policy' for directors, employees and other stakeholders to report genuine concerns, unethical behaviour, fraud or violation of company's code of conduct, has been established.

Over the years, the Company has built a strong reputation for conducting business with honesty and integrity, maintaining a zero-tolerance approach toward unethical behavior or wrongdoing. The policy safeguards whistleblowers' rights to report concerns or grievances and provides direct access to the chairman of the audit committee.

During the year under review, no instance has been reported under this policy. The said policy is available on the website of the Company www.accretionpharma.com.

STATUTORY AUDITORS

M/s V S S B & Associates, Chartered Accountants (Firm Registration No. 121356W), were re-appointed as the Statutory Auditors of the Company by the Board of Directors, which was subsequently approved by the Shareholders at the 2nd Annual General Meeting held on 25 September 2025. They have been appointed for a second term of five (5) consecutive years to hold office from the conclusion of the 2nd Annual General Meeting until the conclusion of the 7th Annual General Meeting of the Company to be held in the year 2030.

M/s V S S B & Associates, Chartered Accountants have carried out the Statutory Audit of the Company for financial year 2025-26 and the Report of the Statutory Auditor forms part of the Annual Report. The Statutory Auditors have not raised any qualification, observations or adverse remarks in their report. There were no frauds reported by the Statutory Auditors under the provisions of Section 143 of the Companies Act, 2013.

REPORTING OF FRAUD BY AUDITORS

There have been no instances of fraud reported by the Auditors u/s 143 (12) of the Companies Act, 2013 and rules framed there under either to the Company or to the Central Government.

COST AUDITORS AND RECORDS

In terms of the provisions of Section 148 of the Companies Act, 2013 read with the Companies (Cost Records and Audit) Rules, 2014, as amended from time to time, the Company is not required to maintain the Cost Records and Cost Accounts. Hence, the appointment of Cost Auditors is not applicable to the Company.

SECRETARIAL AUDITORS

The Board pursuant to Section 204 of the Companies Act, 2013 read with Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 had appointed Mr. Nimish Chunibhai Sakhiya, Proprietor, M/s. Sakhiya & Co., Practicing Company Secretary to conduct Secretarial Audit for the financial year 2025-26.

The Secretarial Audit Report in Form MR-3 for the financial year ended 31 March, 2026 which is annexed herewith as **Annexure C**, which forms part of this report. There were no qualifications, reservation, adverse remark or disclaimer in the report.

RISK MANAGEMENT

The Company has established a comprehensive risk management framework designed to identify potential risks across all aspects of its business and implement remedial measures to minimize any adverse impact. Recognizing that risk evaluation and mitigation are continuous processes, the Company remains fully committed to proactively identifying and addressing risks at every level of the organization.

The Risk Management Policy has been formulated and adopted by the Board of Directors in accordance with the provisions of the Companies Act, 2013 and the SEBI Listing Regulations. The Management periodically reviews the risk management framework and policies to ensure their effectiveness. The Board has identified and assessed the key risks outlined in the policy and has implemented appropriate mitigation strategies. As of now, there are no risks which, in the opinion of the Board, may threaten the existence of the Company.

ENVIRONMENT, HEALTH AND SAFETY

The Company remains fully committed to upholding the highest standards of Environment, Health, and Safety across all its operations. We firmly believe that a safe and healthy workplace is fundamental to the long-term success and sustainability of our business.

The Company pledges to identify and manage environmental and social risks associated with its operations, comply with all applicable environmental laws and regulations, and set and pursue targets aimed at avoiding, reducing, or mitigating negative impacts. Additionally, the Company is committed to promoting sustainable development through the responsible use and conservation of natural resources.

INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY

The Company has established a robust internal control system commensurate with the scale and complexity of its operations. The Company believes in a strong internal control framework, which is necessary for business efficiency, management effectiveness and safeguarding assets. The Company has a well-defined internal control system in place, which is designed to provide reasonable assurance related to operation and financial control.

The Company has a well-defined organizational structure, authority levels, internal rules and guidelines for conducting business transactions. The Company intends to undertake additional measures as necessary in line with its intent to adhere to procedures, guidelines and regulations as applicable in a transparent manner. The Management of the Company is responsible for ensuring that Internal Financial Control has been laid down in the Company and that controls are adequate and operating efficiently.

PROHIBITION OF INSIDER TRADING

In terms of the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended ("SEBI PIT Regulations"), the Company has adopted the revised "Code of Conduct to Regulate, Monitor and Report Trading by Insiders" ("the Code"). The Code is applicable to promoters, all directors, designated persons and connected persons and their immediate relatives, who are expected to have access to unpublished price sensitive information relating to the Company. The Company has also formulated a 'Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI)' in compliance with the PIT Regulations. The aforesaid codes are available on the website of the Company and can be accessed at www.accretionpharma.com.

SECRETARIAL STANDARDS

The Company has followed the applicable secretarial standards issued by the Institute of Company Secretaries of India (ICSI) during the year under review.

CORPORATE SOCIAL RESPONSIBILITY

The Company is committed to creating sustainable and measurable social impact through its Corporate Social Responsibility ("CSR") initiatives. The Company's CSR approach goes beyond statutory compliance and focuses on improving healthcare accessibility, affordability, and availability of quality healthcare. The Company aims to bridge the healthcare gap, promote preventive health, to improve healthcare infrastructure through strategic partnerships or contribution in various projects and to create sustainable and measurable social impact through healthcare interventions.

In terms of provisions of Section 135 of the Act read with the Companies (Corporate Social Responsibility Policy) Rules, 2014 ['the CSR Rules'], the Company has formulated a Corporate Social Responsibility Policy ('CSR Policy') outlining the framework and activities to be undertaken by the Company. The CSR Policy is available on the website of the Company and can be accessed at www.accretionpharma.com.

During the year, the Company was required to spend CSR expenditure of ₹11.76 Lacs as per the provisions of the Act. The Company has spent a total amount of ₹12.11 Lacs towards CSR activities during the year. The Annual Report on CSR activities in terms of the requirements of CSR Rules is annexed herewith as **Annexure D**, which forms part of this report.

DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORK PLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company believes in providing a safe and harassment free workplace for each and every individual working for it through various interventions and practices. It is the continuous endeavour of the management to create and provide an environment to all its employees that is free from discrimination and harassment including sexual harassment. It has adopted a policy against sexual harassment in line with the provisions of Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the rules framed thereunder. All employees (Permanent, Contractual, Temporary and Trainees) are covered under this Policy.

Your directors state that during the year under review, there were no complaints relating to sexual harassment nor any cases filed pursuant to the said Act.

DISCLOSURE UNDER THE MATERNITY BENEFIT ACT, 1961

During the year under review, the Company has complied with the provisions of the Maternity Benefit Act, 1961, as amended from time to time.

EXTRACT OF THE ANNUAL RETURN

The Annual Return of the Company as on 31 March, 2026 is available on the website of the Company i.e. www.accretionpharma.com pursuant to the provisions of Section 92 read with Section 134 of the Companies Act, 2013 and rules made there under.

CORPORATE GOVERNANCE

As the Company is listed on the NSE SME EMERGE platform, it is exempt from certain Corporate Governance regulations under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Nevertheless, the Company remains committed to practicing sound Corporate Governance by taking timely and appropriate actions to enhance and meet stakeholder expectations. It continues to comply with all mandatory provisions and actively strives to adhere to the non-mandatory guidelines of Corporate Governance.

Report on Corporate Governance Practices and the Auditors Certificate regarding compliance of conditions of Corporate Governance and certification by CEO & CFO is not applicable to your Company as per regulation 15(2)(b) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERN STATUS AND COMPANY'S OPERATIONS IN FUTURE

During the financial year, the Company received a Show Cause Notice from the Securities and Exchange Board of India (SEBI) vide letter no. SEBI/HO/EAD/EAD1/P/OW/2025/00027452/1 dated 28 October, 2025 under Rule 4(1) of the SEBI (Procedure for Holding Inquiry and Imposing Penalties) Rules, 1995, read with Section 15-I of the Securities and Exchange Board of India Act, 1992. The Company submitted its response to the said Show Cause Notice and subsequently attended a personal hearing pursuant to the notice issued by SEBI vide letter no. SEBI/HO/EAD/EAD-1/AK/RK/OW/2025/000030276/1 dated 03 December, 2025. Thereafter, SEBI passed an Adjudication Order bearing no. Order/AK/RK/2025-26/31951-31952 dated 07 January, 2026, imposing a monetary penalty of ₹1,00,000 under Section 15HB of the SEBI Act. The Company has duly complied with the said Order by paying the prescribed penalty.

The management believes that the aforesaid matter has been appropriately addressed and resolved through compliance with the Adjudication Order. The said Order does not have any material adverse impact on the Company's financial position, operational performance, or its ability to continue as a going concern.

Accordingly, except for the matter stated above, there were no significant and material orders passed by any regulator, court, or tribunal during the year which could have an adverse impact on the going concern status of the Company or its future operations.

DIRECTORS' RESPONSIBILITY STATEMENT

In accordance with the provisions of section 134(3)(c) of the Act, 2013, with respect to Director's Responsibility Statement, it is hereby stated :

- a. that in the preparation of the annual accounts for the year ended 31 March, 2026, the applicable accounting standards had been followed along with proper explanation relating to material departures, if any;
- b. that such accounting policies as mentioned in Notes to the Financial Statements had been selected and applied consistently and judgment and estimates have been made that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at 31 March, 2026 and of the profit of the Company for the year ended on that date;
- c. that proper and sufficient care had been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

- d. that the annual accounts for the year ended 31 March, 2026 had been prepared on a going concern basis;
- e. The Company is following up the proper Internal financial controls and such internal financial controls are adequate and are operating effectively; and
- f. that systems to ensure compliance with the provisions of all applicable laws were in place and were adequate and operating effectively.

GENERAL DISCLOSURES

Your Directors state that no disclosure or reporting is required in respect of the following items, as there were no transactions/events of this nature during the year under review:

- a. Issue of equity shares with differential rights as to dividend, voting or otherwise.
- b. Provision of money by company for purchase of its own shares by employees or by trustees for the benefit of employees.
- c. Issue of employee stock options scheme.
- d. Issue of Shares (including Sweat Equity Shares) to employees of your Company under any scheme.
- e. There was no application made or proceeding pending under the Insolvency and Bankruptcy Code, 2016 (31 of 2016) during the year.
- f. There has been no instance of valuation done for settlement or for taking loan from the Banks or Financial Institutions.
- g. The Company did not face any incidents or breaches or loss of data breach in cyber security.

ACKNOWLEDGMENTS

The Directors wish to express their sincere appreciation to all business associates for their valuable support and contributions during the year. The Directors also extend their gratitude to the Company's employees, customers, suppliers, alliance partners, bankers, and all other stakeholders for their continued support and the confidence they have placed in the management.

By Order of the Board of Directors

For Accretion Pharmaceuticals Limited

Date : 08 May, 2026

Place : Ahmedabad

Harshad Nanubhai Rathod

Director and CFO

DIN: 09108392

Vivek Ashok Kumar Patel

Managing Director

DIN: 09130357

ANNEXURE A

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

[Section 134(3) (m) of the Act read with Rule 8(3) of the Companies (Accounts) Rules, 2014]

A Conservation of energy

i) The steps taken or impact on conservation of energy

The Company remains committed to sustainable manufacturing practices and continuously undertakes initiatives to improve energy efficiency across its operations. Various energy conservation measures have been implemented at the manufacturing facilities, including optimization of process parameters, efficient utilization of utilities, preventive maintenance of equipment, and monitoring of energy consumption. These initiatives have contributed to reduced energy wastage, improved operational efficiency, and responsible utilization of natural resources.

ii) The steps taken by the company for utilising alternate sources of energy

As part of its commitment to environmental sustainability and reduction of carbon footprint, the Company has adopted renewable energy solutions. A rooftop solar power generation system has been installed at the manufacturing facility to supplement the Company's energy requirements through a clean and sustainable source of power. The solar installation currently contributes approximately 15% of the total electricity requirement of the manufacturing operations, thereby reducing dependence on conventional energy sources.

iii) The capital investment on energy conservation equipments

The Company continued to utilize its rooftop solar power generation system with an installed capacity of 129 KVA at its manufacturing facility. This investment reflects the Company's ongoing commitment towards energy conservation, sustainability, and operational efficiency.

B Technology Absorption

i) The efforts made towards technology absorption

As a Contract Development and Manufacturing Organization (CDMO) serving the pharmaceutical industry, the Company continuously focuses on the absorption, adaptation, and implementation of advanced technologies to enhance manufacturing capabilities, process efficiency, product quality, and regulatory compliance. Ongoing efforts include process optimization, automation of critical operations, strengthening quality systems, and adoption of modern manufacturing and analytical practices in line with current industry standards and customer requirements.

ii) The benefits derived like product improvement, cost reduction, product development or import substitution

The technology initiatives undertaken by the Company have resulted in significant benefits, including: improved process efficiency and manufacturing productivity, enhanced product quality, consistency, and regulatory compliance, optimization of resource utilization and reduction in operational costs, improved energy efficiency and environmental performance, strengthening of development and manufacturing capabilities for existing and new products and enhanced competitiveness in domestic and international markets.

iii) In case of imported technology (imported during the last three years reckoned from the beginning of the financial year) – Not Applicable

- a) The details of technology imported – Nil.
- b) The year of import – Not Applicable
- c) Whether the technology been fully absorbed – Not Applicable
- d) If not fully absorbed, areas where absorption has not taken place, and the reasons thereof – Not Applicable

iv) The expenditure incurred on Research and Development – Not Applicable

C Foreign exchange earnings and Outgo

The Foreign Exchange earned in terms of actual inflows during the year and the Foreign Exchange outgo during the year in terms of actual outflows.

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Foreign Exchange Earned	766.44	476.39
Outgo of Foreign Exchange	16.28	0.00

By Order of the Board of Directors

For Accretion Pharmaceuticals Limited

Date : 08 May, 2026

Place : Ahmedabad

Harshad Nanubhai Rathod

Director and CFO

DIN: 09108392

Vivek Ashok Kumar Patel

Managing Director

DIN: 09130357

ANNEXURE B

STATEMENT OF DISCLOSURE OF REMUNERATION UNDER SECTION 197 OF THE COMPANIES ACT 2013 AND RULE 5(1) OF THE COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL) RULES, 2014

- i) Ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the financial year ended 31 March, 2026.

Name	Designation	Ratio of Remuneration of each director to median remuneration of employees
Harshad Nanubhai Rathod	Chairman and Director and Chief Financial Officer	10.04
Vivek Ashokkumar Patel	Managing Director	10.04
Mayur Popatlal Sojitra	Director	10.04
Hardik Mukundbhai Prajapati	Director	10.04

Further, all the Independent Directors of the Company are entitled for sitting fees.

- ii) The percentage increase in remuneration of each Director, Chief Executive Officer, Chief Financial Officer, Company Secretary, or Manager, if any, in the financial year ended 31 March, 2026:

Name	Designation	Percentage (%) increase in Remuneration in the year 2025-26
Harshad Nanubhai Rathod	Chairman and Director and Chief Financial Officer	65.63%
Vivek Ashokkumar Patel	Managing Director	65.63%
Mayur Popatlal Sojitra	Director	65.63%
Hardik Mukundbhai Prajapati	Director	65.63%
*CS Bhavika Dhaval Makadia	Company Secretary	-----
*CS Roshni Shah	Company Secretary	Not Applicable

*CS Bhavika Dhaval Makadia has resigned and CS Roshni Shah has appointed w.e.f. 01 September, 2025.

iii)

Particulars	Details
% increase in the median remuneration of employees in the financial year ended 31 March, 2026	18.55%
Total number of permanent employees on the rolls of the company as on 31 March 2026 (on standalone basis)	132
The median remuneration of employees of the Company during the year under review	2,64,000
Average percentile increases already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration	The average increase in salaries of employees other than managerial personnel in 2025-2026 was about 11.15%. Percentage increase in the managerial remuneration for the year was 65.63%. The increase in managerial remuneration is as per the resolution approved by shareholders in the general meeting and inconsistent with the overall performance of the company. Annual increment in the salary is based on the different grades, industry pattern, qualification, expertise and experience of individual employee. As such the annual increment / remuneration is as per the terms of appointment and is in conformity with the remuneration policy of the Company.

iv) The Company affirms remuneration is as per the Remuneration Policy of the Company.

By Order of the Board of Directors

For Accretion Pharmaceuticals Limited

Date : 08 May, 2026

Place : Ahmedabad

Harshad Nanubhai Rathod

Director and CFO

DIN: 09108392

Vivek Ashok Kumar Patel

Managing Director

DIN: 09130357

ANNEXURE C

Form No. MR-3

SECRETARIAL AUDIT REPORT

FOR THE FINANCIAL YEAR ENDED 31 MARCH, 2026

[Pursuant to section 204(1) of the Companies Act, 2013 and rule No.9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014]

SECRETARIAL AUDIT REPORT

FOR THE FINANCIAL YEAR ENDED 31 MARCH, 2026

To,

The Members,

Accretion Pharmaceuticals Limited

29, Xcelon Industrial Park 1,

B/h Intas Pharmaceuticals,

Vasna Chacharvadi, Sanand,

Ahmedabad – 382 213, Gujarat, India

I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Accretion Pharmaceuticals Limited (CIN: L21004GJ2023PLC146545) hereinafter called “the company”. Secretarial Audit was conducted in a manner that provided me/us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, I hereby report that in my opinion, the company has, during the audit period covering the financial year ended on 31 March, 2026 complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

I have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on 31 March, 2026 according to the provisions of:

- 1) The Companies Act, 2013 (the Act) and the rules made thereunder;
- 2) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made thereunder;
- 3) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- 4) Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder;
- 5) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-
 - a) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009;

- b) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
- c) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992;
- d) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- e) The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999; - Not Applicable
- f) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; - Not Applicable
- g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009; - Not Applicable
- h) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998; - Not Applicable

I/we further report that,

During the period under review, the Securities and Exchange Board of India (SEBI) issued Adjudication Order No. **Order/AK/RK/2025-26/31951-31952 dated 07 January, 2026**, imposing a monetary penalty of **₹ 1,00,000/- (Rupees One Lac Only)** on the Company under Section 15HB of the SEBI Act, 1992. The penalty was imposed for non-compliance with **Regulation 263 read with Clauses 1, 5 and Explanation I of Schedule IX of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 ('SEBI ICDR Regulations')**, on account of forward-looking financial projections (revenue estimates) made by the management during an Investors' Meet held on 13 May, 2025 prior to the opening of the Initial Public Offering (IPO), which were not disclosed in the Draft Red Herring Prospectus (DRHP) or Red Herring Prospectus (RHP) of the Company.

We further report that the Company has duly paid and remitted the said penalty amount of ₹ 1,00,000/- to SEBI within the prescribed time-line of 45 days, thereby fully settling the adjudication proceeding.

We have examined in a very limited manner, the systems and processes in place to ensure compliance with specific laws like the Drugs (Control) Act, 1950, Food Safety and Standards Act, 2006, Drugs and Cosmetics Act, 1940, The Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, Environment (Protection) Act, 1986, The Hazardous and other Wastes (Management and Transboundary Movement) Rules, 2016, The Water (Prevention & Control of Pollution) Act, 1974, The Air (Prevention & Control of Pollution) Act, 1981, the Bio-Medical Waste Management Rules, 2016, The Petroleum Act, 1934, Indian Boilers Act, 1923 and The Narcotic Drugs and Psychotropic Substances Act, 1985 considering and relying upon confirmations made by the Company and its Officers for systems and mechanism formed by the Company for compliances under these laws.

We have also examined compliance with the applicable Standards/ Regulations of the following:

- i) Secretarial Standards with regard to Meeting of the Board of Directors (SS-1) and General Meetings (SS-2) issued by The Institute of Company Secretaries of India;

- ii) The Listing Agreements entered into by the Company with the Stock Exchanges: Applicable to the extent of Equity shares listed during the period under review.

During the period under audit, the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above.

I/we further report that,

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors including a Woman Director and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notices were given to all directors of the Company as regards the schedule of the Meetings of the Board (including Meetings of its Committees), except where consent of the directors were received for scheduling the meetings at a shorter notice. Agenda and detailed notes on agenda were also sent to all the directors of the Company at least seven days in advance, except where consent of directors was received for circulation of the Agenda and notes on Agenda at a shorter notice. A system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for ensuring meaningful participation by the directors at the meetings. All decisions at the Meetings of the Board and its Committees were carried out unanimously as recorded in the minutes of the meetings of the Board of Directors or Committees of the Board, as the case may be.

Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes.

We further report that there are adequate systems and processes in the Company commensurate with its size and operations to monitor and ensure compliance with the applicable laws, rules, regulations and guidelines.

We further report that during the period under audit, no specific events/ actions which having a major bearing on the Company's affairs have taken place, in pursuance of the above referred laws, rules, regulations and standards.

We further report that during the period under audit, the following specific events/actions having major bearing on the Company's affairs have taken place in pursuance of the above referred laws, rules, regulations and standards:

- i) The Company allotted 29,46,000 equity shares of face value of ₹ 10/- each at a premium of ₹ 91/- per share (issue price of ₹ 101/- per share) as on 19 May, 2025 pursuant to the Initial Public Offer (IPO).
- ii) The equity shares of the Company were officially listed and commenced trading on the SME platform of the National Stock Exchange of India Limited (NSE Emerge) with effect from 21 May, 2025.
- iii) The Company passed Special resolution, at Annual General Meeting held on 25 September, 2025, for

- a) Revision of limits of advancing loan(s), giving any guarantee(s) and/or to providing any security (ies) to the Subsidiary (ies) of the Company.
- b) Appointment of Mr. Chand Rameshbhai Kanabar (DIN: 10706050) as an Independent Director.
- c) Appointment of Ms. Nishtha Harivanshi Pamnani (DIN: 10881910) as an Independent Director.
- d) Re-designation of Mr. Mayur Popatlal Sojitra (DIN: 09108404), Executive Director as the Non-Executive, Non-Independent of the Company and approval remuneration.
- e) Revision in remuneration of Mr. Harshad Nanubhai Rathod (DIN: 09108392), Director and CFO of the Company.
- f) Revision in remuneration of Mr. Vivek Ashokkumar Patel (DIN: 09130357), Managing Director of the Company.
- g) Revision in remuneration of Mr. Hardik Mukundbhai Prajapati (DIN: 09108403), Director of the Company.

We further report that our Audit was subjected only to verifying adequacy of systems and procedures that are in place for ensuring proper compliance by the Company and we are not responsible for any lapses in those compliances on the part of the Company. The compliance with provisions of applicable laws which have been subject to other audits have not been independently reviewed by us and the reports wherever shown to us have been relied upon in rendering our report.

We further report that we have conducted the secretarial audit whenever required through online verification and examination of records, as requested and facilitated by the company, for the purpose of issuing this Report.

For Sakhiya & Co.

Practicing Company Secretaries
ICSI Firm Unique Code: S2019GJ689300
Peer Review Certificate No. 4057/2023

CS Nimish Sakhiya

ProprietorPlace : Rajkot
ICSI Membership No. : 35847
ICSI Certificate of Practice No. : 22239
ICSI Unique Document Identification Number : A035847H000309835

Date : 08 May, 2026
Place : Rajkot

Note: This report is to be read with our letter of even date which is annexed as **Annexure A** and forms an integral part of this report.

Annexure A

To,

The Members,

Accretion Pharmaceuticals Limited

29, Xcelon Industrial Park 1,

B/h Intas Pharmaceuticals,

Vasna Chacharvadi, Sanand,

Ahmedabad – 382 213, Gujarat, India

Auditor's Responsibility

Based on audit, our responsibility is to express an opinion on the compliance with the applicable laws and maintenance of records by the Company. We conducted our audit in accordance with the auditing standards CSAS 1 to CSAS 4 (“CSAS”) prescribed by the Institute of Company Secretaries of India (“ICSI”). These standards require that the auditor complies with statutory and regulatory requirements and plans and performs the audit to obtain reasonable assurance about compliance with applicable laws and maintenance of records.

Due to the inherent limitations of an audit including internal, financial and operating controls, there is an unavoidable risk that some misstatements or material non-compliances may not be detected, even though the audit is properly planned and performed in accordance with the CSAS. Our report of even date is to be read along with this letter.

- 1) Maintenance of secretarial record is the responsibility of the management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.
- 2) We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
- 3) We have not verified the correctness and appropriateness of financial records, financial statements and Books of Accounts of the company and for which we relied on the report of statutory auditor.
- 4) Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
- 5) The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.

- 6) The Secretarial Audit report is neither an assurance as to the future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the company.

For Sakhiya & Co.

Practicing Company Secretaries
ICSI Firm Unique Code: S2019GJ689300
Peer Review Certificate No. 4057/2023

CS Nimish Sakhiya

ProprietorPlace : Rajkot
ICSI Membership No. : 35847
ICSI Certificate of Practice No. : 22239
ICSI Unique Document Identification Number : A035847H000309835

Date : 08 May, 2026
Place: Rajkot

ANNEXURE D

REPORT ON CORPORATE SOCIAL RESPONSIBILITY (CSR) ACTIVITIES

1) Brief outline on CSR Policy of the Company.

Accretion Pharmaceuticals Limited is committed to creating sustainable and measurable social impact through its Corporate Social Responsibility ("CSR") initiatives. The Company's CSR approach goes beyond statutory compliance and focuses on improving healthcare accessibility, affordability, and availability of quality healthcare. We aim to bridge the healthcare gap, promote preventive health, to improve healthcare infrastructure through strategic partnerships or contribution in various projects and to create sustainable and measurable social impact through healthcare interventions.

The Company's CSR programs are aligned with Schedule VII of the Companies Act, 2013 and are designed to improve healthcare accessibility, promote preventive healthcare, support public health infrastructure, and contribute toward healthier communities.

2) Composition of CSR Committee:

Name	Designation / Nature of Directorship	Number of meetings of CSR Committee held during the year	Number of meetings of CSR Committee attended during the year
Vivek Ashokkumar Patel	Chairman / Managing Director	1	1
Harshad Nanubhai Rathod	Member / Director and Chief Financial Officer	1	1
Hardik Mukundbhai Prajapati	Member / Director	1	1
Vijay Bharatbhai Anadkat®	Member / Independent and Non-Executive Director	-----	-----
Chand Rameshbhai Kanabar^	Member / Independent and Non-Executive Director	1	1

@Mr. Vijay Bharatbhai Anadkat ceased to be a Member of the Committee upon his resignation from the Board w.e.f. 26 May, 2025.

^Mr. Chand Rameshbhai Kanabar was appointed as a Member of the Committee w.e.f. 10 June 2025.

3) Provide the web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the Board are disclosed on the website of the company:

- Composition of CSR Committee: <https://accretionpharma.com/committees/>
- CSR Policy: <https://accretionpharma.com/wp-content/uploads/2026/06/CORPORATE-SOCIAL-RESPONSIBILITY-POLICY.pdf>
- CSR projects approved by the Board: <https://accretionpharma.com/corporate-social-responsibility/>

4) Provide the executive summary along with web-link (s) of Impact Assessment of CSR Projects carried out in pursuance of sub-rule (3) of rule 8, if applicable : Not applicable

- 5) a) Average net profit of the Company as per sub-section (5) of section 135 : ₹ 587.94 Lacs
- b) Two percent of average net profit as per sub-section (5) of section 135 : ₹ 11.76 Lacs
- c) Surplus arising out of the CSR projects or programmes or activities of the previous financial years : Nil
- d) Amount required to be set off for the financial year, if any : Nil
- e) Total CSR obligation for the financial year $[5(b) + 5(c) - 5(d)]$: ₹ 11.76 Lacs
- 6) a) Amount spent on CSR Projects (both Ongoing Project and other than Ongoing Project):

Name of the Project.	Item from the list of activities in Schedule VII to the Act.	Local area (Yes/No).	Location of the Project.		Amount spent for the Project (₹ in Lacs).	Mode of Implementation Direct (Yes / No).	Mode of Implementation Through Implementing Agency	
			State	District			Name	CSR Registration number
Contribution towards Healthcare	Clause (i) Promoting Healthcare	Yes	Gujarat	Ahmedabad	₹ 12.11	No	Lilavati Foundation	CSR00022421

- b) Amount spent in Administrative overheads : Nil
- c) Amount spent on Impact Assessment, if applicable. : Not Applicable
- d) Total amount spent for the Financial Year $[6(a)+6(b)+6(c)]$: ₹ 11.76 Lacs
- e) CSR amount spent or unspent for the financial year:

Total Amount Spent for the Financial Year. (in ₹)	Amount Unspent (in ₹)				
	Total Amount transferred to Unspent CSR Account as per sub-section (6) of section 135.		Amount transferred to any fund specified under Schedule VII as per second proviso to sub-section (5) of section 135.		
	Account	Date of Transfer	Name of fund	Account	Date of Transfer
₹ 11.76 Lacs	NIL		NIL		

f) Excess amount for set off, if any:

Particular	₹ in Lacs
Two percent of average net profit of the company as per sub-section (5) of section 135	11.76
Total amount spent for the financial year	12.11
Excess amount spent for the financial year [(ii)-(i)]	0.35
Surplus arising out of the CSR projects or programmes or activities of the previous financial years, if any	Nil
Amount available for set off in succeeding financial years [(iii)-(iv)]	0.35

7) Details of unspent CSR amount for the preceding three financial years:

Preceding Financial Year	Amount transferred to Unspent CSR Account under sub-section (6) of section 135 (₹ in Lacs)	Balance Amount in Unspent CSR Account under sub-section (6) of section 135 (₹ in Lacs)	Amount spent in the reporting Financial Year (₹ in Lacs)	Amount transferred to any fund specified under Schedule VII as per section 135(6), if any.		Amount remaining to be spent in succeeding financial years. (₹ in Lacs)	Deficiency, if any
				Amount (₹ in Lacs)	Date of Transfer		
2024-25	NIL						
2023-24							
2022-23							

8) Whether any capital assets have been created or acquired through Corporate Social Responsibility amount spent in the Financial Year : No**9) Specify the reason(s), if the company has failed to spend two per cent of the average net profit as per sub-section (5) of section 135 : Not Applicable**

By Order of the Board of Directors

For Accretion Pharmaceuticals LimitedDate : 08 May, 2026
Place : Ahmedabad**Harshad Nanubhai Rathod**
Director and CFO and
Member of CSR Committee
DIN: 09108392**Vivek Ashok Kumar Patel**
Managing Director and
Chairman of CSR Committee
DIN: 09130357

FINANCIAL STATEMENT

INDEPENDENT AUDITOR'S REPORT

To,

The Members of,

ACCRETION PHARMACEUTICALS LIMITED

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the accompanying Standalone financial statements of **Accretion Pharmaceuticals Limited** ("the Company"), which comprise the balance sheet as at 31 March 2026, and the statement of profit and loss and statement of cash flows and notes to the financial statement, for the year ended 31 March 2026, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Standalone Financial Statements gives the information required by the Companies Act, 2013 ("the ACT") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March, 2026, and its **Profit**, its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit of the Standalone Financial Statements in accordance with the Standard on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Statements* section of our report. We are independent of the Company in accordance with the *Code of Ethics* issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the Standalone Financial Statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on Standalone Financial Statement.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the Standalone Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined the matters described below to be the key audit matters to be communicated in our report.

SR No.	Key Audit Matter	How our audit addressed the key audit matter
01	Revenue Recognition: The Revenues of the Company consists primarily of sale of products and is recognized when control of products being sold is transferred to customer and there is no unfulfilled obligation. Revenue is measured at fair value of the consideration received or receivable and is accounted for net of trade discounts. Considering the materiality of amounts involved, the same has been considered as a key audit matter.	Our key procedures included, but were not limited to, the following: a) Assessed the appropriateness of the Company's revenue recognition accounting policies, including those relating to trade discounts by comparing with the applicable accounting standards; b) Tested the design and operating effectiveness of the general IT control environment and the manual controls for recognition of revenue, calculation of discounts; c) Performed test of details: • Tested, on a sample basis, sales transactions to the underlying supporting documentation which includes goods dispatch notes and shipping documents; • Reviewed, on a sample basis, sales agreements and the underlying contractual terms related to delivery of goods, Company's revenue recognition policies with reference to the requirements of the applicable accounting standards; • Obtained supporting documentation for a sample of credit notes issued after the year end to determine whether the transaction was recognized in the correct accounting period; and d) Assessed the appropriateness of the Company's description of the accounting policy, disclosures related to discounts, and incentives and whether these are adequately presented in the standalone financial statements.

Information other than the Standalone financial statements and Auditor's Report Thereon

- The Company's Management and Board of Directors are responsible for the other information. The other information comprises the information included in the Annual Report, but does not include the standalone financial statements and our auditor's report thereon.

- Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.
- In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's and Board of Directors' Responsibilities for the Standalone Financial Statements

The Company's Management and Board of Directors are responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, cash flows in accordance with the accounting principles generally accepted in India, including the accounting standards specified under section 133 of the Act.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, Management and Board of Director's are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the Standalone Financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Standalone Financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to Standalone Financial statement in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Standalone Financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial statements, including the disclosures, and whether the Standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Standalone Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Standalone Financial Statements may be influenced.

We consider quantitative materiality and qualitative factors (i) in planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Standalone Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Standalone Financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

- 1) As required by Section 143(3) of the Act, based on our audit, we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the accompanying Standalone Financial Statements.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books except for the matter stated in the paragraph 1h(F) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.
 - c) The standalone balance sheet, the standalone statement of profit and loss, and the standalone statement of cash flows dealt with by this Report are in agreement with the books of account.
 - d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - e) On the basis of the written representations received from the directors as on 31 March, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.
 - f) The modification relating to the maintenance of accounts and other matters connected therewith are as stated in the paragraph 1(b) above on reporting under Section 143(3) (b) of the Act and paragraph 1h(F) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.
 - h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
 - A. The Company does not have any pending litigations which would impact its financial position
 - B. The Company does not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - C. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

- D. i) The management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
- ii) The management has represented, that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
- iii) Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e) of the Companies (Audit and Auditors) Rules, 2014, as provided under (a) and (b) above, contain any material misstatement.
- E. The company has not declared or paid any dividend during the year in contravention of the provisions of section 123 of the Companies Act, 2013.
- F. Based on our examination, which included test checks, the Company has used accounting software systems for maintaining its books of account for the year ended 31 March, 2026 which have the feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software systems. Further, during the course of our audit we did not come across any instance of the audit trail feature being tampered with, and the audit trail has been preserved by the Company as per the statutory requirements for record retention.
- 2) As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government in terms of Section 143(11) of the Act, we give in "**Annexure B**" a statement on the matters specified in paragraphs 3 and 4 of the Order.
- 3) As required by section 197(16) of the Act based on our audit, we report that the Company has paid remuneration to its directors during the year in accordance with the provisions of and limits laid down under section 197 read with Schedule V to the Act.

Date : 08 May, 2026
Place : Ahmedabad

For, V S S B & Associates
Chartered Accountants
Firm No. 0121356W

Vishves A. Shah
Partner
M. No. 109944
UDIN: 26109944KXOBZD4848

“ANNEXURE A” to Independent Audit Report

(Referred to in paragraph 1(g) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Report on the Internal Financial Controls with reference to Standalone Financial Statement under clause (i) of sub-section 3 of section 143 of the Companies Act, 2013 (“the Act”)

We have audited the Internal Financial Controls over financial reporting of **Accretion Pharmaceuticals Limited** (“the Company”) as of 31 March, 2026 in conjunction with our audit of the Standalone Financial Statements of the Company for the year ended on that date.

Management's and Board of Director's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control with reference to Standalone Financial Statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under -section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to Standalone Financial Statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to Standalone Financial Statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to Standalone Financial Statements and their operating effectiveness. Our audit of internal financial controls with reference to Standalone Financial Statements included obtaining an understanding of internal financial controls with reference to Standalone Financial Statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to Standalone Financial Statements.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that

- 1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
- 2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and
- 3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to Standalone Financial Statements to future periods are subject to the risk that the internal financial control with reference to Standalone Financial Statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls with reference to Standalone Financial Statements and such internal financial controls with reference to Standalone Financial Statements were operating effectively as at 31 March, 2026, based on the criteria for internal financial control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

Date : 08 May, 2026

Place : Ahmedabad

For, V S S B & Associates

Chartered Accountants

Firm No. 0121356W

Vishves A. Shah

Partner

M. No. 109944

UDIN: 26109944KXOBZD4848

“ANNEXURE B” to the Independent Audit Report

(Referred to in paragraph 2 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

The Annexure referred to in our Independent Auditor's Report to the members of the Company on the Standalone Financial Statements for the year ended 31 March, 2026, we report that:

i) In respect of the Company's Property, Plant and Equipment and Intangible Assets:

- a) i) According to the information and explanation given to us and the records produced to us for our verification, the Company is maintaining proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.
- ii) According to the information and explanation given to us and the records produced to us for our verification, the Company has no intangible assets during the financial year. Hence this clause is not applicable.
- b) According to the information and explanation given to us and the records produced to us for our verification, the Company has a regular programme of physical verification of its Property, Plant and Equipment's by which all Property, Plant and Equipment's are verified by the management at least once in every three years. In accordance with this programme, certain Property, Plant and Equipment were verified during the year and the discrepancies noticed on verification were not material and have been appropriately dealt with in the books of accounts. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets.
- c) According to the information and explanation given to us and the records produced to us for our verification, the title deeds of all the immovable properties disclosed in the Standalone Financial Statements are held in the name of the Company.
- d) According to the information and explanation given to us and the records produced to us for our verification, the Company has not revalued its Property, Plant and Equipment (including ROU) or intangible assets or both during the year. Accordingly, clause 3(i)(d) of the Order is not applicable.
- e) According to the information and explanation given to us and the records produced to us for our verification, no proceedings have been initiated or are pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 (as amended in 2016) and rules made thereunder.

ii) In respect of the Company's Inventories

- a) The Inventory other than goods in transit, have been physically verified by the management during the year at reasonable intervals. In our opinion, the frequency of verification is reasonable and the coverage and procedure of such verification is appropriate. The discrepancies noticed on verification between the physical stocks and the book records were not 10% or more in aggregate and have been appropriately dealt with in the books of account.

- b) According to the information and explanation given to us and the records produced to us for our verification, the Company has been sanctioned working capital limits in excess of five crore rupees, in aggregate from banks on the basis of security of current assets and the quarterly returns/statements filed by the Company with such banks are in agreement with the books of account of the Company.
- iii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured to companies, firms, limited liability partnership or any other parties during the year other than loan to employees. Therefore, the provisions of Clause 3(iii), (iii)(a), (iii)(b) and (iii)(c) of the said Order are not applicable to the Company.
- iv) In our opinion and according to information and explanations given to us and representations made by the Management, the Company has not made investments, given any loans, or provided guarantees or securities, to the parties covered under section 185 of the Companies Act, 2013. Further, the Company has complied with the provisions of Section 186 of the Companies Act, 2013 in relation to investments made, loans and security given and guarantees provided by the Company.
- v) In our opinion and according to the information and explanations given to us, the Company has not accepted any deposits or any amount deemed to be deposits from the public within the meaning of the directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Act and the rules framed there under. Accordingly, clause 3(v) of the Order is not applicable to the Company.
- vi) The maintenance of cost records has not been specified by the Central Government under Section 148(1) of the Act, for the business activities carried out by the Company. Thus, reporting under clause (vi) of the Order is not applicable.
- vii) According to the information and explanations given to us, in respect of statutory dues:
- a) The Company has been regular in depositing statutory dues, including Goods and Service Tax, Cess and other material statutory dues applicable to it with the appropriate authorities. There were no undisputed amounts payable in respect of Goods and Service Tax, Cess and other material statutory dues in arrears as at 31 March, 2026 for a period of more than six months from the date they became payable.
 - b) There has been no statutory dues referred to in sub clause (a) in dispute. Hence, this clause is not applicable.
- viii) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not surrendered or disclosed previously undisclosed transactions as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961). Accordingly, clause 3(viii) of the Order is not applicable to the Company.

ix) In respect of loans and borrowings of the Company

- a) Based upon the audit procedures performed, the Company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender, although certain loans taken from related parties, which fell due during the year, were renewed/ extended prior to the due date and interest accrued and remaining unpaid has been added to loans outstanding at year end, as per terms of the agreement.
 - b) According to the information and explanations given to us and on the basis of our audit procedures, we report that the Company has not been declared willful defaulter by any bank, financial institution or any other lender.
 - c) According to the information and explanations given to us by the management, the Company has utilized the money obtained by way of term loan during the year for the purposes for which they were obtained.
 - d) According to the information and explanations given to us, and the procedures performed by us, and on an overall examination of the Standalone Financial Statements of the Company, we report that, prima facie, no funds raised on short term basis have been used by the Company for long-term purposes.
 - e) According to the information and explanations given to us and on an overall examination of the standalone financial statements of the Company, we report that the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures as defined under the Act.
 - f) The Company does not have any subsidiaries, joint ventures or associate companies. Therefore, the question of raising loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies does not arise.
- x) a) The Company has raised funds through an Initial Public Offer (IPO) by issuing equity shares as on 21 May 2025. Based on our examination of the records of the company and information and explanations provided to us, the funds raised have been applied for the purposes for which they were raised.
- b) During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally) and hence reporting under clause (x)(b) of the Order is not applicable to the Company.
- xi) a) During the course of our examination of the books and records of the Company, carried out in accordance with the generally accepted auditing practice in India, and according to the information and explanation given to us, no fraud by the Company or on the Company by its officers or employees has been noticed or reported during the year.
- b) According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Act has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of the Companies (Audit and Auditors) Rules, 2014 with the Central Government.

- c) As represented to us by the Management there were no whistle-blower complaints received by the Company during the year and up to the date of this report. As represented to us by the Management there were no whistle-blower complaints received by the Company during the year and up to the date of this report.
- xii) According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable.
- xiii) In our opinion, the Company is in compliance with section 177 and 188 of the Companies Act where applicable, for all transactions with the related parties and the details of related party transactions have been disclosed in the standalone financial statements etc. as required by the applicable accounting standards.
- xiv) a) In our opinion and based on our examination, the company has an internal audit system Commensurate with the size and nature of its business.
- b) We have received internal audit report hence we have considered internal audit report which were provided by the company during the audit period.
- xv) According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into any non-cash transactions, within the meaning of Section 192 of the Act, with directors or persons connected with them.
- xvi) a) In our opinion and according to the information and explanations given to us, the Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3 (xvi) (a) of the Order is not applicable to the Company.
- b) According to the information and explanations given to us and based on our examination of the records of the Company has not conducted any Non-Banking Financial or Housing Finance activities. Accordingly, clause 3 (xvi) (b) of the Order is not applicable to the Company.
- c) In our opinion and according to the information and explanations given to us, the company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3 (xvi) (c) of the Order is not applicable to the Company.
- d) There is no Core Investment Company as a part of the Group, hence, the requirement to report on clause 3 (xvi) (d) of the Order is not applicable to the Company.
- xvii) Based on our examination of the records of the Company, the Company has not incurred any cash losses during the financial year covered by our audit and in the immediately preceding financial year.
- xviii) There has been no resignation of the statutory auditors of the Company during the year. Accordingly, clause 3(xviii) of the Order is not applicable to the Company.

- xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the Standalone Financial Statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- xx) The Company has fully spent the required amount towards Corporate Social responsibility (CSR) and there are no unspent CSR amounts for the year requiring a transfer to a fund specified in Schedule VII of the Act or special account in compliance with the provision of sub-section (6) of Section 135 of the Act. Accordingly, reporting under clause 3(xx) of the Order is not applicable for the year.
- xx) The reporting under clause (xxi) is not applicable in respect of audit of the Company as company is not required to prepare Consolidated Financial Statement. Therefore, the provisions of Clause (xxi) of paragraph 3 of the order are not applicable to the Company.

Date : 08 May, 2026

Place : Ahmedabad

For, V S S B & Associates

Chartered Accountants

Firm No. 0121356W

Vishves A. Shah

Partner

M. No. 109944

UDIN: 26109944KXOBZD4848

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)
Balance Sheet as at 31 March, 2026

(₹ in lacs)

Particulars	Note	31 March, 2026	31 March, 2025
I. EQUITY AND LIABILITIES			
(1) Shareholders' Funds			
(a) Share Capital	3	1,111.60	817.00
(b) Reserves and Surplus	4	4,359.25	711.65
(c) Money Received against Share Warrants		-	-
Total		5,470.85	1,528.65
(2) Share application money pending allotment		-	-
(3) Non-current liabilities			
(a) Long-term Borrowings	5	86.25	116.77
(b) Deferred Tax Liabilities (Net)	6	27.24	19.45
(c) Other Long term Liabilities		-	-
(d) Long-term Provisions		-	-
Total		113.49	136.22
(4) Current liabilities			
(a) Short-term Borrowings	7	1,145.87	1,293.58
(b) Trade Payables	8		
- Due to Micro and Small Enterprises		158.87	183.90
- Due to Others		417.70	574.72
(c) Other Current Liabilities	9	7.86	4.47
(d) Short-term Provisions	10	353.42	265.90
Total		2,083.72	2,322.57
Total Equity and Liabilities		7,668.06	3,987.44
II. ASSETS			
(1) Non-current assets			
(a) Property, Plant and Equipment and Intangible Assets			
(i) Property, Plant and Equipment	11	1,321.17	609.09
(ii) Intangible Assets		-	-
(iii) Capital Work-in-progress	11	20.20	-
(iv) Intangible Assets under Development		-	-
(b) Non-current Investments		-	-
(c) Deferred Tax Assets (net)		-	-
(d) Long-term Loans and Advances	12	6.50	7.66
(e) Other Non-current Assets	13	280.65	26.17
Total		1,628.52	642.92
(2) Current assets			
(a) Current investments		-	-
(b) Inventories	14	2,837.46	2,060.97
(c) Trade Receivables	15	2,240.01	1,166.11
(d) Cash and cash equivalents	16	402.06	5.08
(e) Short-term Loans and Advances	17	558.33	110.26
(f) Other Current Assets	18	1.68	2.10
Total		6,039.54	3,344.52
Total Assets		7,668.06	3,987.44

See accompanying notes to the financial statements

1

* Prior to the 29 November 2023, Company is working on the status of Partnership Firms. It is converted into the unlisted public company as on 29 November, 2023. Hence, some ledger balances prior to 29 November 2023, is/was adjusted accordingly. Furthermore, Company is listed on NSE - Emerge platform of stock exchange as on 21 May, 2025.

As per our report of even date
For M/s V S S B & Associates
Chartered Accountants
Firm's Registration No. 0121356W

For and on behalf of the Board of
ACCRETION PHARMACEUTICALS LIMITED

Vishves A. Shah
Partner
Membership No. 109944
UDIN: 26109944KXOBZD4848

Harshad Rathod
Director & CFO
DIN: 09108392

Vivek Patel
Managing Director
DIN: 09130357

Roshni Shah
Company Secretary
Mem. No. A47037

Date : 08 May, 2026
Place : Ahmedabad

Date : 08 May, 2026
Place : Ahmedabad

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)
Statement of Profit and Loss for the year ended 31 March, 2026

(₹ in lacs)

Particulars	Note	31 March, 2026	31 March, 2025
Revenue from Operations	19	8,962.72	5,737.62
Other Income	20	19.05	9.44
Total Income		8,981.77	5,747.06
Expenses			
Cost of Material Consumed	21	6,941.63	4,371.01
Purchases of Stock in Trade		-	-
Change in Inventories of work in progress and finished goods	22	(426.34)	(380.04)
Employee Benefit Expenses	23	457.03	371.96
Finance Costs	24	87.01	143.69
Depreciation and Amortization Expenses	25	121.11	77.45
Other Expenses	26	493.02	186.61
Total expenses		7,673.46	4,770.68
Profit/(Loss) before Exceptional and Extraordinary Item and Tax		1,308.31	976.38
Exceptional Item		-	-
Profit/(Loss) before Extraordinary Item and Tax		1,308.31	976.38
Prior Period Item		-	-
Extraordinary Item		-	-
Profit/(Loss) before Tax		1,308.31	976.38
Tax Expenses	27		
- Current Tax		335.72	259.93
- Deferred Tax		7.78	19.32
- MAT Credit Entitlement		-	-
- Prior Period Taxes		-	-
- Excess/Short Provision Written back/off		(1.94)	17.78
Profit/(Loss) for the Period from Continuing Operations		966.75	679.35
Profit/(loss) from Discontinuing Operation (before tax)		-	-
Tax expenses of discontinuing operation		-	-
Profit/(loss) from Discontinuing Operation (after tax)		-	-
Profit/(Loss) for the period		966.75	679.35
Earnings Per Share (Face Value per Share ₹10 each)			
- Basic (In ₹)	28	9.03	8.48
- Diluted (In ₹)	28	9.03	8.48

See accompanying notes to the financial statements

1

As per our report of even date
For M/s V S S B & Associates
Chartered Accountants
Firm's Registration No. 0121356W

Vishves A. Shah
Partner
Membership No. 109944
UDIN: 26109944KXOBZD4848

Date : 08 May, 2026
Place : Ahmedabad

For and on behalf of the Board of
ACCRETION PHARMACEUTICALS LIMITED

Harshad Rathod
Director & CFO
DIN: 09108392

Vivek Patel
Managing Director
DIN: 09130357

Roshni Shah
Company Secretary
Mem. No. A47037

Date : 08 May, 2026
Place : Ahmedabad

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)
Cash Flow Statement for the year ended 31 March, 2026

(₹ in lacs)

Particulars	Note	31 March, 2026	31 March, 2025
CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit before tax		1,308.31	976.38
Depreciation and Amortisation Expense		121.11	77.45
Finance Costs		93.44	143.69
Operating Profit before working capital changes		1,522.86	1,197.52
Adjustment for:			
Inventories		(776.49)	(613.38)
Trade Receivables		(1,073.90)	(585.67)
Loans and Advances		(443.91)	44.51
Other Current Assets		(1.22)	(6.73)
Other Non current Assets		(255.85)	(2.70)
Trade Payables		(182.05)	100.87
Other Current Liabilities		3.39	1.48
Short-term Provisions		87.52	79.94
Cash (Used in)/Generated from Operations		(1,119.64)	215.83
Tax paid(Net)		333.78	277.71
Net Cash (Used in)/Generated from Operating Activities		(1,453.42)	(61.88)
CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of Property, Plant and Equipment		(853.38)	(161.08)
Net Cash (Used in)/Generated from Investing Activities		(853.38)	(161.08)
CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from Issue of Share Capital		2,975.46	300.00
Repayment of Long Term Borrowings		(30.52)	(574.31)
Repayment of Short Term Borrowings		(147.72)	636.87
Interest Paid		(93.44)	(143.69)
Net Cash (Used in)/Generated from Financing Activities		2,703.79	218.87
Net Increase/(Decrease) in Cash and Cash Equivalents		396.98	(4.09)
Opening Balance of Cash and Cash Equivalents		5.08	9.16
Closing Balance of Cash and Cash Equivalents	16	402.06	5.08

Components of cash and cash equivalents	31 March, 2026	31 March, 2025
Cash on hand	2.06	4.37
Balances with banks in current accounts	-	0.71
Bank Deposit having maturity of less than 3 months	400.00	-
Cash and cash equivalents as per Cash Flow Statement	402.06	5.08
Other Bank Balance		
Cash and bank balance as per Balance Sheet	402.06	5.08

Note:

The above Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard 3 (AS-3), "Cash Flow Statements".

See accompanying notes to the financial statements

1

As per our report of even date
For M/s V S S B & Associates
Chartered Accountants
Firm's Registration No. 0121356W

For and on behalf of the Board of
ACCRETION PHARMACEUTICALS LIMITED

Vishves A. Shah
Partner
Membership No. 109944
UDIN: 26109944KXOBZD4848

Harshad Rathod
Director & CFO
DIN: 09108392

Vivek Patel
Managing Director
DIN: 09130357

Roshni Shah
Company Secretary
Mem. No. A47037

Date : 08 May, 2026
Place : Ahmedabad

Date : 08 May, 2026
Place : Ahmedabad

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)

Notes forming part of the Financial Statement

1. COMPANY INFORMATION

Accretion Pharmaceuticals limited ('the Company') is a listed public company domiciled in India and incorporated under the provisions of Companies Act, 2013, having its registered office at 29 Xcelon Industrial Park 1, B/h, Intas Pharmaceuticals, Vasna Chacharvadi, Ahmedabad, Sanand, Gujarat, India, 382213. Its shares are listed on the NSE Emerge Platform of the Stock Market. The Company is in the business of manufacturing of pharmaceutical products such as Tablets, Capsules, Oral Liquid, Oral powder etc.. The company's manufacturing facility is in compliance with WHO.

Accretion Pharmaceuticals Limited is one of the most promising and fast-growing companies in the global healthcare landscape. Established in 2012, and have built a strong foundation rooted in innovation, quality, and trust, delivering high-performance pharmaceutical products that improve lives and support healthier communities.

2. SIGNIFICANT ACCOUNTING POLICIES

a) Basis of Preparation (AS –1 Disclosure of Accounting Policies)

These standalone financial statements have been prepared to comply with the Generally Accepted Accounting Principles (Indian GAAP), including Accounting Standards notified under the relevant provisions of the Companies Act, 2013. The standalone financial statements have been prepared on accrual basis under the historical cost convention. The accounting policies not specifically referred, are consistently applied from the past accounting periods.

b) Use of Estimates (AS –1 Disclosure of Accounting Policies)

The preparation of standalone financial statements in conformity with the Generally Accepted Accounting Policies requires the management to make estimates and assumptions that affect the reported amount of assets, liabilities, revenues and expenses and disclosures of contingent assets and liabilities. The estimates and assumptions used in the accompanying standalone financial statements are based upon management's evaluation of the relevant facts and circumstances as on the date of the standalone financial statements. Actual results may differ from the estimates and assumptions used in preparing the accompanying financial statements. Any differences of actual results to such estimates are recognized in the period in which the results are known/materialized.

c) Property, Plant and Equipment (AS –10)

a) Fixed Assets

Fixed Assets are value at cost less depreciation. The depreciation has been calculated as prescribed in Companies Act, 2013 on single shift and if the Asset is purchased during the year depreciation is provided on the days of utilisation in that year.

d) Depreciation and amortization (AS-10)

In accordance with the provisions of the Companies Act, 2013, effective from 1 April, 2014, the Company has revised the depreciation rates on tangible fixed assets based on the useful lives specified in Part 'C' of Schedule II of the Act.

Depreciation is calculated using the Written Down Value (WDV) Method over the estimated useful lives of the assets, as prescribed under Schedule II or as estimated by the management, wherever applicable.

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)
Notes forming part of the Financial Statement
Key Depreciation Policies :
➤ Component Accounting :

Where the cost of a part of an asset is significant in relation to the total cost of the asset and the useful life of that part differs from the rest of the asset, such part is depreciated separately based on its own useful life.

➤ Pro-Rata Depreciation :

Depreciation is charged pro-rata for assets acquired or disposed of during the year from the date the asset is available for use or until the date of disposal.

➤ Measurements Basis :

Tangible fixed assets are stated at cost less accumulated depreciation and impairment losses, if any. Direct costs attributable to bringing the asset to its working condition for its intended use are capitalized.

➤ Depreciation Rates :

Depreciation is provided on the Written Down Value method, at rates derived based on the useful lives specified in Schedule II to the Companies Act, 2013 or as estimated by the management in cases where the useful life differs from Schedule II.

Type of Assets	Useful Life
Buildings - 9.50%	30 Years
Plant and Equipment - 7.22%	40 Years
Plant and Equipment - 63.13%	3 Years
Plant and Equipment - 13.91%	20 Years
Office equipment-18.10%	15 Years
Office equipment-20.58%	13 Years
Furniture and Fixtures - 25.89%	10 Years
Vehicles - 39.30%	6 Years
Office equipment-45.07%	5 Years

e) Impairment of Assets (AS - 28)

At each balance sheet date, the management reviews the carrying amounts of its assets included in each cash generating unit to determine whether there is any indication that those assets were impaired. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of impairment. Recoverable amount is the higher of an asset's net selling price and value in use. In assessing value in use, the estimated future cash flows expected from the continuing use of the asset and from its disposal are discounted to their present value using a pre tax discount rate that reflects the current market assessments of time value of money and the risks specific to the asset. Reversal of impairment loss is recognised as income in the statement of profit and loss.

f) Inventories (AS - 2)

Raw materials are carried at the lower of cost and net realisable value. Cost is determined on a FIFO (First In First Out) basis. Purchased goods-in-transit are carried at cost. Work-in-progress is carried at the lower of cost and net realisable value. Stores and spare parts are carried at lower of cost and net realisable value. Finished goods produced or purchased by the Company are carried at lower of cost and net realisable value. Cost includes direct material and labour cost and a proportion of manufacturing overheads.

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)
Notes forming part of the Financial Statement

The valuation for inventories is as follows;

(₹ in lacs)

Classification	Valuation Policy	31 March, 2026	31 March, 2025
Finished Goods	At lower of cost or net realizable value.	395.55	231.37
Raw Material	At lower of cost or net realizable value.	1,391.57	1,041.42
WIP	At lower of cost or net realizable value.	1,050.33	788.18

g) Cash Flow Statement (AS - 3)

Cash flows are reported using the indirect method, whereby profit before tax is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the group are segregated.

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short term balances (with an original maturity of three months or less from the date of acquisition) and highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

For the purposes of the cash flow statement, cash and cash equivalents include cash on hand, in banks and demand deposits with banks, net of outstanding bank overdrafts that are repayable on demand, book overdrafts and are considered part of the Company's cash management system.

h) The Effect of changes in Foreign Exchange Rates: (AS -11)

An enterprise may carry on activities involving foreign exchange in two ways. It may have transactions in foreign currencies or it may have foreign operations.

Initial Recognition:

A foreign currency transaction is a transaction which is denominated in or requires settlement in a foreign currency, including transactions arising when an enterprise either:

- buys or sells goods or services whose price is denominated in a foreign currency;
- borrows or lends funds when the amounts payable or receivable are denominated in a foreign currency;
- becomes a party to an unperformed forward exchange contract; or
- otherwise acquires or disposes of assets, or incurs or settles liabilities, denominated in a foreign currency. A foreign currency transaction should be recorded, on initial recognition in the reporting currency, by applying to the foreign currency amount, the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)

Notes forming part of the Financial Statement

At Balancesheet Date

- a) foreign currency monetary items should be reported using the closing rate. However, in certain circumstances, the closing rate may not reflect with reasonable accuracy the amount in reporting currency that is likely to be realised from, or required to disburse, a foreign currency monetary item at the balance sheet date, e.g., where there are restrictions on remittances or where the closing rate is unrealistic and it is not possible to effect an exchange of currencies at that rate at the balance sheet date. In such circumstances, the relevant monetary item should be reported in the reporting currency at the amount which is likely to be realised from, or required to disburse, such item at the balance sheet date;
- b) non-monetary items which are carried in terms of historical cost denominated in a foreign currency should be reported using the exchange rate at the date of the transaction; and
- c) non-monetary items which are carried at fair value or other similar valuation denominated in a foreign currency should be reported using the exchange rates that existed when the values were determined.

i) Revenue Recognition (AS - A)

Revenue from contract with customer is recognised upon transfer of control of promised products or services to customers on complete satisfaction of performance obligations for an amount that reflects the consideration which the Company expects to receive in exchange for those products or services. Revenue is measured based on the transaction price, which is the consideration, adjusted for discounts and other incentives, if any, as per contracts with the customers. Revenue also excludes taxes or amounts collected from customers in its capacity as agent. The specific recognition criteria from various stream of revenue is described below:

Sale of goods: Revenue from the sale of products is recognized at the point in time when control is transferred to the customer. Revenue is measured based on the transaction price, which is the consideration, net of customer incentives, discounts, variable considerations, payments made to customers, other similar charges, as specified in the contract with the customer. Additionally, revenue excludes taxes collected from customers, which are subsequently remitted to governmental authorities.

Interest Income: Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

Dividend is recorded when the right to receive payment is established. Interest income is recognised on time proportion basis taking into account the amount outstanding and the rate applicable.

j) Employee Benefits (AS - 15)

Post –Employment Benefit Plan

Contributions to defined contribution retirement benefit schemes are recognised as expense when employees have rendered services entitling them to such benefits.

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)**Notes forming part of the Financial Statement**

For defined benefit schemes, the cost of providing benefits is determined using the Projected Unit Credit Method, with actuarial valuations being carried out at each balance sheet date. Actuarial gains and losses are recognised in full in the statement of profit and loss for the period in which they occur. Past service cost is recognised immediately to the extent that the benefits are already vested, or amortised on a straight-line basis over the average period until the benefit become vested.

The retirement benefit obligation recognised in the balance sheet represents the present value of the defined benefit obligation as adjusted for unrecognised past service cost, and as reduced by the fair value of scheme assets. Any asset resulting from this calculation is limited to the present value of available refunds and reductions in future contributions to the scheme.

Other employee benefits

The undiscounted amount of short-term employee benefits expected to be paid in exchange for the services rendered by employees is recognised during the period when the employee renders the service. These benefits include compensated absences such as paid annual leave, overseas social security contributions and performance incentives.

Compensated absences which are not expected to occur within twelve months after the end of the period in which the employee renders the related services are recognised as an actuarially determined liability at the present value of the defined benefit obligation at the balance sheet date.

Others

Short term benefits such as salary, bonus, ex-gratia and other benefits as maybe applicable on the Company are accounted for on accrual basis. The Company at present does not have any Defined Contribution Plan or Defined Benefit Plan as contemplated under AS- 15 on 'Employee Benefits'

k) Taxes On Income

Current income tax expense comprises taxes on income from operations in India and in foreign jurisdictions. Income taxpayable in India is determined in accordance with the provisions of the Income Tax Act, 1961. Tax expense relating to foreign operations is determined in accordance with tax laws applicable in countries where such operations are domiciled.

Deferred tax expense or benefit is recognised on timing differences being the difference between taxable income and accounting income that originate in one period and is likely to reverse in one or more subsequent periods. Deferred tax assets and liabilities are measured using the tax rates and tax laws that have been enacted or substantively enacted by the balance sheet date.

The Company offsets deferred tax assets and deferred tax liabilities if it has a legally enforceable right and these relate to taxes on income levied by the same governing taxation laws.

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)

Notes forming part of the Financial Statement

l) Segment Accounting

The Company is engaged only in manufacturing and sale of pharmaceutical products and there are no separate reportable segments as per Accounting Standard (AS) 17 'Segment Reporting'.

m) Earnings Pre Shares (AS - 20)

Basic earning per share is computed by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. Diluted earning per share is computed by taking into account the weighted average number of equity shares outstanding during the period and the weighted average number of equity shares which would be issued on conversion of all dilutive potential equity shares into equity shares

n) Contributed Equity

Equity shares are classified as equity.

Earnings per Share: Basic earnings per share is calculated by dividing:

- the profit attributable to the owners group
- by the weighted average number of equity shares outstanding during the year.

o) Provisions, Contingent liabilities and Contingent Assets (AS - 29)

A provision is recognised when the Company has a present obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which reliable estimate can be made. Provisions (excluding retirement benefits and compensated absences) are not discounted to its present value and are determined based on best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates. Contingent liabilities are not recognised in the financial statements. A contingent asset is neither recognised nor disclosed in the financial statements.

p) Current Assets, Loans, and Advances & Liabili

In the Opinion of the Board, the value on realization of the current assets, loans and advances, if realized in the ordinary course of business, shall not be less than the amount, which is stated, in the current year Balance sheet. The provision for all known liabilities is reasonable and not in excess of the amount considered reasonably necessary.

q) Other Notes

1. As per the Ministry of Corporate Affairs (MCA) notification, proviso to Rule 3(i) of the Companies (Accounts) Rules, 2014, from the financial year commencing April 1, 2023, every company which uses accounting software for maintaining its books of account, shall use only such accounting software which has a feature of recording audit trail of each and every transaction,

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)**Notes forming part of the Financial Statement**

creating an edit log of each change made in the books of account along with the date when such changes were made and ensuring that the audit trail cannot be disabled. The interpretation and guidance on what level edit log and audit trail needs to be maintained evolved during the year and continues to evolve.

In the company, the accounting software has a feature of audit trail, and it is enable at an application level for maintenance of books of accounts and relevant transactions. However, the global standard ERP used by the Company has not been enabled with the feature of audit trail log at the database layer to log direct transactional changes, due to present design of ERP. This is being taken up with the vendor. In the meanwhile, the Company continues to ensure that direct write access to the database is granted only via an approved change management process.

2. Compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015
The Company has adopted a Code of Conduct and established internal controls in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, to regulate, monitor and report trading activities of Designated Persons and their Immediate Relatives.

The Company has implemented adequate procedures for identification handling, communication and protection of Unpublished Price Sensitive Information (UPSI). Access to UPSI is restricted on a need-to-know basis to ensure its confidentiality and integrity.

The Company also maintains a Structured Digital Database and other necessary records as prescribed under the applicable regulations and has put in place appropriate mechanisms to prevent insider trading and unauthorized disclosure of UPSI. The Company has complied with the applicable provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015 during the year.

3. Additional Notes

1. Balance of cash on hand at the end is accepted as certified by the management of the company.
2. Balance of Trade Receivable, Trade Payable, Loans & advances are subject to confirmation of the parties taken from the Management of Company.
3. As certified by the company that it was received written representation from all the directors, that companies in which they are directors had not defaulted in terms of section 164(2) of the companies Act, 2013, and the representation from directors taken in Board that Director is disqualified from being appointed as Director of the company.

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)**Notes forming part of the Financial Statement**

4. Certain ledger account balances have been regrouped and reclassified for presentation purposes. Such regrouping and reclassification do not affect the overall financial performance, financial position, or results of operations of the Company.

As per our report of even date
For M/s V S B & Associates
 Chartered Accountants
 Firm's Registration No. 0121356W

Vishves A. Shah
 Partner
 Membership No. 109944
 UDIN: 26109944KXOBZD4848

Date : 08 May, 2026
 Place : Ahmedabad

For and on behalf of the Board of
ACCRETION PHARMACEUTICALS LIMITED

Harshad Rathod
 Director & CFO
 DIN: 09108392

Vivek Patel
 Managing Director
 DIN: 09130357

Roshni Shah
 Company Secretary
 Mem. No. A47037

Date : 08 May, 2026
 Place : Ahmedabad

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)
Notes forming part of the Financial Statement
3 Share Capital

(₹ in lacs)

Particulars	Note	31 March, 2026	31 March, 2025
Authorised Share Capital			
Equity Shares, of ₹ 10 each, 13000000 (Previous Year - 13000000) Equity Shares		1,300.00	1,300.00
Total		1,300.00	1,300.00
Issued, Subscribed and Fully Paid up Share Capital			
Equity Shares, of ₹ 10 each, 11116000 (Previous Year - 8170000) Equity Shares paid up		1,111.60	817.00
Total		1,111.60	817.00

During the FY 2025-26, The company had made an initial public offering (IPO) of 29,46,000 equity shares of face value of ₹ 10 each fully paid up for cash at a price of ₹ 101 per equity shares (including share premium of ₹ 91 per equity share) aggregating to ₹ 29,75,46,000/- The equity shares of the company got listed on NSE Emerge Platform on 21 May, 2025.

During the FY 2024-25; The Company has issued 3,00,000 equity share as a Right Issue having pari passu rank with the existing equity shares of the company and also issued bonus shares 38,70,000 equity shares in the ratio of 9:10 i.e. 9 shares for each 10 shares.

i) Reconciliation of number of shares

Particulars	31 March, 2026		31 March, 2025	
	No. of shares	(₹ in lacs)	No. of shares	(₹ in lacs)
Equity Shares				
Opening Balance	8,170,000	817.00	4,000,000	400.00
Issued during the year	2,946,000	294.60	4,170,000	417.00
Deletion	-	-	-	-
Closing balance	11,116,000	1,111.60	8,170,000	817.00

ii) Rights, preferences and restrictions attached to shares

- Equity Shares :**
- 1) The Company has only one class of Equity Shares having a par value of ₹ 10/- per share. Each holder of Equity Share is entitled to one vote per share. The Company has not declared any dividend.
 - 2) In the event of liquidation of the Company, the holders of Equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of Equity shares held by the shareholders.

iii) Details of Shares held by shareholders holding more than 5% of the aggregate shares in the company

Equity Shares	31 March, 2026		31 March, 2025	
	No. of shares	In %	No. of shares	In %
Name of Shareholder				
Mr.Harshad N Rathod	1,966,500	17.69%	1,966,500	24.00%
Mr.Mayur P Sojitra	1,966,500	17.69%	1,966,500	24.00%
Mr.Vivek A Patel	1,966,500	17.69%	1,966,500	24.00%
Mr.Hardik M Prajapati	1,966,500	17.69%	1,966,500	24.00%

iv) Shares held by Promoters at the end of the year 31 March, 2026

Name of Promoter	Class of Shares	No. of Shares	% of total shares	% Change during the year
Mr.Harshad N Rathod	Equity	1,966,500	17.69%	-6.31%
Mr.Mayur P Sojitra	Equity	1,966,500	17.69%	-6.31%
Mr.Vivek A Patel	Equity	1,966,500	17.69%	-6.31%
Mr.Hardik M Prajapati	Equity	1,966,500	17.69%	-6.31%
Ankita Vivek Patel	Equity	76,000	0.68%	-0.32%
Pooja Harshad Rathod	Equity	76,000	0.68%	-0.32%
Shweta Sojitra	Equity	76,000	0.68%	-0.32%
Vaishaki Hardik Prajapati	Equity	76,000	0.68%	-0.32%
Rekhaben Karshandas Ghetiya	Equity	2,400	0.02%	0.02%

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)
Notes forming part of the Financial Statement
Shares held by Promoters at the end of the year 31 March, 2025

Name of Promoter	Class of Shares	No. of Shares	% of total shares	% Change during the year
Mr.Harshad N Rathod	Equity	1,966,500	24.00%	0.00%
Mr.Mayur P Sojitra	Equity	1,966,500	24.00%	0.00%
Mr.Vivek A Patel	Equity	1,966,500	24.00%	0.00%
Mr.Hardik M Prajapati	Equity	1,966,500	24.00%	0.00%
Ankita Vivek Patel	Equity	76,000	1.00%	0.00%
Pooja Harshad Rathod	Equity	76,000	1.00%	0.00%
Shweta Sojitra	Equity	76,000	1.00%	0.00%
Vaishaki Hardik Prajapati	Equity	76,000	1.00%	0.00%
Rekhaben Karshandas Ghetiya	Equity	-	0.00%	0.00%

v) Equity shares movement during 5 years preceding 31 March, 2026

Particulars	Year 1 (FY 2025-26)	Year 2 (FY 2024-25)	Year 3	Year 4	Year 5
Equity shares issued as bonus		3,870,000			
Equity shares issued through Initial Public Offer (IPO)	2,946,000				
Equity shares issued through Right issue		300,000			

During the FY 2025-26, The company had made an initial public offering (IPO) of 29,46,000 equity shares of face value of ₹ 10 each fully paid up for cash at a price of ₹ 101 per equity shares (including share premium of ₹ 91 per equity share) aggregating to ₹ 29,75,46,000/- The equity shares of the company got listed on NSE Emerge Platform on 21 May, 2025.

During the FY 2024-25; The Company has issued 3,00,000 equity share as a Right Issue having pari passu rank with the existing equity shares of the company and also issued bonus shares 38,70,000 equity shares in the ratio of 9:10 i.e. 9 shares for each 10 shares.

4 Reserves and Surplus

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Securities Premium		
Opening Balance	-	-
Add: Issue of Shares	2,680.86	270.00
(Add)/Less: Adjustment	-	270.00
Closing Balance	2,680.86	-
Statement of Profit and loss		
Balance at the beginning of the year	711.65	149.29
Add: Profit/(loss) during the year	966.75	679.35
Less: Appropriation		
Utilized for Bonus Shares issued	-	117.00
Balance at the end of the year	1,678.39	711.65
Total	4,359.25	711.65

Nature of Reserve and Surplus

Securities Premium

During FY 2024-25; Security Premium amounting to ₹ 2,70,00,000, is fully utilized for the issue of Bonus Shares.

5 Long term borrowings

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Secured Term loans from banks		
- Secured Term loans from Banks	-	23.23
Unsecured Term loans from banks		
- Unsecured Term loans from Banks	33.75	43.71
- Unsecured Term loans from NBFC	52.50	49.83
Total	86.25	116.77

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)
Notes forming part of the Financial Statement
6 Deferred tax liabilities Net

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Deferred tax liabilities Net	27.24	19.45
Total	27.24	19.45

Significant components of Deferred Tax

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Deferred Tax Liability		
Difference between book depreciation and tax depreciation	27.24	19.45
Gross Deferred Tax Liability (A)	27.24	19.45
Deferred Tax Asset		
Gross Deferred Tax Asset (B)	-	-
Net Deferred Tax Liability (A)-(B)	27.24	19.45

7 Short term borrowings

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Current maturities of long-term debt	247.95	354.61
Secured Loans repayable on demand from banks	897.92	938.97
Total	1,145.87	1,293.58

- 1) Term loan from Indian bank is secured against exclusive hypothecation of plant & machinery purchased out of bank's finance along with all other fixed assets of the company. It carries ROI @ 9.55% and payable in 24 monthly installments.
- 2) These loans are further secured by Equitable Mortgage of land and building situated at 28-29, Xcelon Industrial Park-1, Behind Intas Pharmaceuticals, At. Vasna-Chachrawadi, TA Sanand admeasuring 1565 Sq. Mts.
- 3) Further secured by personal guarantees of Mr. Mayur Popatlal Sojitra, Mr. Vivek Ashokkumar Patel, Mr. Harshad Nanubhai Rathod, Mr. Hardik Mukundbhai Prajapati.
- 4) Cash Credit from Indian Bank – The present and future stocks hypothecated with the bank for the sanction limit of ₹ 10.73 Crores in Cash credit account for the tenure of one year with the annual renewal option.

8 Trade Payables

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Due to Micro and Small Enterprises	158.87	183.90
Due to others	417.70	574.72
Total	576.57	758.62

8.1 Trade Payable ageing schedule as at 31 March, 2026

(₹ in lacs)

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
MSME	158.87				158.87
Others	417.70				417.70
Disputed dues - MSME					-
Disputed dues - Others					-
Sub total					576.58
MSME - Undue					
Others - Undue					
Total					576.58

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)
Notes forming part of the Financial Statement
8.2 Trade Payable ageing schedule as at 31 March, 2025

(₹ in lacs)

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
MSME	183.90				183.90
Others	574.72				574.72
Disputed dues- MSME					-
Disputed dues- Others					-
Sub total					758.62
MSME - Undue					
Others - Undue					
Total					758.62

The disclosures under the Micro, Small and Medium Enterprises Development Act, 2006 have been made in respect of such vendors to the extent they could be identified as micro and small enterprises on the basis of information available with the Company. Company has made payment to MSME within stipulated time period as per the Micro, Small and Medium Enterprises Development Act, 2006.

9 Other Current Liabilities

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Statutory dues		
- GST Payable - RCM	2.51	-
- Others	1.57	1.31
- TDS/TCS Payable	3.78	3.16
Total	7.86	4.47

10 Short-term Provisions

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Provision for income tax	335.72	259.93
Provision for others		
- Provision for Audit Fees	2.00	1.50
- Provision for Gratuity	15.00	4.47
- Provision for Internal Audit Fees	0.70	-
Total	353.42	265.90

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)
Notes forming part of the Financial Statement

(₹ in laos)

11 Property, Plant and Equipment

Name of Assets	Gross Block		Depreciation and Amortization		Net Block	
	As on 1 April, 25	Addition	Deduction	As on 31 March, 26	As on 31 March, 26	As on 31 March, 25
(i) Property, Plant and Equipment						
Land - 0.00	47.98	-	-	47.98	47.98	47.98
Plant & Machinery - 7.22%	50.14	-	-	50.14	40.69	43.86
Factory Building - 9.50%	223.10	264.11	-	487.21	433.82	198.87
Plant & Machinery - 13.91%	351.41	504.20	-	855.61	725.29	294.15
Office Equipment - 18.10%	1.73	-	-	1.73	1.10	1.34
Office Equipment - 20.58%	1.86	1.33	-	3.19	2.34	1.31
Furniture & Fixtures - 25.89%	9.90	52.46	-	62.36	53.36	8.20
Vehicle - 39.30%	14.95	-	-	14.95	5.06	8.34
Office Equipment - 45.07%	3.90	6.57	-	10.47	7.02	2.31
Plant and Machinery - 63.16%	3.92	4.51	-	8.43	4.50	2.75
Total	708.89	833.18	-	1,542.07	1,321.17	609.09
Previous Year	547.81	161.08	-	708.89	609.09	525.46
(iii) Capital Work-in-progress					20.20	-

(₹ in laos)

(iii) Capital Work-in-progress						
Particulars						
Opening Balance						
Add: Addition during the year						
Less: Capitalised during the year						
Closing Balance						

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)
Notes forming part of the Financial Statement
12 Long term loans and advances

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Other loans and advances (Unsecured, considered good)		
- Interest Receivable	-	0.66
- Loan to Staff	6.40	6.90
Others		
- Rent Deposit	0.10	0.10
Total	6.50	7.66

13 Other non current assets

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Security Deposits		
- Deposits	24.03	16.08
Others		
- Preliminary Expense (to the extent not Write off)	256.62	10.09
Total	280.65	26.17

14 Inventories

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Raw materials	1,391.57	1,041.42
Work-in-progress	1,050.33	788.18
Finished goods	395.55	231.37
Total	2,837.46	2,060.97

15 Trade receivables

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Unsecured considered good	2,240.01	1,166.11
Total	2,240.01	1,166.11

15.1 Trade Receivables ageing schedule as at 31 March, 2026

(₹ in lacs)

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months- 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade receivables- considered good	2,176.66	10.17	0.31	52.86		2,240.01
Undisputed Trade Receivables- considered doubtful						-
Disputed Trade Receivables considered good						-
Disputed Trade Receivables considered doubtful						-
Sub total						2,240.01
Undue - considered good						
Total						2,240.01

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)
Notes forming part of the Financial Statement
15.2 Trade Receivables ageing schedule as at 31 March, 2025

(₹ in lacs)

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed Trade receivables- considered good	1,096.44		69.68			1,166.12
Undisputed Trade Receivables- considered doubtful						-
Disputed Trade Receivables considered good						-
Disputed Trade Receivables considered doubtful						-
Sub total						1,166.12
Undue - considered good						
Total						1,166.12

16 Cash and cash equivalents

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Cash on hand	2.06	4.37
Balances with banks in current accounts	-	0.71
Bank Deposit having maturity of less than 3 months	400.00	-
Total	402.06	5.08

17 Short term loans and advances

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Loans and advances to employees		
- Loan to Staff	1.75	3.60
Balances with Government Authorities		
- Advance Tax	236.00	-
- GST Receivables	285.16	78.83
- RCM Receivables	2.06	-
- TDS/TCS Receivables	31.05	25.50
Other loans and advances (Unsecured, considered good)		
- TDS Receivable from NBFC	2.31	2.33
Total	558.33	110.26

18 Other current assets

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Interest accrued		
- Accrued Interest	-	0.33
Others		
- Pre-Paid Expenses	1.68	1.77
Total	1.68	2.10

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)
Notes forming part of the Financial Statement
19 Revenue From Operations

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Sale of products		
- Domestic Sales	8,196.27	5,261.23
- Export Sales	766.45	476.39
Total	8,962.72	5,737.62

20 Other Income

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Interest Income	0.43	-
Duty Drawback	8.51	2.17
Foreign Exchange Gain / Loss	8.84	4.74
Other Income	1.27	2.53
Total	19.05	9.44

21 Cost of Material Consumed

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Raw Material Consumed		
Opening stock	1,041.42	808.08
Purchases	6,996.31	4,348.66
Direct Expense	295.47	255.69
Less: Closing stock	1,391.57	1,041.42
Total	6,941.63	4,371.01
Total	6,941.63	4,371.01

22 Change in Inventories of work in progress and finished goods

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Opening Inventories		
Finished Goods	231.37	105.33
Work-in-progress	788.18	534.18
Less: Closing Inventories		
Finished Goods	395.55	231.37
Work-in-progress	1,050.33	788.18
Total	(426.34)	(380.04)

23 Employee Benefit Expenses

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Salaries and wages	282.80	295.54
Contribution to provident and other funds	9.57	7.70
Staff welfare expenses	8.46	0.26
Total continued	300.83	303.50

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)
Notes forming part of the Financial Statement
Employee benefit expenses

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Total continued from previous page	300.83	303.50
Conveyance Allowance	9.80	-
Director Remuneration	98.00	63.99
Gratuity Expense	10.53	4.47
Other Allowance	30.48	-
Special Allowance	7.39	-
Total	457.03	371.96

Defined Contribution Plan

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Employers Contribution to Provident Fund	8.70	6.49
Employers Contribution to Employee State Insurance	0.87	1.21

Defined Benefit Plan
Changes in the present value of the defined benefit obligation

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Defined Benefit Obligation at beginning of the year	4.47	-
Current Service Cost	10.53	3.37
Interest Cost	-	0.55
Actuarial (Gain) / Loss	-	0.55
Defined Benefit Obligation at year end	15.00	4.47
Fair value of plan assets as at the end of the year	-	-

Reconciliation of present value of defined benefit obligation and fair value of assets

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Present value obligation as at the end of the year	15.00	4.47
Amount classified as:		
Short term provision	15.00	4.47
Long term provision	-	-

Expenses recognized in Profit and Loss Account

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Current service cost	10.53	3.37
Interest cost	-	0.55
Expected return on plan assets	-	0.55
Total expense recognised in Profit and Loss	10.53	4.47

Actuarial assumptions

Particulars	31 March, 2026	31 March, 2025
Discount Rate	7.75%	7.00%
Expected Rate of increase in Compensation Level	5.00%	5.00%
Expected Rate of return on Plan assets	NA	NA
Mortality Rate	Indian Assured	Indian Assured
Retirement Rate	2.00% p.a. for all	2.00% p.a. for all

General Description of the Plan

The Entity operates gratuity plan through a trust wherein every employee is entitled to the benefit equivalent to fifteen days salary last drawn for each completed year of service. The same is payable on termination of service or retirement, whichever is earlier. The benefit vests after five years of continuous service. In case of some employees, the Entity's scheme is more favourable as compared to the obligation under Payment of Gratuity Act, 1972.

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)
Notes forming part of the Financial Statement
a) DEFINED CONTRIBUTION PLAN:

Provident Fund: The Company makes provident fund contributions to a defined contribution retirement benefit plan for qualifying employees. The provident fund plan is operated by the Regional Provident Fund Commissioner. The plan envisages contribution by the employer and employees and guarantees interest at the rate notified by the Provident Fund Authority. The contribution by employer and employee, together with interest, are payable at the time of separation from service or retirement, whichever is earlier.

b) DEFINED BENEFIT PLAN :

Gratuity: The Company makes annual contribution to the Gratuity fund administered through a master policy with the Life Insurance Corporation of India for the qualifying employees but it does not contribute fund towards the liability of the Directors. Gratuity is payable to all eligible employees on superannuation, death or on separation / termination at the rate of 15 days salary for each year of service subject to a maximum of ₹ 20 lac.

The company operates a defined benefit gratuity plan for its employees and is governed by the Payment of Gratuity Act, 1972. The liability for the Defined Benefit Plan is provided on the basis of actuarial valuation, using the projected unit credit method, as at the balance sheet date, carried out by an independent actuary.

c) Basis Used to Determine Expected Rate of Return on Assets:

The expected return on plan assets is determined based on several factors like the composition of plan assets held, assessed risks of asset management, historical results of the return on plan assets and the Company's policy for plan asset management.

24 Finance costs

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Interest expense	73.97	138.63
Bank Charges	2.23	2.08
Other Finance Cost	10.81	2.98
Total	87.01	143.69

25 Depreciation and amortization expenses

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Depreciation on property, plant and equipment	121.11	77.45
Total	121.11	77.45

26 Other expenses

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Auditors' Remuneration	3.10	1.50
Administrative Expenses	0.23	-
Advertisement	6.97	1.66
Commission	101.45	6.27
Consultancy fees	3.05	-
Freight Inward	-	0.10
Insurance	5.19	1.99
Power and fuel	0.11	-
Professional fees	83.61	19.17
Rent	25.05	3.93
Repairs to buildings	12.37	8.38
Repairs to machinery	36.93	2.80
Rates and taxes	15.08	2.40
Total continued	293.14	48.20

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)
Notes forming part of the Financial Statement
Other expenses

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Total continued from previous page	293.14	48.20
Selling & Distribution Expenses	0.13	-
Miscellaneous expenses	11.39	13.88
Air Freight Charges	5.71	-
Balances Written off	3.03	-
Brokerage Expenses	1.90	-
CSR Expenditure	12.11	-
Design Charges	2.65	-
Director sitting Fees	2.95	3.25
Documentation Charges	-	0.29
Donation Expense	-	0.11
Exhibition Expenses	9.62	-
Interest on Professional Tax	-	0.09
Interest on TDS	0.02	0.02
IPO expense	-	5.75
Legal and Professional Fee	1.01	4.88
Licencing Expense	0.01	0.62
Marketing Expenses	0.85	-
Membership Fees	1.75	1.31
Packaging Expense	-	2.28
Packing Material Expenses	0.07	-
Preliminary Expense	1.36	2.86
Retainer Fees	9.80	-
Seminar Fees	-	0.12
Shipping Charges	31.15	0.15
Sponsorship Fees	0.51	-
Stationary, Printing and Courier Expenses	10.92	8.77
Stock Audit Charges	0.21	-
Tea and Refreshment Expenses	-	5.97
Testing Charges	31.82	23.19
Transportation Expenses	19.07	29.06
Travelling & Conveyance Expense	14.47	11.58
Waste Cloth Expenses	2.03	2.52
Water Expense	25.34	21.71
Total	493.02	186.61

27 Tax Expenses

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Current Tax	335.72	259.93
Deferred Tax	7.78	19.32
Excess/Short Provision Written back/off	(1.94)	17.78
Total	341.56	297.03

Significant components of Deferred Tax charged during the year

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Difference between book depreciation and tax depreciation	7.78	19.32
Total	7.78	19.32

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)
Notes forming part of the Financial Statement
28 Earning per share

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Profit attributable to equity shareholders (₹ in lacs)	966.75	679.35
Weighted average number of Equity Shares	10,704,367	8,015,397
Earnings per share basic (₹)	9.03	8.48
Earnings per share diluted (₹)	9.03	8.48
Face value per equity share (₹)	10	10

29 Auditors' Remuneration

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Payments to auditor as		
- Auditor	3.10	1.50
Total	3.10	1.50

30 Earnings in Foreign Currencies

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Export of Goods calculated on FOB basis	766.44	476.39
Total	766.44	476.39

30 Segment Reporting
Additional Information by Geographies

(₹ in lacs)

Particulars	31 March, 2026	31 March, 2025
Revenue by Geographical Market		
- In India	8,196.27	5,261.23
- Outside India	766.44	476.39
Total	8,962.71	5,737.62

31 Related Party Disclosure
i) List of Related Parties
Relationship

Mr. Harshad Nanubhai Rathod	Director & CFO
Mr. Mayur Popatlal Sojitra	Director
Mr. Vivek Ashok Kumar Patel	Managing Director
Mr. Hardik Mukundbhai Prajapati	Director
Roshni Dharmendrabhai Shah	Company Secretary
Accretion Nutraveda Limited	Directors having Significant Influence and Others
Accretion INC	Directors having Significant Influence and Others
Mrs. Rathod Pooja Harshad	Part of Promoter Group
Mrs. Shweta Sojitra	Part of Promoter Group
Mrs. Ankita Vivek Patel	Part of Promoter Group
Mrs. Vaishaki Hardik Prajapati	Part of Promoter Group
Karshandas Madhavdas Ghetiya	Part of Promoter Group
Madhavdas Jethabhai Ghetiya (HUF)	Part of Promoter Group
Rekhaben Karshandas Ghetiya	Part of Promoter Group
Mrs. Hiral Dipen Shah (w.r.t Listing Date)	Part of Promoter Group
Accresha Lifecare Private Limited	Directors having Significant Influence and Others

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)
Notes forming part of the Financial Statement
ii) Related Party Transactions

(₹ in lacs)

Particulars		31 March, 2026	31 March, 2025
Remuneration			
- Mr. Harshad Nanubhai Rathod	Director & CFO	24.50	15.98
- Mr. Mayur Popatlal Sojitra	Director	24.50	15.98
- Mr. Vivek Ashok Kumar Patel	Managing Director	24.50	15.98
- Mr. Hardik Mukundbhai Prajapati	Director	24.50	15.98
Salary			
- Mrs. Rathod Pooja Harshad	Part of Promoter Group	-	5.50
- Mrs. Shweta Sojitra	Part of Promoter Group	-	5.50
- Mrs. Ankita Vivek Patel	Part of Promoter Group	-	5.50
- Mrs. Vaishaki Hardik Prajapati	Part of Promoter Group	-	5.50
- Mrs. Hiral Dipen Shah (w.r.t Listing date)	Part of Promoter Group	6.39	-
Sales			
- Accretion Nutraveda Limited	Directors having Significant Influence and Others	0.19	77.97
- Accretion INC	Directors having Significant Influence and Others	18.37	23.67
- Accresha Lifecare Private Limited	Directors having Significant Influence and Others	106.57	152.07
Purchase			
- Accretion Nutraveda Limited	Directors having Significant Influence and Others	57.18	24.23
- Accretion INC	Directors having Significant Influence and Others	-	10.64
Interest on Loan			
- Mr. Harshad Nanubhai Rathod	Director & CFO	-	2.54
- Mr. Mayur Popatlal Sojitra	Director	-	2.40
- Mr. Vivek Ashok Kumar Patel	Managing Director	-	2.56
- Mr. Hardik Mukundbhai Prajapati	Director	-	2.32
Loan Taken			
- Mr. Harshad Nanubhai Rathod	Director & CFO	-	3.00
- Mr. Vivek Ashok Kumar Patel	Managing Director	-	3.00
- Mr. Hardik Mukundbhai Prajapati	Director	-	0.75
Loan Repaid			
- Mr. Mayur Popatlal Sojitra	Director	-	76.78
- Mr. Harshad Nanubhai Rathod	Director & CFO	-	82.13
- Mr. Vivek Ashok Kumar Patel	Managing Director	-	83.47
- Mr. Hardik Mukundbhai Prajapati	Director	-	75.03
Equity contribution			
- Mr. Harshad Nanubhai Rathod	Director & CFO	-	75.00
- Mr. Mayur Popatlal Sojitra	Director	-	75.00
- Mr. Vivek Ashok Kumar Patel	Managing Director	-	75.00
- Mr. Hardik Mukundbhai Prajapati	Director	-	75.00
Bonus shares issued			
- Mr. Harshad Nanubhai Rathod	Director & CFO	-	93.15
- Mr. Mayur Popatlal Sojitra	Director	-	93.15
- Mr. Vivek Ashok Kumar Patel	Managing Director	-	93.15
- Mr. Hardik Mukundbhai Prajapati	Director	-	93.15
- Mrs. Rathod Pooja Harshad	Part of Promoter Group	-	3.60
- Mrs. Shweta Sojitra	Part of Promoter Group	-	3.60
- Mrs. Ankita Vivek Patel	Part of Promoter Group	-	3.60
- Mrs. Vaishaki Hardik Prajapati	Part of Promoter Group	-	3.60
Professional Fees			
- Mr. Harshad Nanubhai Rathod	Director & CFO	2.00	-
- Mr. Mayur Popatlal Sojitra	Director	2.00	-
- Mr. Vivek Ashok Kumar Patel	Managing Director	2.00	-
- Mr. Hardik Mukundbhai Prajapati	Director	2.00	-
Services Received			
- Mrs. Ankita Vivek Patel	Part of Promoter Group	0.80	-

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)
Notes forming part of the Financial Statement
iii) Related Party Balances

(₹ in lacs)

Particulars	Relationship	31 March, 2026	31 March, 2025
Remuneration			
- Mr. Harshad Nanubhai Rathod	Director & CFO	1.95	-
- Mr. Mayur Popatlal Sojitra	Director	1.95	-
- Mr. Vivek Ashok Kumar Patel	Managing Director	1.95	-
- Mr. Hardik Mukundbhai Prajapati	Director	1.95	-
- Mrs. Hiral Dipen Shah (w.r.t Listing date)	Part of Promoter Group	0.47	-
Debtor			
- Accresha Lifecare Private Limited	Directors having Significant Influence & Others	84.48	-

Independent Director is not considered as Related Parties.

32 Security of Current Assets Against Borrowings

The present and future stocks hypothecated with the bank for the sanction limit of ₹ 10.73 Crores in Cash credit account for the tenure of one year with the annual renewal option.

33 Registration of Charge

Cash Credit from Indian Bank – The present and future stocks hypothecated with the bank for the sanction limit of ₹ 10.73 Crores in Cash credit account for the tenure of one year with the annual renewal option.

34 Ratio Analysis

Particulars	Numerator/Denominator	31 March, 2026	31 March, 2025	Change in %
(a) Current Ratio	$\frac{\text{Current Assets}}{\text{Current Liabilities}}$	2.90	1.44	101.28%
(b) Debt-Equity Ratio	$\frac{\text{Total Debts}}{\text{Shareholder's Equity}}$	0.23	0.92	-75.59%
(c) Debt Service Coverage Ratio	$\frac{\text{Earning available for Debt Service}}{\text{Debt Service}}$	5.70	3.99	42.77%
(d) Return on Equity Ratio	$\frac{\text{Profit after Tax}}{\text{Average Shareholder's Equity}}$	27.62%	123.68%	-77.67%
(e) Inventory turnover ratio	$\frac{\text{Total Turnover}}{\text{Closing Inventories}}$	3.16	2.78	13.46%
(f) Trade receivables turnover ratio	$\frac{\text{Total Turnover}}{\text{Closing Trade Receivable}}$	4.00	4.92	-18.68%
(g) Trade payables turnover ratio	$\frac{\text{Total Purchases}}{\text{Closing Trade Payable}}$	12.13	5.73	111.68%
(h) Net capital turnover ratio	$\frac{\text{Total Turnover}}{\text{Closing Working Capital}}$	2.27	5.61	-59.64%
(i) Net profit ratio	$\frac{\text{Net Profit}}{\text{Total Turnover}}$	10.79%	11.84%	-8.90%
(j) Return on Capital employed	$\frac{\text{Earning before interest and taxes}}{\text{Capital Employed}}$	20.73%	37.86%	-45.24%
(k) Return on investment	$\frac{\text{Return on Investment}}{\text{Total Investment}}$	0.00%	0.00%	

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)

Notes forming part of the Financial Statement

Reasons for Variances

Current Ratio : The Current Ratio increased by 101.28% during the year primarily due to a significant increase in current assets and improvement in the Company's liquidity position as compared to the previous year.

Debt-Equity Ratio : The Debt-Equity Ratio decreased by 75.79% during the year primarily due to reduction in borrowings and/or increase in shareholders' equity.

Debt Service Coverage Ratio : The Debt Service Coverage Ratio increased by 42.77% during the year primarily due to improvement in operating profitability and enhanced debt servicing capacity of the Company.

Return on Equity : The Return on Equity decreased by 77.67% during the year primarily due to the increase in shareholders' equity consequent to the IPO, while the corresponding increase in profitability was not proportionate.

Trade Payables Turnover Ratio : The Trade Payables Turnover Ratio increased by 111.68% during the year primarily due to higher purchase volume and faster settlement of trade payables as compared to the previous year.

Net Capital Turnover Ratio : The Net Capital Turnover Ratio decreased by 59.64% during the year primarily due to a significant increase in working capital as compared to the growth in revenue.

Return on Capital Employed : The Return on Capital Employed decreased by 45.24% during the year primarily due to a significant increase in capital employed as compared to the growth in operating profits.

35 Other Statutory Disclosures as per the Companies Act, 2013

- 1) Title deeds of Immovable Property are held in name of the Company.
- 2) The Company has not granted any Loans or Advances in the nature of loans to promoters, Directors, KMPs and the related parties (as defined under Companies Act, 2013,) either severally or jointly with any other person, that are (a) repayable on demand or (b) without specifying any terms or period of repayment.
- 3) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.
- 4) The Company has not declared willful defaulter by any bank or financial institution or other lender
- 5) Based on the information available with the Company, the Company does not have any transactions with companies struck off u/s 248 of the Companies Act, 2013.
- 6) The Company has not traded or invested in Crypto currency or Virtual Currency during the audited period.
- 7) The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.

ACCRETION PHARMACEUTICALS LIMITED
(CIN: L21004GJ2023PLC146545)**Notes forming part of the Financial Statement**

- 8) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall: (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- 9) The Company has not entered into any such transaction which is not recorded in the books of account that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961.

36 Subsequent Events

The company had made an initial public offering (IPO) of 29,46,000 equity shares of face value of ₹ 10 each fully paid up for cash at a price of ₹ 101 per equity shares (including share premium of ₹ 91 per equity share) aggregating to ₹ 29,75,46,000/- The equity shares of the company has been listed on NSE Emerge Platform on 21 May, 2025.

37 Regrouping

The figures of the previous year have been re-arranged, re-grouped and re- classified wherever necessary.

38 Additional Disclosure : Statement on Utilisation of proceeds from the Initial Public Offer of the Equity Shares

Pursuant to the issue of Fresh Equity Shares, the Company has received proceeds from the Initial Public Offer of the Equity Shares from the allottees. The utilisation of such funds as of 31 March, 2026 is detailed below:

Total proceeds from the Initial Public Offer of the Equity Shares : ₹ 2975.46 (₹ In Lacs)

Actual utilisation of fund till 31 March, 2026 : ₹ 2975.46 (₹ In lacs)

Balance amount to be utilised : NIL - The balance amount remains invested in short-term fixed deposits or bank balances, pending deployment for approved purposes.

- 39** The Company has not entered into any scheme of arrangement therefore approval of competent authority in terms of sections 230 to 237 of the Companies Act, 2013 is not required.
- 40** The Company does not have any charges or satisfaction which is yet to be registered with Registrar of Companies beyond the statutory period.

As per our report of even date
For M/s V S S B & Associates
Chartered Accountants
Firm's Registration No. 0121356W

For and on behalf of the Board of
ACCRETION PHARMACEUTICALS LIMITED

Vishves A. Shah
Partner
Membership No. 109944
UDIN: 26109944KXOBZD4848

Harshad Rathod
Director & CFO
DIN: 09108392

Vivek Patel
Managing Director
DIN: 09130357

Roshni Shah
Company Secretary
Mem. No. A47037

Date : 08 May, 2026
Place : Ahmedabad

Date : 08 May, 2026
Place : Ahmedabad

NOTICE

NOTICE IS HEREBY GIVEN THAT THE THIRD (3RD) ANNUAL GENERAL MEETING OF THE MEMBERS OF **ACCRETION PHARMACEUTICALS LIMITED** will be held on Thursday, 27 August, 2026 at 11:00 A.M. through Video Conferencing (“VC”) / Other Audio Visual Means (“OAVM”) to transact the following businesses:

ORDINARY BUSINESSES

- (1) To receive, consider and adopt the Standalone Financial Statements as at 31 March, 2026 including the Audited Balance Sheet as at 31 March, 2026, the Statement of Profit and Loss for the year ended on that date and reports of the Board of Directors and Auditors thereon.
- (2) To appoint a director in place of Mr. Hardik Mukundbhai Prajapati (DIN: 09108403), Director, who retires by rotation and being eligible, offers himself for re-appointment.

29, Xcelon Industrial Park 1,
B/h, Intas Pharmaceuticals,
Vasna Chacharvadi, Sanand,
Ahmedabad – 382 213.

Date : 08 May, 2026
Place : Ahmedabad

By Order of the Board of Directors
For Accretion Pharmaceuticals Limited

Roshni Shah
Company Secretary & Compliance Officer
Membership No.: A47037

NOTES

- 1) The Ministry of Corporate Affairs (“MCA”) has vide its circular no. 20/2020 dated 05 May, 2020 read with circular nos. 14/2020 and 17/2020 dated 08 April, 2020 and 13 April, 2020 respectively (collectively referred to as “MCA Circulars”) permitted the holding of the Annual General Meeting (“AGM”) through VC / OAVM, without the physical presence of the Members at a common venue. MCA had vide circular no. 03/2025 dated 22 September, 2025 has allowed the Companies to conduct their AGMs in accordance with the requirement provided in this Circular. In compliance with the provisions of the Companies Act, 2013 (“Act”), SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) and MCA Circulars, the 3rd AGM of the Company is being held through VC / OAVM. The detailed procedure for participation in the meeting through VC / OAVM is as per Note no. 22 and is also available at the Company's website www.accretionpharma.com.
- 2) In accordance with the MCA Circulars, provisions of the Act and SEBI Listing Regulations, the AGM of the Company is being held through VC / OAVM. The deemed venue for the AGM shall be the Registered Office of the Company.
- 3) Pursuant to MCA Circular no. 14/2020 dated 08 April 2020, the facility to appoint proxy to attend and cast vote for the members is not available for this AGM. However, the Body Corporates are entitled to appoint Authorised Representatives by uploading a duly certified copy of the Board Resolution authorising their representatives to attend the AGM through VC/ OAVM and participate thereat and cast their votes through e-voting.
- 4) The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. All the members of the Company are encouraged to attend and vote at the AGM through VC/OVAM.
- 5) The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.
- 6) Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended), the Secretarial Standard on General Meetings (SS-2) issued by the ICSI and Regulation 44 of SEBI Listing Regulations (as amended), and pursuant to the MCA Circulars, the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with Central Depository Services (India) Limited (“CDSL”) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote e-voting system as well as voting on the day of the AGM will be provided by CDSL. Members of the Company holding shares as on the cut-off date i.e. 20 August, 2026 may cast their vote either by remote e-voting or e-voting system as on date of AGM. A person who is not a member as on the cut-off date should treat this Notice for information purpose only.

7) In compliance with the MCA and SEBI Lising Regulations, Notice of the 3rd AGM along with the Annual Report 2025-26 is being sent through electronic mode only to those Members whose e-mail id is registered with the Company's Registrar and Share Transfer Agent ("RTA") / Depository Participants ("DPs"). Members may note that the Notice of 3rd AGM and the Annual Report of the Company for the financial year 2025-26 is uploaded on the Company's website www.accretionpharma.com and may be accessed by the members and may be accessed by the members and will also be available on the website of National Stock Exchange of India Limited at www.nseindia.com and on the website of the CDSL at www.evotingindia.com.

Any Member desirous of obtaining physical copy of the Notice of the 3rd AGM along with the Annual Report may send a request to the Company at compliance@accretionpharma.com mentioning their name, demat account number, email id and mobile number.

- 8) Only bonafide members of the Company whose names appear on the Register of Members as on 20 August, 2026 being cut-off date will be permitted to attend the Meeting. The Company reserves its right to take all steps as may be deemed necessary to restrict non-members from attending the AGM.
- 9) As per the provision of Section 72 of the Act and SEBI Circulars, the facility for making Nomination is available for the members in respect of their shareholding in the Company either in single or with joint names. The members are requested to submit the complete and signed form SH-13 with their Depository Participant (DP) who holds the shares in dematerialized form. If a Member desires to opt out or cancel the earlier nomination and record a fresh nomination, he / she may submit the same in Form No. SH-14. Members are requested to submit the said details to their respective DPs, in case the shares are held by them in dematerialised form.
- 10) Members holding shares in dematerialized mode are requested to register complete bank account details with the Depository Participants.
- 11) Process for those Members whose email ids are not registered with the Depositories or the Company for obtaining login credentials for e-voting:
- Members holding shares in physical form may request for the same along with providing necessary details like Folio No., Name of Member, self attested scan copy of PAN Card and Aadhar Card by email to compliance@accretionpharma.com.
 - Members holding shares in demat form may request for the same along with providing Demat account details (CDSL-16 digit beneficiary ID or NSDL - 8 character DPID + 8 character Client ID), Name of Member, client master or copy of Consolidated Account statement, self-attested scan copy of PAN Card and Aadhar Card by email to compliance@accretionpharma.com.
- 12) Process for updation of email ids / mobile no of the members whose email ids / mobile no. are not registered with the Company or Depositories –

- Members holding shares in physical form – Update your email id and mobile no by providing Form ISR-1 and ISR-2 available on the website of the RTA.
 - Members holding shares in demat form – Update your email id & mobile no. with your respective Depository Participant (DP); for individual members holding shares in demat form, updation of email id and mobile no. is mandatory for e-voting and joining virtual meetings through depositories.
- 13) The Register of Directors and Key Managerial Personnel and their shareholding maintained under Section 170 of the Act, the Register of Contracts or arrangements in which Directors are interested under Section 189 of the Act and all the relevant documents referred to in this Notice will be available for inspection in the electronic mode upto the date of AGM and will also be available electronically for inspection by the Members during the AGM. Members seeking to inspect such documents can send the e-mail to compliance@accretionpharma.com.
 - 14) Pursuant to Regulation 36 of the SEBI Listing Regulations read with the Secretarial Standard on General Meetings (SS-2), brief resume and other details in respect of Director seeking re-appointment at the AGM has been provided in the explanatory statement to the Notice.
 - 15) Members seeking any information or clarification on the accounts or any other matter to be placed at AGM are requested to send written queries to the Company on compliance@accretionpharma.com atleast 10 days before the date of the meeting to enable the management to respond appropriately.
 - 16) The remote e-voting period commences at 09:00 a.m. IST on 24 August, 2026 and ends at 5:00 p.m. IST on 26 August, 2026. During this period, members of the Company holding shares as on Cut-off date of 20 August, 2026 ('Cut-off date'), may cast their vote by remote e-voting. No remote e-voting shall be allowed beyond the aforesaid date and time and the remote e-voting module shall be disabled for voting upon expiry of the aforesaid period. Once the vote on a resolution is cast by the member, the member shall not be allowed to change it subsequently.
 - 17) Mr. Nimish Chunibhai Sakhiya, Proprietor, Sakhiya & Co., Practicing Company Secretary (Membership No. A35847) has been appointed as the Scrutinizer to scrutinize the e-voting process in a fair and transparent manner failing him CS Mukesh Pamnani, Proprietor, Mukesh Pamnani & Associates, Practicing Company Secretary (Membership No. FI0166) can carry on the Scrutinising process.
 - 18) The Scrutinizer shall submit a consolidated Scrutinizer's Report (votes casted during the AGM and votes casted through remote e-voting) of the total votes cast in favour or against, if any, within two working days of conclusion of the 3rd AGM to the Chairman of the Company. The Chairman, or any other person authorised by the Chairman, shall declare the result of the voting forthwith. The result declared along with the consolidated Scrutinizer's Report shall be placed on the Company's website www.accretionpharma.com and on the website of CDSL immediately after the result is declared by the Chairman and the same shall be simultaneously communicated to National Stock Exchange of India Limited.

- 19) The resolution shall be deemed to be passed on the date of AGM, subject to the receipt of sufficient votes.
- 20) Since the AGM will be held through VC / OAVM in accordance with the MCA Circulars, the route map, proxy form and attendance slip are not attached to the Notice.
- 21) The toll free number regarding any query / assistance for participation in the AGM through VC / OAVM is 1800 21 09911.
- 22) Voting process and instruction regarding e-voting:

Section A: Voting Process:

Members should follow the following steps to cast their votes electronically:

Login method for e-voting and joining virtual meeting for individual members holding shares in demat form:

- i) Pursuant to SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 09 December, 2020, under Regulation 44 of the Listing Regulations, Listed Companies are required to provide remote e-voting facility to its members, in respect of all members' resolutions.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed companies in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the members.

In order to increase the efficiency of the voting process, all the demat account holders have been enabled for e-voting by way of a single login credential, through their demat accounts / websites of Depositories / Depository Participants. Demat account holders would be able to cast their vote without having to register again with the ESPs.

- ii) Members are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Pursuant to abovesaid SEBI Circular, login method for e-Voting and joining virtual meetings for Individual members holding shares in Demat mode is given below:

Type of Members

Individual Members holding securities in Demat mode with **CDSL Depository**

Login Method

- 1) Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login to Easi / Easiest are requested to visit CDSL website www.cdslindia.com and click on login icon & My Easi New (Token) Tab.
- 2) After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the voting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly.

- 3) If the user is not registered for Easi/Easiest, option to register is available at CDSL website www.cdslindia.com and click on login & My Easi New (Token) Tab and then click on registration option.
- 4) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.

Individual Members holding securities in demat mode with **NSDL Depository**

- 1) If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: <https://eservices.nsdl.com> either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.
- 2) If the user is not registered for IDeAS e-Services, option to register is available at <https://eservices.nsdl.com>. Select "Register Online for IDeAS" Portal or click at <https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp>
- 3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. 8-digit DP ID followed by 8-digit Client ID), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.
- 4) For OTP based login you can click on <https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp>. You will have to enter your 8-digit DP ID, 8-digit Client ID, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Individual Members (holding securities in demat mode) login through their **Depository Participants (DP)**

You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Members holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

LOGIN TYPE

Individual Members holding securities in Demat mode with **CDSL**

Individual Members holding securities in Demat mode with **NSDL**

HELPDESK DETAILS

Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 21 09911

Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at : 022 - 4886 7000 and 022 - 2499 7000

Login method for e-voting and joining virtual meeting for members other than individual members holding shares in demat form & members holding in physical mode:

- 1) Open the web browser during the voting period and log on to the e-voting website www.evotingindia.com.
- 2) Click on "Shareholders" to cast your vote(s).
- 3) Please enter your User ID
 - a) For account holders in CDSL: 16 digits beneficiary ID,
 - b) For account holders in NSDL: 8 Character DP ID followed by 8 Digits Client ID,
 - c) Members holding shares in Physical Form should enter Folio Number registered with the Company.
- 4) Next enter the Image Verification as displayed and Click on Login.
- 5) If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier e-voting of any company, then your existing password is to be used. If you have forgotten the password, then enter the User ID and the image verification code and click on "FORGOT PASSWORD" and enter the details as prompted by the system.
- 6) If you are a first-time user follow the steps given below:

Individual Members holding securities in Demat mode with **CDSL**

Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders).

- Shareholders who have not updated their PAN with the Company/ Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.

Individual Members holding securities in Demat mode with **NSDL**

Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login.

- If both the details are not recorded with the depository or company, please enter the member id / folio number in the Dividend Bank details field.

- 7) After entering these details appropriately, click on "SUBMIT" tab.

- 8) Members holding shares in physical form will then directly reach the Company selection screen. However, Members holding shares in demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- 9) For Members holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- 10) Click on the EVSN for the relevant ACCRETION PHARMACEUTICALS LIMITED on which you choose to vote.
- 11) On the voting page, you will see "RESOLUTION DESCRIPTION" and against the same the option "YES/NO" for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- 12) Click on the "RESOLUTIONS FILE LINK" if you wish to view the entire Resolution details.
- 13) After selecting the resolution, you have decided to vote on, click on "SUBMIT". A confirmation box will be displayed. If you wish to confirm your vote, click on "OK", else to change your vote, click on "CANCEL" and accordingly modify your vote.
- 14) Once you "CONFIRM" your vote on the resolution, you will not be allowed to modify your vote. You can also take a print of the votes cast by clicking on "Click here to print" option on the Voting page.

Section B: Other instructions regarding remote e-voting:

- i) The voting period shall begin on 24 August, 2026 from 09:00 A.M. and end on 26 August, 2026 at 05:00 P.M. During this period Members of the Company, holding shares, as on the cut-off date i.e. 20 August, 2026, may cast their vote electronically. Thereafter the e-voting module shall be disabled.
- ii) Non-Individual Members (i.e. other than Individuals, HUF, NRI etc.) and Custodians are additionally required to note and follow the instructions mentioned below:
 - The are required to log on to www.evotingindia.com and register themselves in the "Corporates" module.
 - A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
 - After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
 - The list of accounts linked in the login will be mapped automatically & can be delink in case of any wrong mapping.
 - It is Mandatory that, a scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.

- iii) Alternatively, Non-Individual members are required mandatory to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz; cssakhiyaandco@gmail.com, if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.
 - iv) Members holding multiple folios / demat accounts shall choose the voting process separately for each folio / demat account.
 - v) In case you have any queries or issues regarding e-voting, you may refer the Frequently Asked Questions (FAQs) and e-voting manual available at www.evotingindia.com, under help section or contact Mr. Rakesh Dalvi, Assistant Vice President, CDSL, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mills Compounds, N. M. Joshi Marg, Lower Parel (East), Mumbai – 400013 or write an email to helpdesk.evoting@cdslindia.com or call Toll free No-1800 21 09911 during working hours on all working days.
- 23) **The instructions for members for e-voting on the day of the AGM are as under:-**
- a) The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for remote e-voting.
 - b) Only those Members/ Shareholders, who will be present in the AGM through VC/ OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the AGM.
 - c) Members who have voted through Remote e-Voting will be eligible to attend the AGM. However, they will not be eligible to vote at the AGM.
- 24) **Instructions for members for attending the AGM through VC/OAVM are as under:**
- a) The link for VC / OAVM to attend the AGM will be available where the EVSN of the Company will be displayed after successful login as per instruction mentioned above for remote e-voting.
 - b) Members are encouraged to join the Meeting through Laptops / IPads for better experience. Please note that Participants connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio / Video loss due to fluctuation in their respective network. It is therefore recommended to use stable Wi-Fi or LAN connection to mitigate any kind of aforesaid glitches.
 - c) For ease of conduct, Members who would like to express their views / ask questions during the meeting may register themselves as a speaker by sending their request atleast 10 days prior to the date of meeting mentioning their name, demat account number / folio number, email id, mobile number at compliance@accretionpharma.com. The Shareholders who do not wish to speak during the AGM but have queries may send their queries mentioning their name, demat account number / folio number, email id, mobile number at compliance@accretionpharma.com. These queries will be replied to by the Company suitably by email.
 - d) Those Members who have registered themselves as a speaker will only be allowed to express their views / ask questions during the meeting. Further the Members will be required to allow the camera for participation in the meeting as a speaker.

Information pursuant to the provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the provisions of the Secretarial Standard on General meetings ('SS-2') issued by the Institute of Company Secretaries of India regarding the Director proposed to be re-appointed:

Name of Director	Mr. Hardik Mukundbhai Prajapati
Director Identification Number	09108403
Date of Birth	09 December, 1987
Age as on 08 May, 2026	38 Years
Date of first appointment on Board	29 November, 2023
Qualification	Bachelor's degree in Pharmacy and Master's in Pharmacy
Brief Profile / Experience including expertise in specific functional areas	He brings over 16 years of deep, hands-on experience in pharmaceutical production to the leadership team. He holds a Bachelor's degree in Pharmacy from Gujarat University and a Master's degree in Pharmacy from Gujarat Technological University, anchoring his career in robust technical excellence. Mr. Prajapati characterized by his unwavering commitment to innovation and precision, his technical mastery and entrepreneurial insight are pivotal in shaping a bright, progressive future for Accretion Pharmaceuticals Limited.
No. of Shares held as on 08 May, 2026	19,66,500 Equity Shares
Terms and conditions of re-appointment	He is due for retirement by rotation at the ensuing AGM. Hence, he is being re appointed in compliance with the applicable provisions of the Companies Act, 2013.
Directorships held in other companies*	Accretion Nutraveda Limited
Directorship of listed entities from which director has resigned in the past 3 years	Nil
Chairman / Member of the Committees in other Companies**	Nil
Remuneration sought and last drawn	₹ 26,50,000/-
Number of meetings of the Board attended during the year (2025-26)	Eight (8)
Relationship with other Directors and other Key Managerial Personnel of the Company	NIL

Note: *excludes directorships held in Private / Foreign Companies and includes deemed public companies.

*The Committee of the Board of Directors includes only Audit committee and Stakeholders Relationship committee as per Regulation 26 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 of public companies.

29, Xcelon Industrial Park 1,
B/h, Intas Pharmaceuticals,
Vasna Chacharvadi, Sanand,
Ahmedabad – 382 213.

Date : 08 May, 2026
Place : Ahmedabad

By Order of the Board of Directors
For Accretion Pharmaceuticals Limited

Roshni Shah
Company Secretary & Compliance Officer
Membership No.: A47037

CORPORATE INFORMATION

BOARD OF DIRECTORS

Harshad Nanubhai Rathod

Chairman and Director and Chief Financial Officer

Vivek Ashokkumar Patel

Managing Director

Hardik Mukundbhai Prajapati

Executive Director

Mayur Popatlal Sojitra

Non- Executive Director (Re-Designation w.e.f. 01 September, 2025)

Grishma Ajayrao Shewale

Independent Director

Shyam Bhadresh Kapadia

Independent Director (Resigned w.e.f. 19 April, 2025)

Vijay Bharatbhai Anadkat

Independent Director (Resigned w.e.f. 26 May, 2025)

Chand Rameshbhai Kanabar

Independent Director (Appointed w.e.f. 19 April, 2025)

Nishtha Harivanshi Pamnani

Independent Director (Appointed w.e.f. 10 June, 2025)

COMPANY SECRETARY

Bhavika Dhaval Makadia

(Resigned w.e.f. 01 September, 2025)

Roshni Dharmendrabhai Shah

(Appointed w.e.f. 01 September, 2025)

AUDIT COMMITTEE

Shyam Bhadresh Kapadia

Chairman (upto 19 April, 2025)

Chand Rameshbhai Kanabar

Chairman (w.e.f. 19 April, 2025)

Grishma Ajayrao Shewale

Member

Harshad Nanubhai Rathod

Member

Vijay Bharatbhai Anadkat

Member (upto 26 May, 2025)

STAKEHOLDERS RELATIONSHIP COMMITTEE

Shyam Bhadresh Kapadia

Chairman (upto 19 April, 2025)

Chand Rameshbhai Kanabar

Chairman (w.e.f. 19 April, 2025)

Grishma Ajayrao Shewale

Member

Harshad Nanubhai Rathod

Member

Vijay Bharatbhai Anadkat

Member (upto 26 May, 2025)

NOMINATION AND REMUNERATION COMMITTEE

Shyam Bhadresh Kapadia

Chairman (upto 19 April, 2025)

Chand Rameshbhai Kanabar

Chairman (w.e.f. 19 April, 2025)

Grishma Ajayrao Shewale

Member

Harshad Nanubhai Rathod

Member

Vijay Bharatbhai Anadkat

Member (upto 26 May, 2025)

Nishtha Harivanshi Pamnani

Member (w.e.f. 10 June, 2025)

CORPORATE SOCIAL RESPONSIBILITY

Vivek Ashokkumar Patel

Chairman

Harshad Nanubhai Rathod

Member

Hardik Mukundbhai Prajapati

Member

Vijay Bharatbhai Anadkat

Member (upto 26 May, 2025)

Chand Rameshbhai Kanabar

Member (w.e.f. 10 June, 2025)

STATUTORY AUDITOR

M/s. V S S B & Associates, Chartered Accountants

A/912, 9th Floor, Ratnaakar Nine Square,

Opp. ITC Narmada Hotel, Vastrapur, Ahmedabad - 380015

SECRETARIAL AUDITOR

M/s. Sakhiya & Co., Practicing Company Secretaries

Office - 502, RK Empire, Opp. Sanskar Heights, Nr. Mavdi Chowkdi,

150 Feet Ring Road, Rajkot-360 004, Gujarat, India.

BANKER

INDIAN BANK

Paldi Branch

REGISTRAR & TRANSFER AGENT

KFIN TECHNOLOGIES LIMITED

Selenium Tower-B, Plot No. 31 & 32, Financial District,

Nanakramguda, Hyderabad – 500 032.

Toll free No: 18003094001

Email Id: cinward.ris@kfintech.com

Website: www.kfintech.com

REGISTERED OFFICE

ACCRETION PHARMACEUTICALS LIMITED

CIN: L21004GJ2023PLC146545

29 Xcelon Industrial Park 1, B/h Intas Pharmaceuticals, Vasna Chacharvadi,

Sanand, Ahmedabad - 382213, Gujarat, India

Mobile: +91-9714882929

E-Mail: compliance@accretionpharma.com

Website: www.accretionpharma.com

CORPORATE OFFICE

516, Iconic Shyamal, Shyamal Cross Road, 132 Feet Ring Road, Satellite,

Ahmedabad 380015 - Gujarat, India

SYMBOL AND ISIN


NSE Symbol : ACCPL


ISIN : INEOT8T01010

TOGETHER FOR IMPACT TOGETHER FOR HEALTH

Accretion Pharmaceuticals Limited

NOTES





GROWING TOGETHER



CIN: L21004GJ2023PLC146545

CONTACT US

-  **Corporate Office:**
516, Iconic Shyamal, Shyamal Cross Road, 132 Feet Ring Road,
Satellite, Ahmedabad 380015 – Gujarat, India.
-  **Registered Office:**
29 Xcelon Industrial Park 1, B/h Intas Pharmaceuticals,
Vasna Chacharvadi, Sanand, Ahmedabad-382213, Gujarat, India.
-  +91 79 45906329
-  compliance@accretionpharma.com
-  www.accretionpharma.com



Scan For Website